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Background: Osteoporotic fractures constitute a major health- and economic burden 
worldwide and because of an aging population the burden is estimated to rise. The individual 
consequences of fractures are severe. Norway has one of the highest fracture incidences in the 
world. The etiology of fracture risk at old age is less optimal bone mass accumulation in 
childhood and adolescence, rapid subsequent age-related bone loss or a combination of both. 
Therefore, peak bone mass (PBM) is a predictor of future fracture risk and to optimize bone 
accretion in young age identification of predictors of modifiable factors is essential. 
Objectives: The aim of this thesis was to describe changes in bone traits during two years in 
late adolescence, investigate the degree of tracking of those bone traits and explore the 
associations between lifestyle factors such as body weight and snuff use and bone mineral 
density changes in Norwegian girls and boys between 15-19 years of age. 
Methods: In 2010-2011 we invited all first comprehensive school students in Tromsø to the 
Fit Futures study and 1038 adolescents (93%) attended. We measured total body (TB), total 
hip (TH), and femoral neck (FN) areal bone mineral density (aBMD) as g/cm² by DXA (GE 
Lunar prodigy). Two years later, in 2012-2013, we invited all participants to a follow-up 
survey and 820 adolescents attended, providing 688 repeated measures of aBMD. We 
measured body weight and height and information on lifestyle were collected by 
questionnaires.  
Results: Girls between 17 and 19 years of age were approaching PBM at femoral sites, while 
boys were still accumulating bone mass between 17 and 19 years of age. There was a high 
degree of tracking of bone traits during two years in late adolescence and drift between 
quartiles was limited. Body weight and body mass index (BMI) were associated with bone 
accretion in late adolescence, but in a healthy young population, the influence and clinical 
implications were limited. However, low BMI was associated with low aBMD and 
particularly among boys with low BMI, an increase in BMI could be beneficial for bone 
health. Use of snuff was associated with lower rate of bone accretion in boys, but its relation 
to maturation requires further investigation.  
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Osteoporosis, and its clinical expression, fragility fractures constitute a substantial and 
growing public health challenge worldwide [1]. If  preventive measures are not taken, 
projections estimate the incidence to more than double during the next few decades [2]. Along 
with the high financial burden on society, there are often severe individual consequences such 
as pain, physical disability and loss of independence, reduced quality of life, increased 
morbidity and excess mortality [3, 4]. Fracture incidence vary significantly among 
populations [5, 6]. The Scandinavian countries are high fracture risk areas, and Norway has 
one of the highest incidence of hip- and wrist fractures worldwide [7, 8]. The reasons for 
these bone fragility disparities are not well-understood [9].  
The primary cause of fragility fractures is compromised bone strength due to reduced amount 
of bone mass and diminished bone quality [10, 11]. Research and therapy have traditionally 
focused on mechanisms of bone loss and interventions following the first low-trauma fracture. 
However, attention to prevention has increased, and it is recognized that bone fragility late in 
life may have its antecedents in childhood and adolescence. In both girls and boys, bone mass 
increases substantially during growth and at the end of skeletal maturation the amount of bone 
mass peaks. Peak bone mass (PBM) is usually acquired between second and third decade of 
life and is followed by a consolidation phase before the gradual age-related degeneration 
begins [12]. Thus, bone mass levels in the elderly is a result of bone accrued during childhood 
and adolescence, less subsequent bone loss [13].  
Adolescence refers to individuals between ages 10 and 19 and is a life phase in which the 
opportunities for establishing future health patterns are great [14, 15]. Approximately one 
third of PBM is determined by lifestyle choices and behavioural factors and at the end of 
adolescence, 95 % of PBM is achieved [12]. It has been calculated that 10% increase in PBM 
equals 50 % reduced risk of fracture later in life and an estimated delayed onset of 
osteoporosis by 13 years [16]. This makes optimization of PBM during growth a strategy for 
reduced risk of osteoporotic fracture and identification of predictors of PBM is essential. 
The combination of an increasing elderly population and unhealthy lifestyle habits among 
children and adolescents may lead to increased incidence of osteoporosis [17]. Bone 
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accretion, and its determinants, from late adolescence into early adulthood, are understudied 
compared to time periods like childhood, puberty and post-menopause [12]. On this 
background, the focus of this thesis is bone mass and modifiable lifestyle factors in 
Norwegian girls and boys in their late adolescence. 
1.2 Epidemiology of osteoporosis and fractures 
1.2.1 Definition of osteoporosis and fragility fractures 
“Osteoporosis” originates from Latin and literally means porous bone (os =”bone”, porus 
=”an opening”). Over the years, there have been many definitions of osteoporosis because it 
is challenging to cover all its manifestations [18]. A frequently cited definition is from the 
1993 Consensus Development Conference:  
“…a systemic skeletal disease characterized by low bone mass and microarchitecture 
deterioration of bone tissue, with consequent fragility and susceptibility to fracture” [19].  
The susceptibility of fracture is a complex matter, but one of its determinants is bone strength. 
Laboratory studies show correlation between the amount of bone mass and bones resistance to 
fracture [20, 21]. Bone mass predicts 60-70 % of the bone strength variation [16, 22]. 
Structural design and material composition explains the remaining variation. A number of 
properties like bone size, shape, physical properties of component material, micro damage 
accumulation, cortical thickness/porosity and distribution of trabecular and cortical bone all 
contribute to the strength of bone [11].  
The National Institutes of Health Consensus Development Conference in year 2000 proposed 
an updated definition that included the concept of bone strength:  
 “A skeletal disorder characterized by compromised bone strength predisposing to an 
increased risk of fracture” [23]. 
Fracture is another hallmark of osteoporosis. This definition emphasizes risk of fracture as 
the clinical outcome. Osteoporosis is often referred to as “silent”. Initial symptoms like low 
back pain, are not easily linked to skeletal disease and before the clinical manifestation of a 
fragility fracture, most people who are at risk unaware of it [2].  
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Osteoporosis has a syndromic nature and its etiology is multifactorial. Low bone mass is 
essentially related to failure to reach an adequate PBM, excessive bone loss, or both. The 
skeletal disorder broadly divides into two categories based on causation. Primary 
osteoporosis is when no underlying cause is identified, typically “natural” progressive bone 
deterioration caused by increasing age, lifestyle factors and/or menopause. Secondary 
osteoporosis is due to diseases and/or medical treatments [17].  
Fragility fractures can be defined as low-trauma fractures due to forces generated by falls 
from standing height or lower. Kanis et al. defined osteoporotic fractures “as occurring at a 
site associated with low BMD and which at the same time increased in incidence after the age 
of 50 years” [24]. Apart from low bone mass, a leading mechanism of fragility fractures is 
excessive bone loading, i.e. falls. Ninety percent of all hip fractures are caused by a fall, and 
frequently in combination with low bone mass [25]. However, occasionally osteoporotic 
related fractures may also occur spontaneously [2]. 
Bone mass is an unspecified general term that often includes one of three following 
expressions (1). Bone mineral content (BMC; g), which is the most basic parameter, refers to 
the one-dimensional amount of bone mineral in grams, irrespective of width or depth (2). 
Bone mineral density (BMD), or areal bone mineral density (aBMD; g/cm2) is a two 
dimensional measure of the quantity of minerals (BMC) per unit area of bone (BA) (3). 
Volumetric bone mineral density (vBMD; g/cm3) is a three-dimensional measure comprising 
both width and depth. All three parameters can be elicited from bone densitometry 
techniques. 
1.2.2 Dual Energy X-ray Absorptiometry, aBMD and diagnosis of osteoporosis 
Bone’s resistance to fracture is challenging to assess non-invasively. To date, aBMD 
measured by Dual Energy X-ray Absorptiometry (DXA) is recognized as the current “gold 
standard” for diagnosis of osteoporosis and fracture risk assessment [26].  The technique is a 
surrogate measure of bone strength and uses dual-energy x-ray beams to create a two 
dimensional image by the attenuation of photons by bone minerals as they pass through bone 
[27]. DXA is a widely used method because of its high precision, reproducibility, 
accessibility, low radiation, safety and low cost [28, 29].  
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There are numerous other approaches to assess properties of bone such as X-ray, metabolic 
assessment by bone turnover markers, volumetric BMD measured by Peripheral quantitative 
computed tomography and bone stiffness by Quantitative ultrasound etc. The two latter 
techniques can explore more subtle structural components of bone than DXA can, but are 
currently mostly used as research tools [30]. These aforementioned methods may be utilized 
in the diagnosis of osteoporosis, but the most common modality used is a DXA aBMD T-
score.  
The World Health Organization (WHO) classifies osteoporosis as a femoral neck (FN) aBMD 
value 2.5 standard deviations (SD) or more below the average score of young healthy 
Caucasian female reference population (20-29 years of age) [31]. This operational definition 
identifies individuals at greatest risk of fractures. The greater negative number, the lower 
aBMD and higher risk of fracture. In most situations, one SD equals 10-12% difference in 
aBMD [32]. Thus, an aBMD approximately 25% lower (i.e T-score of -2.5) than the average 
30-year-old white female is the threshold for osteoporosis diagnosis. Although controversial, 
the diagnostic criteria for men is also based on the female reference population. This is based 
on evidence that the fracture risk at a given aBMD score is independent of gender [33]. 
“Established osteoporosis” is the preferred term for an individual with an osteoporosis 
diagnosis (T-score <-2.5) and one or more documented fragility fractures [34]. 
Figure 1 
 
Normal vs. osteoporotic trabecular bone, from Dempster et al. [35], with permission of The 




Having a low aBMD score does not necessarily mean an osteoporosis diagnosis. The 
definition of osteopenia is a T-score between -2.5 and -1 SD. “Penia” means thinning and is 
not characterized as a disease. Normal aBMD is defined as a T-score above -1 SD [31]. 
aBMD T-score may be inappropriate for diagnosis in some cases. In children and adolescents, 
other diagnostic criteria and use of Z-score may be necessary, i.e. comparing with an average 
aBMD of individuals of same age and gender. 
1.2.3 aBMD and fracture risk prediction 
The rationale behind use of aBMD in diagnosis of osteoporosis is its ability to predict fracture 
risk. Low aBMD is a risk factor of almost all types of fractures in both sexes, but the 
predictive value depends on age and aBMD value. Low aBMD at a younger age is associated 
with a significantly higher gradient of risk [36, 37]. The relationship between aBMD and 
fracture risk is nonlinear. The risk increases exponentially as the aBMD decreases and small 
changes in aBMD can lead to greater than expected changes in fracture risk [38].  
Measurements at the hip is the gold standard as it has the highest predictive value of the most 
serious outcome, hip fracture. In addition, measurements of the hip strongly correlates to most 
fracture types [39]. The predictive value of aBMD may be enhanced by taking other clinical 
factors like age, family history and use of medication into consideration. A prior fracture 
increases the risk of a subsequent fracture 2-5 fold [40].  
Although at highest risk of fracture, the proportion of fractures attributable to osteoporosis 
(by the WHO criteria, ie. aBMD T-score < -2.5) is modest and ranges from <10 to 44 % [41]. 
The major burden of fractures in the overall population occurs at the osteopenic levels since 
more than half of all fractures in postmenopausal women occur in individuals with an aBMD 
score defined as osteopenia or normal. The main reason for this is that the majority of the 
population is within this T-score range [42-44].  
1.2.4 Burden of osteoporosis and related fractures 
Osteoporosis affects individuals in all age groups, both sexes and all races, but is more 
common in older people, women and Caucasians [45]. Advanced age is one of the major risk 
factors of osteoporosis and the risk of hip fracture increases substantially around 70 years of 
age [46]. Women (>50 years of age) have a four times higher rate of osteoporosis and a two 
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times higher rate of osteopenia compared with men [47]. The geographical disparities in 
osteoporotic related fracture incidences are substantial. Fracture rates in Northern America 
and Northern Europe are higher than in Asia and South America, and this diversity is only 
partly attributable to ethnicity [48-50].  
Estimates suggest that there are 200 million people with osteoporosis globally [2]. In 2017, 
new fragility fractures in the largest five countries in Europe, (Germany, France, Italy, Spain 
and the UK) plus Sweden (EU6) were estimated at 2.7 million [51]. In the most recent 
estimate for the EU countries from 2010 (EU 27), approximately 22 million women and 5.5 
million men between 50 and 84 years of age were affected by osteoporosis [52]. One in two 
women and one in five for men over 50 years of age will suffer a fracture during their lifetime 
[53]. In 2005, the lifetime risk for a fracture at age of 50 in UK, Sweden, Australia and US 
was estimated to 39-53 % and 13-22 % in women and men, respectively [54]. In Norway, 
9000 people suffer from hip fracture each year (mean 80 years of age). That amounts to an 
average of one hip fracture per hour. Seven out of ten hip fractures is sustained by a woman 
[55]. In addition, 15000 forearm fractures and 23000 persons with vertebral fractures are 
registered annually [56]. 
The most frequent fragility fractures sites are proximal femur (18%), vertebrae (16%) and 
distal forearm (19%) [4]. Hip fractures are considered the most severe consequence of 
osteoporosis [40]. Breaking a hip at old age is life threatening, and men are more likely to die 
after a hip fracture. Excess mortality ranges from 8 to 36 % during the first year [57]. A study 
from Norway shows that mortality within the first year post hip fracture was 21% for women 
and 33% for men, and the excess mortality remained significantly increased for 12 years [58]. 
Only half of hip fracture survivors regain their pre-fracture status judged by ability to walk 
and need for aid [54]. 
The economic consequences of fractures are huge. Total cost of osteoporotic fractures within 
the EU6 were stipulated to €37.5 billion in 2017 [51] . In Norway, the annual cost of hip 
fractures is estimated to be 7-9 billion NOK and the price of a single hip fracture is estimated 
to be 550 000 NOK the first year [55].  
Fracture incidence rates seems to be declining in many western countries [59] and recent 
years there has been a 1.5 % annual decline in hip fracture incidence in Norway [9, 60, 61]. 
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The reason for this decline is still unclear. However, the overall burden is likely to increase 
[62]. According to the International Osteoporosis Foundation, trend analysis project that 
demographic changes with longer survival and a higher proportion of older people worldwide 
will at least double the incidence of bone and joint related diseases in the next 20 years. 
Unless appropriate preventive measures are taken the incidence of hip fracture is estimated to 
increase by 240% in women and 310% in men by 2050 [2]. Other estimates indicate that 1.66 
million hip fractures in 1990 will rise to 6.26 million in 2050 [63]. 
1.3 Bone tissue 
1.3.1 Function and components 
Bone is a complex dynamic connective tissue undergoing constant renewal throughout life 
[64]. The human body comprises 305 bones at birth, but because some bones combine during 
growth, the adult skeleton consists of 206 bones. The skeleton serves mechanical and 
metabolic functions. Bones have mechanical properties for protection of vital inner organs 
and the brain, support against gravity and locomotion as they act as levers for muscles to pull 
on as a framework for movement [27]. Bone tissue is very metabolically active, highly 
vascularized and acts as the primary site for hematopoietic cell maturation [65]. Both red- and 
white blood cells originate and develop in the bone marrow. Bones are crucial in mineral 
homeostasis and serve as a depot for important minerals like calcium, phosphate, magnesium, 
potassium and sodium. Bones contain approximately 99 % of the body’s calcium stores. The 
serum mineral levels are kept at a narrow range and various minerals are released into the 
bloodstream when needed and stored if concentration is too high [66].  
There are especially three hormones critical in the regulation of calcium and phosphate: 
parathyroid hormone, which increases serum calcium; calcitonin, which has the opposite 
effect of parathyroid hormone and inhibits bone breakdown; and calcitriol (vitamin D) that 
promotes absorption of dietary calcium from the gastrointestinal tract [32]. Yellow bone 
marrow are responsible of storage of fat and adipocytes. Lastly, bone also maintain other 
functions like short time electrolyte balance and acid/base balance [64]. 
Imbalance between competing responsibilities of bone can potentially compromise important 
functions, i.e. situations with repeatedly high demands of calcium in the bloodstream may be 




The skeleton weighs approximately 10 kg and accounts for about 15 % of the body weight 
[2]. The axial skeleton includes the head and the trunk, while the limbs and pelvic girdle make 
up the appendicular skeleton. Long bones make up most of the limbs and its typical structure 
is the diaphysis (the shaft), the metaphysis, (growth plate) and epiphysis (the ends). The 
periosteum covers the outer surface except articular surfaces and contains osteoprogenitor 
cells, blood vessels and nerves. A thin membrane called the endosteum covers the medullary 
cavity, the hollow space within the diaphysis [65].  
Essentially, the building blocks of bone are collagen fibers, reinforced by minerals. The 
inorganic mineral matter make up 60 % of total weight of bone, 8-10 % is water, while 
organic matrix constitute the remaining. The inorganic matter consists predominantly of 
calcium phosphate crystals, 85 % hydroxyapatite (Ca10 (PO4)6 (OH2). The organic matter is 
mainly type1 collagen and non-collagenous proteins (98%), and the remainder is cells. These 
materials are fashioned into two types of osseous tissue: cortical- and trabecular bone [68]. 
Figure 2 
  
Illustration of bone structure. Periosteum covering the outer surface, longitudinally oriented 
osteons, Haversian canals containing blood vessels, and trabecular bone located interiorly. 
Creative commons license.  
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The majority (80%) of the skeleton consists of compact and dense cortical bone found in the 
hard outer layer predominantly in diaphyseal regions of long bones. The functional unit of 
cortical bone is the osteon [64]. Osteons are longitudinally oriented and consists of successive 
concentric layers called lamella. These layers surrounds the central canal (Haversian canal) 
that contains small blood vessels, nerves and lymphatic vessels. Volkmann’s canals run 
perpendicular to Haversian canals and connects osteons with outer blood vessels [65]. 
Trabecular bone is cancellous, honeycomb-like spongy bone present in the interior of the 
axial skeleton and in epiphysis of long bones. Because of the characteristic network of 
lamellar plates and rods, this osseous tissue has lesser density and directional homogeneity 
than cortical bone does. There are no vessels within trabeculae and the bone is supplied by 
diffusion from bone marrow [25]. 
The two types of bones has different properties because of its composition, structure and 
spatial distribution of minerals. Because function and demands of physical attributes vary 
from bone to bone and within bone, the proportions of the two different types vary 
extensively throughout the skeleton and the multiscale hierarchical macro- and microstructure 
optimizes their properties and function [65]. 
Bones have contradictory needs. They must be strong to not break, but also be lightweight in 
order to move easily. They have to be rigid and stiff to resist deformation, but also flexible to 
absorb energy from tension and compression without structural failure [27, 69]. The 
combination of inorganic and organic matter makes bones both strong and resilient. Collagen 
give bones tensile strength by its cross-linking profile and mineralization strengthens the 
mechanical resistance [70]. It has been calculated that minerals provides 80-90 % of the 
compressions strength in bone [71].  
In long bones and at skeletal sites that needs to resists bending and rotational forces, the 
stiffness and cortical bone is favored. The femoral neck is approximately three quarters 
cortical bone [32], while the vertebrae is more of a shock absorber and consists mainly (60-
70%) of spongy trabecular bone [11, 68]. For lightness, the principle is to minimize the 
amount of mass needed for appropriate bone strength. The porosity of trabecular bone is 40-
95%, compared to cortical 5-20 % [69]. The bone size and the position of the cortex related to 
the neutral axis determines strength, as the bending strength of a bone increases 
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proportionally to the fourth power of the radius [11]. This means that doubling the diameter 
of a hollow bone without increasing mass increases its strength eightfold [72].  
1.3.3 Cellular composition 
There are three primary types of cells in bone.  
Osteoblast are specialized bone-forming cells responsible for production of the organic 
matrix. They secrete and synthesize collagen, and contribute to the mineralization process by 
initiating the calcification [73]. As osteoblasts mature, they have three different pathways: 
remain osteoblasts, become osteocytes or become “resting osteoblasts” and form bone lining 
cells on the surface of bone [74].  
Osteocytes are mature osteoblast and make up more that 90 % of the bone cells in the adult 
skeleton. Imbedded in mineralized bone they occupy the “empty spaces” in bone matrix 
lacunae, communicate with each other through their long dendritic processes and form the 
intricate lacunar canaliculi network. [73]. In addition to nutrition and oxygen supply, 
osteocytes play a key role in mechanotransduction. This process transfers mechanical loading 
into electrochemical activity. Information about magnitude and distribution of stress and 
interstitial fluid flow are passed on to bone cells that subsequently maintain and modify bone 
mineralization [75].  
Osteoclast are absorption cells. They are derived from multiple stem cells and have many 
nuclei. Osteoclasts operates on the bone surface in hollow depressions called Howship’s 
lacunae, and digests bone with an enzyme called tartrate resistant acid phosphatase using their 
ruffeled boarder facing the matrix. Acids separate minerals from proteins and disrupt the 
bonding forces of bone [74].  
1.3.4 Bone remodeling 
Remodeling is a cellular mechanism that maintain and repair bone. The process occur 
throughout life and is orchestrated by coordinated activities of osteoblasts and osteoclasts. 
This cellular link, known as coupling, is a continuous, tightly regulated process of bone tissue 
breaking down (resorption) and regenerating (formation) to prevent accumulation of micro 
damage. Micro-cracks due to loading are removed and replaced with new bone, ensuring the 
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integrity and strength of bone. It is a balanced sum of two processes and replacement 
normally occur in equal proportions and leads to minimal change in architecture [67].  
Most remodeling sites are random and takes place in the basic multicellular unit. Ten to 20 % 
of the skeleton is replaced each year while the total volume is maintained. This means that we 
have a new skeleton each 7-10 years [64]. The remodeling cycle takes 3-6 months and have 5 
stages: activation, resorption (2-4 weeks), reversal, formation (4-6 months) and termination 
[73, 76].  
The surface of trabecular bone is 10 times larger than cortical bone and the turnover rate is 
five to ten times higher. This indicates that trabecular bone responds easier to mineral 
metabolic demands, but it also makes it vulnerable during life phases of bone mass reduction. 
The combination of weight bearing and spongy bone skeletal cites are at risk: the lumbar 
vertebrae, hip and the distal forearm (falling) [64]. 
Because women have smaller and thinner bones, earlier onset and accelerated bone loss 
around menopause, they tend to have earlier onset of osteoporosis compared to men. The 
rapid decline in estrogen production increases the lifespan of osteoclasts (estrogen promotes 
apoptosis) and this leads to net loss of bone mass due to an imbalanced remodeling process 
with increased resorption and inadequate deposition [73]. 
1.3.5 Bone growth and modeling 
During childhood, and especially puberty, the skeleton changes substantially and the 
predominant process behind this is modeling [73]. Skeletal development follows a specific 
pattern according to age and is a coordinated action between resorption and deposition 
according to a genetic program [77]. In the modeling process bone resorption and bone 
formation are uncoupled. It involves destruction and putting bone in new places, moving bone 
surfaces in tissue space, changing its size, density, shape and architecture [67]. Modeling 
starts with fetal growth and ends with epiphyseal fusion in the twenties [12]. Longitudinal 
growth is driven by bone formation at the diaphysis side of the epiphyseal plate, while 
appositional growth occur because of periosteal deposition and endosteal resorption. 
Periosteal apposition increases the diameter of the bone, while endosteal resorption excavates 
the medullary cavity and shifting the cortex away from the neutral axis [73].  
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There are two different processes behind formation of bone tissue: intramembranous 
ossification is the process of forming bone from fibrous membranes and mainly occur in flat 
bones in the skull, mandible and clavicle. Rudimentary formation and longitudinal growth of 
long bones is primarily caused by endochondral ossification, which creates bone tissue from 
cartilage.  
The quantity of bone minerals is approximately 70-90 g at birth and eventually mounts up to 
2400 g and 3300 g in women and men, respectively [78]. The skeleton grows slowly and 
consistently in childhood, then the accumulation of bone mass increases rapidly in puberty 
throughout the growth spurt. Both height velocity and bone mineral accretion rate peaks 
during puberty [79]. Roughly, 40 % of adult bone mass is accrued during the four years 
surrounding the growth spurt. This is as much bone as most people lose throughout four 
decades later in life [10, 80]. Pubertal bone growth is due to increased bone size rather than 
increased bone mineral density and peak height velocity precedes peak bone mineral accretion 
by 6 to 12 months. This lag and imbalance between size and mineral accumulation makes the 
skeleton susceptible to fracture for a short period of time [81]. 
aBMD continues to rise to final stature and beyond, and men continue to accrue aBMD for 
several years longer than women do. By 4 years following peak mineral accretion, 95 % of 
adult bone mass is accumulated [10, 82]. Between the second and third decade of life 
accretion flattens depending on the skeletal site and the consolidation phase begins [12, 83]. 
Skeletal characteristics influencing structural strength like cortical density and size continues 
to increase into the third decade. Certain bones, including femur, continue to expand even 
after cessation of linear growth [84-86].  
The purposes of modelling and remodeling during growth and adulthood are not the same. In 
childhood and adolescence, the purpose is construction and the attainment of peak bone 
strength, i.e. bone formation is higher that bone resorption. Once the skeleton has reached 
maturity and longitudinal growth has ended, regeneration continues to maintain strength. In 
the consolidation phase the processes balances out, while during age-related bone loss, bone 
resorption is higher that formation leading to net bone loss [27].  
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1.3.6 Pubertal maturation and sex differences in bone development 
Until puberty, the bone maturation and skeletal growth are more or less equal between girls 
and boys. At the onset of puberty, endocrine and hormonal differences leads to disparities in 
development [87]. Boys tend to have equal or higher BMC and aBMD than girls at the end of 
puberty depending on skeletal site, but at a later age and mostly due to greater bone size [47]. 
Cortical thickness in girls and boys are similar. The most apparent difference is the position 
of the cortex related to the long axis of the bone. In girls, increased estrogen production 
throughout puberty suppresses periosteal apposition and endosteal resorption leading to a 
smaller skeleton. The bones diameters are smaller, but not necessarily less dense [11]. 
Compared to boys, girls have a larger trabecular area and this may enable easy access to 
minerals during pregnancy without compromising bone strength [81]. 
Studies suggest that, in girls, the highest BMC accumulation rate takes place from 12-15 
years of age, compared to 14-16 years of age among boys. Bone accrual levels off in girls and 
boys by the age of 16-18 and 17-20 years, respectively [88].   
1.4 Peak bone mass and its determinants 
PBM can be defined as the highest amount of bone mass achieved at skeletal maturation [10]. 
Age-determination and timing of PBM has been under some controversy, but the prevailing 
view is that PBM occurs by the end of the second or early in the third decade of life, 
depending on gender and skeletal site [10]. The concept of PBM has different nuances. 
Individually it refers to the optimization of the genetic potential for bone mass, while at a 
population level, PBM is achieved when age related changes level off and a stable skeletal 
state has been attained. Even more broadly, it could capture peak bone strength as well. PBM 
is a widely recognized determinant of osteoporosis [12]. During growth, the normal range in 
values of bone traits around the age-specific means are large (10-15 %) compared to those 
related to rate of bone loss (1 %). Thus, it has been advocated that the determinants of 
accretion is likely to be at least as, and maybe even more, important as those preserving bone 
mass throughout life [77, 89]. 
Heredity and genetics explain 60-80 % of the variance in PBM, while hormonal and 
environmental factors make up the remainder [90]. The genetic influences declines with age 
and the contribution of environmental factors increase [91]. Non-modifiable determinants of 
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PBM include gender, age, race, height, hormonal status, disease and genetics. Potentially 
modifiable factors mainly relates to lifestyle and include physical activity, nutrition (calcium, 
vitamin D), contraceptive use, alcohol consumption and recreational drugs like smoking and 
use of snuff. Body weight, body composition and BMI may be considered as a hybrid of the 
aforementioned categories as they are modifiable, but there is a considerable hereditary 
component as well. Potentially modifiable factors are most influential during growth and an 
unhealthy lifestyle can put individuals at risk of less than optimal PBM [12, 77].  
Figure 3 
 
Bone mass across the lifespan with optimal and suboptimal lifestyle choices. Reprinted from 
Weaver et al [12]. 
The lifelong significance of PBM in relation to fracture risk is not fully understood. The 
clinical importance of maximization of PBM depends on to what degree bone mineral status 
in younger years tracks into old age [12]. Tracking refers to the stability of bone traits within 
a distribution over time and is a critical assumption behind the importance of PBM. Some 
studies suggest a high degree tracking throughout childhood and adolescence [92-96], while 
other creates doubt about the value of early identification of individuals at risk of low bone 
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mass [97-99]. The degree of tracking seems to depend on skeletal site, trait and duration of 
follow-up time. Imperfect tracking indicate the possibility of bone mineral status alternation 
and thus, enhances the need for lifestyle determinant detection. Tracking of bone traits post-
PBM is also documented [100-102]. Better knowledge of the lifelong importance of PBM 
requires expensive and time-consuming longitudinal studies with follow-up from childhood 
into old age. Though, the feasibility of such studies has been questioned [103]. 
1.4.1 Body weight and body composition 
Bone mass is closely related to body weight and –height because the skeleton needs to be 
appropriate for body size [67].  Body weight is a major determinant of bone mass explaining a 
large proportion of the variance at a population level in the adult population [85]. As height 
and weight are interrelated, body mass index (BMI) is a common tool of weight adequacy 
considering a person’s height. There is evidence of a nonlinear relationship between fracture 
risk and BMI in older individuals, with a marked increase in risk from normal to low BMI 
(<25) [104]. The prevalence of osteoporosis (low BMD) is negatively associated with BMI. In 
women, there is a decrease from 45 % in BMI<18.5 to <1% in obese (BMI>30) [105]. 
The prevalence of obesity among adolescents (BMI>30 kg/m2) is rising in Norway [106] and 
worldwide [107]. Studies suggest an increased fracture incidence in obese children [108]. 
Several studies have investigated the relation between weight and bone in childhood and 
adolescence and reports on whether excess weight interfere with bone mineral accumulation 
are controversial [108-113]. A resent systematic review and meta-analysis including 27 
studies and 5958 individuals concluded that overweight children had significantly higher 
aBMD compared to children of normal weight  [114]. Other studies have found lower than 
expected spinal BMC and bone area in obese children and adolescents [115].  
Individuals of tall stature naturally have higher BMC than shorter do. Baxter-Jones et al. 
reported that height accounted for nearly 70 % of prediction of total body BMC at peak height 
velocity in a study of bone mineral accretion among eighty-five boys and 67 girls measured 
annually for seven consecutive years in a mixed longitudinal design from the age of 8 to 19 
years. Body weight (lean mass and fat mass combined) had a contribution of 29 percent [83].  
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Body weight could exert an effect on bone accretion through diverse direct, or indirect, 
underlying mechanisms related to both mechanical forces and hormonal status. Growing bone 
is highly responsive to mechanical loading (as well as unloading). Early in the 19th century, 
Wolff proposed a hypothesis that trabecular bone adapted and aligned with the stress 
directions though a self-regulated structure-function relationship process [69, 116]. Frost 
further developed the theory with the hypothesis that if peak strain is higher or lower than 
normal, compensatory mechanisms are initiated. The mechanostat theory postulates that these 
mechanisms removes bone where mechanical forces are low and adds bone at skeletal sites 
where demands are high [72]. Load determines the structure of bone and its form follows 
function [69]. This way, the system avoids both unnecessary bone and catastrophic failure. 
However, this also makes bone vulnerable for atypical loads, like falls inflicting of-axis loads 
on the trabecular bone, i.e. falling sideways and breaking the femoral neck [67].  
BMI and body weight are commonly used metrics in relation to bone research, but have 
inadequacies when exploring the exclusive influence of adiposity and muscles. Individuals 
with equal BMI may have very different body composition and measures that are more 
refined are available. In addition to gravitational load on weight-bearing bones, increased 
muscle mass is likely to contribute to the positive influence of high BMI on bone. The impact 
of lean mass on bone during growth [117, 118] and in adults [119] is established, while the 
significance of fat mass is more controversial and appears to vary with age from adolescence 
to adulthood [109]. The mechanostat mechanism of fat mass seems to be limited to weight 
and gravity. Obesity may be related to bone thru increased mechanical loading (both gravity 
and higher lean mass), diet and due to excess fat mass. However, fat mass could also exert an 
endocrine function [67]. Hormonal changes attributed to adipose tissue may be the reason 
why obesity is associated with compromised cortical bone quality in young individuals and 
may not always protect against osteoporosis in old age [120]. The influence of body weight 
on skeletal health may also be modified by sedentary behavior and other lifestyle factors.  
1.4.2 Pubertal development 
There are considerable maturational differences between adolescents at the same 
chronological age [88] and timing of bone mineral accretion is closely related to pubertal 
development [81]. The onset of puberty at older age is associated lower PBM, particularly in 
girls [121]. aBMD and BMC scores at 20 years of age appear to be lower in individuals with 
 
17 
late onset independent of bone pre-scores and duration of puberty. Furthermore, there are 
indications that maturational timing are most influential at the TB [79]. Nevertheless, the 
long-term importance of pubertal timing on PBM is not clear [12, 122] 
1.4.3 Physical activity and mechanical loading 
There is strong evidence of the impact of physical activity on PBM, even at a recreational 
level [12, 123]. Physical activity is closely related to lean mass and its impact on bone is 
partly explained through mechanostat theory (loading by gravity) and association with 
muscles (by the attached tendons) [124]. The largest strains on the skeleton come from 
muscles forces, not gravity [125]. Studies comparing the playing arm and the non-playing arm 
in tennis players support mechanostat theory and suggest that size and structure adapts to 
loading during growth [46, 126-128]. E.g. the humerus exhibits approximately 40% more 
cortical bone on the arm that holds the racquet [129]. Some forms of physical activities has 
been shown to be more “osteogenic” than others. During walking, weight-bearing bones in 
the lower limbs are subjected to a mechanical load of approximately 1.5 times the body 
weight with a one-second interval [67]. To maximize the benefits for bone the activity should 
be weight-bearing, dynamic, of moderate to high in load magnitude, include odd- or non-
repetitive in load direction and be applied quickly [12]. Furthermore, it is important that the 
mechanical loading of the activities exceed an individual given threshold set by habitual 
activity, maturation and other factors. 
1.4.4 Tobacco use 
Smoking is widely regarded as detrimental to bone in the adult population at all skeletal sites, 
with an observed clear biological gradient related to dose and duration of exposure. Smoking 
heightens an individual’s fracture risk through both reduced bone mass and bone mass 
independent factors. Potential pathophysiological mechanisms of the adverse effects of 
tobacco on bone are poorly understood [130-132]. The evidence on its deleterious effect on 
PBM is not as compelling. Studies report both statistically significant deficits in aBMD [133-
139] and no differences according to smoking [140-143]. Most studies of the associations 
between smoking and bone have methodological issues, but large studies of military recruits 
provide some evidence of deleterious effects. Generally, the effect sizes in the studies are 
small; however, the accumulated effect over time could be significant [12]. Winther et.al. 
 
18 
found a cross-sectional association between reduced aBMD and smoking in Norwegian boys 
15-17 years of age [136].  
In Norway, an additional public health-related challenge in terms of tobacco use and PBM has 
emerged. Use of snuff (Swedish snus: smokeless, oral tobacco) has been increasing among 
adolescents in Norway for several years, while traditional smoking is decreasing [144]. WHO 
regards smokeless tobacco as a significant part of the overall use of tobacco [145]. There is a 
great diversity of products, with a range of health hazards. The cross-sectional relationships 
between of use of snuff and aBMD among Norwegian adolescents have previously been 
explored and no significant associations were reported [136]. Apart from this study, the 
influence of use of snuff on growing bones is hardly described.  
1.4.5 Other determinants 
There is a wide range of determinants of PBM identified. The evidence of the influence of 
alcohol consumption on bone in adolescence is conflicting. Both positive [146], no 
associations [134] and negative associations [140, 147] between aBMD and alcohol have 
been reported. Use of combined hormonal contraceptives (CHC) and progestin-only methods 
has been shown to be associated with skeletal deficit in girls, but the findings remain 
controversial [148-152]. Nutrients widely regarded as beneficial for bone health are calcium 
(dairy consumption) and vitamin D. Access to calcium during growth influence both bone 
accumulation and fracture risk. Intestinal absorption of calcium depends on adequate vitamin 
D levels [153]. The influence of other micronutrients, dietary components and macronutrients 
like fat and protein, are not compelling [12]. 
1.5 Assessment of bone mineral density in children and adolescents 
The interpretation and reporting of results from DXA –scans in children and adolescents 
differ from those in adults. Because of the large variations in bone size, bone densitometry are 
often difficult to interpret [154]. In growing individuals, current clinical recommendations 
from ISCD is to compare scores with reference values for the same sex, age and race (Z-
score). Because PBM has not occurred yet, it is inappropriate to use a T-score. DXA scans are 
two dimensional and unable to detect bone depth. Therefore, aBMD estimates are size 
dependent and individuals of short stature and smaller bones would get falsely low scores. 
The spine and total body less head are the preferred scanning site according to the ISCD. 
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There are concerns regarding the precision of DXA-results at the hip because of the variations 
in development of skeletal landmarks. However, hip scans can be performed from 11 years of 
age when software better can detect the region of interest, and in later adolescence this issue 
may not be as significant [103, 155].  
Figure 4 
 




2 Aims of the thesis 
Individuals with high PBM after adolescence might have a protective advantage related to 
skeletal health and future fracture risk. A better understanding of the factors that maximize 
acquisition of bone mass during growth is an important public health strategy to improve 
osteoporosis related outcomes. There is a paucity of data on adolescent health behaviour and 
bone accretion from late adolescence through early adulthood. This thesis explores factors 
connected to PBM and describes the influence of potentially modifiable lifestyle factors on 
this achievement. With the prior chapter as a background the aims of the present thesis are to: 
1. Describe changes in- and explore the degree of tracking of aBMD levels over two years in 
adolescence, i.e. find out if participants mainly remain in their original aBMD quartile 
between the age of 15-17 and 17-19 years. 
2. Explore the associations of baseline body weight/BMI and body weight/BMI changes over 
two years on changes in aBMD (ΔaBMD). A question of clinical interest is to what extent 
body weight gain increase peak bone mass acquisition in those with low BMI at baseline. 
3. Evaluate if lifestyle factors such as use of snuff and smoking influence ΔaBMD peak bone 
mass acquisition in adolescence. 
The main outcome of this thesis is aBMD, and particularly ΔaBMD. However, parameters of 
BMC and BA are frequently reported to support the understanding of growth and bone 





3 Material and methods 
3.1 Study design and samples 
The Tromsø study is an ongoing population-based study initiated in 1974. The study consists 
of seven health surveys conducted in the municipality of Tromsø [156]. This thesis utilizes 
data from The Tromsø Study: Fit Futures (TFF), which is an extension and the youth cohort 
of the Tromsø study. TFF is a collaboration between the University Hospital of North 
Norway, UiT The Arctic University of Norway and the Norwegian Institute of Public Health 
and intends to compliment The Tromsø study with research on adolescents’ lifestyle- and 
health. 
The first wave of TFF was initiated in 2010-2011. All first-year students from all eight upper-
secondary schools in both academic, sports and vocational educational programs from the two 
neighbouring municipalities Tromsø and Balsfjord were invited to Fit Futures I (TFF1). The 
overall attendance rate for upper-secondary school in this region of Norway is more than 90% 
[157]. Out of the 1301 potential students that were registered to start, 184 individuals were 
school dropouts, hindered by disease or individuals that we were not able to contact. The 
invited cohort mainly born in 1993-1994 included 1117 participants. 508 girls and 530 boys 
attended the survey providing an attendance rate of 92.9 %. Ninety five percent of the 
participants were between 15-18 years of age.  
In the second wave two years later, in 2012-2013, all third year upper-secondary school 
students in the same schools were invited to a follow-up survey, Fit Futures 2 (TFF2). 
Participants of TFF1 not attending third year at comprehensive school two years later due to 
relocation etc., were also re-invited in TFF2. A total of 820 adolescents attended, providing 
688 repeated DXA measures of bone traits (66% of the original cohort).  
The study population varies in the three papers due to missing variables and inclusion criteria. 
3.2 Ethics 
The study protocol for TFF1 was approved by The Norwegian Data Inspectorate 27.07.2010 
(Ref. 07/00886-7/CGN) and the Regional Committee of Medical Research Ethics (REK-
Nord) 16.09.2010 (Ref. 2009/1282-23). The study protocol for TFF2 was approved as an 
extension of the prior approval by the Data Inspectorate 31.10.2012 (Ref. 07/00886-15/EOL). 
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Paper I and II were approved by REK-Nord 27.08.13 (Ref. 2013/1459/REK nord) and paper 
III 19.09.2019 (Ref. 2019/31193/REK nord). 
All participants received a descriptive information leaflet regarding the survey in advance and 
gave written informed consent according to the Declaration of Helsinki [158]. Participants 
below 16 years of age had to bring written consent from their superiors to attend the survey. 
After completion of the surveys, participants were given a compensation in form of a 200 
NOK gift voucher. 
3.3 Measurements 
3.3.1 Measurements of aBMD and BMC 
We measured total body (TB), total hip (TH), and femoral neck (FN) BMC (g) and aBMD as 
g/cm² by DXA (GE Lunar prodigy, Lunar Corporation, Madison, Wisconsin, USA) and 
analysed them by Encore paediatric software v. 13.4 [159]. We used auto-analysis mode and 
default region of interest. We used the same densitometer in both TFF1 and TFF2. Trained 
technicians in the University Hospital’s research lab performed the measurements according 
to manufacturer’s procedures, and the DXA scanner was calibrated daily according to the 
same protocol in both surveys and between surveys. Participants were asked to remove all 
jewelry, bracelets, metallic objects, eyeglasses and such, and scanned in supine position in 
light clothing. A wedge were used to ensure correct hip position. DXA scans were 
subsequently assessed for abnormalities and diverse artifacts that might influence BMD 
results. Primarily, we used measurements of left hip at both femoral sites. In 15 cases, the left 
hip measurement was missing or erroneous, and then the right hip was used in replacement. 
The same hip was used in both baseline and follow-up for comparison.  
In paper I, we converted BMC and aBMD measures into sex- and age-standardized internal z-
scores based on the distribution of the study sample. 
3.3.2 Anthropometric measures 
We measured body height and body weight to the nearest 0.1 cm and 0.1 kg on a Jenix DS 
102 Stadiometer (Dong Sahn Jenix, Korea), following standardized procedures according to 
The Tromsø Study. Participants were wearing light clothing, no shoes or metallic objects. 
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BMI was calculated as weight divided by height squared (kg/m2). In paper II participants 
were stratified into weight categories using Cole’s BMI cut-off [160] 
3.4 Self-reported questionnaire 
Through the data program “Questback”, a web-based general health and lifestyle 
questionnaire was used to collect information on lifestyle, nutrition, wellbeing and health 
problems. 
3.4.1 Use of tobacco 
The questions on “Do you smoke?” and “Do you use snuff?” had three alternatives: “No, 
never”, “sometimes” or “daily”. If the response were “sometimes” or “daily”, participants 
were asked follow-up questions on frequency and duration. 
The questions were: “If you use snuff sometimes, how many snuff portions do you usually 
take per week?” Alternatives were “One or less”, “2-3”, “4-6”, “7-10” and “More than 10”. 
For daily users the subsequent question was: “If you use snuff daily, how many snuff portions 
do you usually take per day?”. Alternatives were “1”, “2-3”, “4-6”, “7-10” and “More than 
10”. The age of onset of use of snuff, were elicited by the question: “How old were you when 
you started to use snuff?” The 8 alternatives were: “Below 12 years”, “12 years”, 13 years”,14 
years”, “15 years”, “16 years”, ”17 years”, ”18 years” and “19 years or above”. In the TFF2 
questionnaire, one alternative to the questions on snuff and smoke was added: “In the past, 
but not now”. 
3.4.2 Physical activity 
Physical activity was assessed by the questions from the modernized Saltin-Grimby Physical 
Activity Level Scale (SGPALS) or Gothenburg instrument [161]. The participants were asked 
to grade their time spent on physical activity in leisure time in an average week during the last 
year.  
If their activity varied much, for example between summer and winter, then they were asked 




1) Reading, watching TV, or other sedentary activity? 2) Walking, cycling, or other forms of 
exercise at least 4 hours a week? 3) Participation in recreational sports, heavy outdoor 
activities, snow clearing etc.? 4) Participation in hard training or sports competitions, 
regularly several times a week? 
3.4.3 Pubertal status 
Pubertal status for girls was determined through the following questions: “If you have started 
menstruating, how old were you when you had your first menstruation?”. Participants were 
given the opportunity to respond in years of age, and more specifically month.  Answers were 
categorised into “Early” (<12,5 years at menarche), “Intermediate” (12,5 – 13,9 years) or 
“Late” (> 14 years) sexual maturation.  
Pubertal maturation in boys was examined according to Pubertal Developmental Scale (PDS). 
The boys rated secondary sexual characteristics as growth spurt, pubic hair growth, and 
changes in voice and facial hair growth on a scale from 1 (have not begun) to 4 (completed). 
We summarized the score and divided by 4. We categorised a score <2 as “have not begun”, 
2-2.9 as “barely started”, 3-3.9 as “underway” and a score of 4 as “completed  [162].  
3.4.4 Other covariates 
We assessed the frequency of alcohol consumption with a scale from 1 to 5: “Never”, “Once 
per month or less”, “2-4 times per month”, “2-3 times per week” and “4 or more times per 
week”. Answers were dichotomized into “no” and “yes”. 
3.5 Clinical interviews 
We assessed ethnicity, the possibility of pregnancy (exclusion criterion for DXA), acute and 
chronic diseases, use of medication and use of hormonal contraceptives through clinical 
interviews. Medication and diseases known to affect bone were dichotomized into yes and no. 
Diseases known to have a detrimental influence on bone are hypothyroidism, diabetes type 1, 
various eating disorders, celiac disease, and arthritis. Medication known to affect bone 
negatively are various types of corticosteroids, thyroid preparations and antiepileptic.  
In girls, hormonal contraceptive use were categorized into “no hormonal contraceptive use”, 
“estrogen and progestin” and progestin only” 
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3.6 Statistical analyses 
In all three papers, analyses were performed sex stratified. Descriptive statistics were 
presented by means and standard deviations for continuous variables and by count and 
percentages for categorical variables. We compared and explored differences between 
participants and non-responders using Students t-test and chi-square testing. We used exact 
measurement dates to compute annual change to account for differences in time between 
measurements.  
Significance level was set to p<0.05 in all analysis and all procedures were performed in 
SPSS. In paper I version 23 was used, paper II version 24 and paper III version 26. In paper II 
figures were made in RStudio (RStudio Team (2016). RStudio: Integrated Development for 
R. RStudio, Inc., Boston, MA URL http://www.rstudio.com/) 
3.6.1 Paper I 
Along with the description of changes in bone mineral levels over 2 years in Norwegian 
adolescents aged 15-17 years at baseline, the hypothesis of paper I were: (1) that participants 
remain in their original aBMD quartile between the ages of 15 and 19 years of age, and (2) 
that baseline predictors of positive deviation from tracking can be detected.  
Differences in anthropometric- and DXA measures between TFF1 and TFF2 were tested 
using paired samples t-test, while dichotomous lifestyle factors were tested with McNemar’s 
test. Mean absolute change (TFF2 - TFF1) and percentage change ((TFF2 − TFF1)/TFF1*100) 
for aBMD and BMC for each skeletal site were calculated. Participants were stratified by age 
(15, 16 and 17 years of age) and one-way ANOVA and multiple comparisons with Bonferroni 
post hoc test were used to examine differences in mean aBMD change between age groups. 
Calculations of individual age and sex-specific height-, weight-, FN-, TH- and TB aBMD and 
BMC z-scores (standard deviations away from the sample specific mean) were used to 
examine correlations between baseline and follow-up using Pearson’s correlation coefficient. 
Partial correlation was applied to adjust for TFF1 height and weight as well as change in 
height and weight. Then we examined the proportions of participants that remained within 




Then, an aBMD z-score change variable were computed (Z2 - Z1). Logistic regression were 
utilized to test whether baseline age, anthropometric traits (height, weight) and lifestyle 
factors (PA, alcohol consumption, smoke- and snuff use) were associated with positive 
deviation from tracking (z-score change > 0). The reference category was no change or 
downwards drift (z-score change ≤ 0). Odds ratios (ORs) with 95% confidence intervals (CI) 
for upwards drift during follow-up were calculated.  
All models were adjusted for age, anthropometric measures, lifestyle variables, sexual 
maturation and time between measurements. The influence of other relevant confounders like 
baseline aBMD z-score, ethnicity, chronic disease and medication known to affect bone 
health bone and hormonal contraceptives use (girls) were explored and purposeful selection 
was used to select final model [163]. Relevant 2-way interactions were explored, identified 
and reported. We fitted models for FN, TH and TB separately, ran logistic regression 
diagnostics and assumptions were met.  
3.6.2 Paper II 
In the second paper the hypotheses were that baseline body weight/BMI and body 
weight/BMI changes over two years were associated with changes in aBMD and BMC 
parameters. Population characteristics were presented by BMI quartiles at baseline and we 
compared BMI quartile groups by using ANOVA with Bonferroni correction and χ2 test. 
Welch’s ANOVA with Games-Howell post-hoc procedure was used if equal variances 
assumption was violated. We computed annual bone- and anthropometric change variables to 
account for differences in time between baseline and follow-up measures in ANOVA 
analysis. To describe and explore crude impact of change in weight status on aBMD 
development, we stratified participants into quartiles of ∆BMI. 
Associations between the exposure variables baseline BW, baseline BMI, ∆ BW and ∆ BMI 
and outcomes FN and TH ∆aBMD and ∆BMC during follow-up were further assessed by 
multiple linear regression analyses using the bone mineral follow-up score as outcome and 
baseline score as a covariate (Y2 = β0+ β1Y1+β2X+…). Initially we conducted explorative 
univariate analysis. We then compared the results using change-score analysis (Y2-Y1= β 
0+β1X) and checking for consistency as baseline adjustments in change-score analysis may 
introduce bias [164, 165]. All adjusted models included anthropometric measures, time 
between measurements, pubertal maturation and perceived physical activity level. Other 
variables previously known to be of clinical importance (ethnicity, alcohol consumption, 
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smoking, snuff use, diagnosis known to affect bone, medication known to affect bone, 
hormonal contraceptives use) were then added as covariates using a backwards elimination 
strategy where p=0.10 were used as cut-off to enter or leave the model. Any covariate with 
p≤0.10 in a final model were included in all final models with the same outcome (∆aBMD or 
∆BMC). Based on this procedure alcohol consumption and diagnosis known to affect bone 
were excluded. We fitted separate models for baseline- and change exposure variables. 
Models with ∆BW were adjusted for ∆height. We checked for confounding and plausible 2-
way interactions related to age, pubertal maturation and initial weight vs. weight change 
relationships. Because of statistical significance (p<0.05) we added interaction terms 
BW*menarche age in FN and BMI*menarche age in aBMD TH models in girls. In boys, a 
significant interaction between ∆BMI*BMI were included in FN models. Interactions were 
further explored and visualized by graphs.  
Normal distribution, linearity, homogeneity and outliers were explored by residual analysis. 
In girls, two outliers were excluded in TH ΔaBMD: one in FN ΔaBMD and one in TH ΔBMC 
models. Furthermore, regression of baseline TB BMC on follow-up TB BMC lead to 
heteroscedasticity in residuals, and weighted least square regression approach were applied all 
TB ΔBMC models in girls. 
3.6.3 Paper III 
The hypothesis of inverse association between the exposure of snuff and smoking and the 
outcomes of change in aBMD between TFF1 and TFF2 in paper III where investigated by 
univariate and multiple linear regression models.  
Population characteristics were presented by use of snuff status at baseline and groups were 
compared by using ANOVA with Bonferroni correction and χ2 test. We used TFF2 score as 
outcome and included the TFF1 score as a covariate to estimate the predictive value of 
exposure on change (Y2 = β0+ β1Y1+β2XSnuff+ β3…). We compared the results of the 
ANCOVA models using change-score analysis (Y2-Y1= β 0+β1Xsnuff) and checking for 
consistency as baseline adjustments in change-score analysis may introduce bias in non-
randomized settings [165]  
Initially we conducted crude univariate models. Then potential confounders were added in the 
following way: “The anthropometric model” comprised the crude model plus age, 
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anthropometric baseline parameters and annual change in body weight and- height. In the full 
model, pubertal maturation and perceived baseline physical activity level were mandatory. In 
addition, variables previously known to be of clinical importance like ethnicity, alcohol 
consumption, smoking, diagnosis known to affect bone, medication known to affect bone and 
hormonal contraceptives use (all baseline measures) were then added as covariates using a 
backwards elimination strategy where p=0.10 were used as cut-off to enter or leave the 
model. All models were adjusted for time between measurements. 
Normal distribution, linearity, homogeneity and outliers were explored by residual analysis. 
One outlier in both girls and boys were excluded. As in paper II, we used weighted least 
square regression approach to correct for the heteroscedastic pattern of residuals in the TB 
∆BMC model in girls.  
3.6.4 Handling missing and multiple imputation 
We collected 688 repeated DXA measures at TFF1 and TFF2 and overall, missing variables 
were limited. However, because of late introduction of questions on sexual maturation (PDS-
score) in TFF1 in boys 53 (17.9 %) participants were missing information on pubertal 
maturation. In all three papers multiple imputation of this variable were conducted to avoid 
losing a substantial proportion of the study sample, as recommended by Sterne [166]. In 
addition, a few missing variables of menarche age (n=7), physical activity (boys= 4, girls=1 
missing) and use of snuff (n=2) were imputed. We assumed missing at random and we 
reported pooled estimates based on 20 repetitions [167]. Only exposures and covariates were 
imputed, not outcome variables. We performed sensitivity analyses and compared pooled 





4.1 Summary of paper I 
The study sample were 358 girls and 296 boys and we measured femoral neck (FN), total hip 
(TH) and total body (TB) aBMD as g/cm² by DXA. aBMD increased significantly (p<0.05) at 
all skeletal sites in both sexes. Mean annual percentage increase for FN, TH and TB was 0.3, 
0.5, 0.8 in girls and 1.5, 1.0 and 2.0 in boys, respectively (p<0.05).  
There was a high degree of tracking of aBMD levels over two years in both sexes at aBMD- 
FN, TH and TB: Pearson’s r = 0.960, 0.966 and 0.967 for girls and 0.937, 0.955 and 0.946 for 
boys, respectively (p<0.001). Age stratified coefficients showed somewhat weaker correlation 
at all sites for 15 year old boys (r=0.853 to 0.884). Overall, 73.0 to 79.6% of participants kept 
a stable position within quartile aBMD z-scores depending on site under consideration. 
In girls, several lifestyle factors like snuff use, alcohol consumption and hormonal 
contraceptives use were associated with lower odds of positive deviation from tracking, 
whereas anthropometric measures appeared influential in boys (p<0.05). Baseline z-score was 
associated with lower odds of upwards drift in both sexes.  
We concluded that our results support previous findings on aBMD accrual in adolescence. 
The fact that age is one of the strongest predictors of change is in indication that PBM has not 
been achieved.  Tracking over two years of follow-up was strong. Baseline anthropometry 
and lifestyle factors appeared to alter tracking, but not consistently across sex and skeletal 
sites. 
4.2 Summary of paper II 
Paper II explored the associations of body weight (BW), body mass index (BMI) and changes 
(∆) in weight status with adolescent bone accumulation in a sample of 651 adolescents, 355 
girls and 296 boys, between 15 and 19 years of age. 
Baseline BW and BMI were positively associated with ∆aBMD over two years of follow-up 
at all skeletal sites in boys, but not in girls (p<0.05). In boys, BW models per SD change in 
exposure adjusted for potential confounders showed following results: FN: β=0.009, p=0.009; 
TH: β=0.009, p=0.002; TB: β=0.006, p=0.005. ∆BW and ∆BMI predicted ∆aBMD and 
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∆BMC in both sexes, with the exception of TB ∆aBMD in girls and the TH ∆aBMD model in 
boys.  
Boys classified as underweight had significantly lower aBMD at baseline and this pattern 
persisted during two years of follow up. There were indications of threshold effects of BMI´s 
positive influence on bone as boys classified to be overweight had the higher mean aBMD 
than those classified as obese at both measurements. 
Individuals who lost weight during follow-up demonstrated a slowed progression of aBMD 
accretion compared to those gaining weight, with statistically significant differences between 
BMI losers and BMI gainers in both ∆aBMD and ∆aBMC crude comparisons. The BMI-
gaining boys had average TH aBMD increments around 1 %, while losers accumulated 
roughly half, and the differences were even clearer in ∆BMC. Loss of BW or reduction of 
BMI during two years was not associated with net loss of aBMD in the study population.  
Although statistically significant, the magnitude of these changes in aBMD during follow‐up 
was moderate and unlikely to have significant clinical implication on peak bone mass for 
adolescents with an adequate BW. 
Our results indicate that underweight adolescent boys may benefit from a BMI increase. 
Particularly underweight individuals losing weight during this critical period of bone 
accretion could be at risk of a less than optimal peak bone mass acquisition, thus not 
achieving their full genetic potential for skeletal mass. 
4.3 Summary of paper III 
The main aim of this study was to explore associations between use of snuff and changes (∆) 
in bone mineral parameters over 2 years in Norwegian adolescents aged 15-17 years at 
baseline. In addition, associations with smoking and double use were investigated. The study 
included the 349 girls and 281 boys that responded on questions on use of snuff and smoking 
at both TFF1 and TFF 2.  
The study compared “non-users” with “users” of snuff, non-smokers with individuals that 




In girls, comparisons of 244 “non-users” and 105 “users” of snuff showed no associations 
between use of snuff and ∆aBMD. In boys, 185 “non-users” and 96 “users” were compared 
and use of snuff was associated with reduced bone accretion in all ∆aBMD models. 
Sensitivity analysis with exclusion of “sometimes” users of snuff strengthened associations at 
femoral sites in girls and attenuated all associations in boys. In boys, adjustments for changes 
in anthropometric measures attenuated the associations between snuff and bone accretion.  
In girls, no associations between ∆aBMD and smoking were found. In boys, only the TB 
∆aBMD were significant, with a beta coefficient of -.011 and a p=.037. Moreover, in girls, 
“double users” was similar to smoking with a significant full model in FN ∆aBMC. In boys, 
nearly all models showed statistically significant differences, except the FN ∆aBMD model. 
The study showed a negative association between use of snuff and ∆aBMD between “non-
users” and “users” of snuff among boys and results indicate that snuff use and combined use 
of snuff and smoking in late adolescence could be detrimental to bone accretion and may be a 




5 Methodology discussion 
5.1 Study design  
The three papers in this thesis are based on data collected on two time points from a 
prospective population-based observational cohort study.  
“a cohort study consists of a sample of individuals in a population followed up over 
time to observe changes in health status, to measure diseases incidence, and to examine 
associations between risk factors and health outcomes” [168]. 
Among the advantages of prospective cohort studies are the possibility of planning and 
implementing all the stages and events of the study from baseline to follow-up to fit the 
studies objectives [169]. Cohort data from prospective studies, if unbiased, reflect the “real 
life” cause-effect temporal sequence of events, and information collected from the same 
respondents sequentially over time is called longitudinal data. A two wave cohort designs is, 
in a strict sense, a longitudinal study. Such studies allow estimation of the amount of change 
in some parameters and measurements within a time interval. Although, studies of change are 
one of the cornerstones of research in health sciences, how to measure and represent change is 
a long-standing topic of debate. Nevertheless, there are serious limitations in the study of 
change with only two time points [170], and some authors even claim such studies do not 
qualify as longitudinal studies [171].  
Two wave designs provide information on temporal order of events and are arguably more 
informative than cross-sectional study designs [171]. Temporality, i.e. the effect occurs after 
the cause, is regarded as the only essential Hill criterion for causality [172]. Two subsequent 
measurements on the same individual can detect within-person change and the major strength 
of this design is information on the amount of change with complete control for all time-
stable confounders within the individual and thus, corresponds to a self-matched design [173]. 
However, as stated above it is argued that studies of change between only two time points do 
not estimate any causal or “longitudinal” effect, and “change on change” association models 
from baseline to follow-up are conceptually not estimating anything different from cross-
sectional studies [173-175]. The only change that could be studied is linear and the question is 
whether it captures the true nature of the change [171]. 
 
33 
Two wave design can be used in certain settings and address questions on average rate of 
change or comparing group means, not subject specific time trends and intra-individual 
change [176]. Exploring bone accretion in late adolescence involves change processes during 
growth and development. Developmental trajectories are continuously moving lines and it 
may be unnatural to explore a “chunk of time” between baseline and follow-up [177]. One 
major limitation with two measurements is that the shape of the trajectory is unknown.  
Time is essential in cohort and follow-up studies and the primary aim is to study the influence 
of age [178]. However, there is a tremendous skeletal heterogeneity in adolescence. The 
timing of puberty and its inter-individual variability is essential in the comparison of change 
between groups [81]. Knowing that most modifiable determinants has their critical time-
frames and is most influential during growth, individuals have to be aligned on biological age 
to compare like with like, e.g. in paper II, menarche age moderated the influence of baseline 
BMI on change in FN aBMD. 
Another vital aspect is to determine the intervals of measurement. The spacing of 
observations should be in correspondence with theoretical model of change [171]. There is a 
considerable sex difference in the rate of change in bone properties and girls had significantly 
less change than the boys had, thus the follow-up time may be considered slightly less 
appropriate for girls given that some of the research questions in this thesis is related to 
prediction of change.  
5.2 Internal validity 
Internal validity refers to what extent results from a study are true, or valid, for the source 
population [168]. In other words, the extent to which observed effects in the dependent 
variable can be attributed to the independent variable [179]. Deviation from the truth may be 
due to random error, bias and/or confounding.  
All measurements are subject to error and consists of two parts: the true score plus some 
error. Errors in epidemiological studies is not necessarily a problem if they are random. The 
best way to handle random error is by increasing the precision of measurements [180]. Large 
sample sizes will, according to the central limit theorem, approach the true parameter value 
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and reduce the impact of random error. Error can also be reduced by duration of study and 
frequency of measurements [181]. 
Bias can be defined as a systematic error in a conduct of a study and poses a threat to validity. 
There are no ways to "control for" bias in analysis stage, thus bias is an issue of study design 
and -planning [169, 182]. Awareness of bias helps researchers and readers to interpret 
findings more accurately. In cohort studies, bias can arise from two main sources. The first 
one is the approach chosen for selecting subjects and the second is the approach adopted for 
collecting or measuring data. These are termed as selection bias and information bias, 
respectively [183]. 
5.2.1 Selection bias and loss to follow-up 
Selection bias in cohort studies occurs when a systematic error in the recruitment or retention 
of exposed or unexposed study subjects results in a tendency towards distorting the measure 
expressing the association between exposure and outcome [169].  
Sampling of the Fit Futures cohort was based on geographic area and school. Although the 
majority of Norwegian adolescents attend upper-secondary school (93.4%) [157], of the 
potential 1301 individuals, 184 (14 %) were missing either because they dropped out of 
school, due of persistent disease or because we were unable to get in contact with them. This 
particular subgroup could differ substantially from the attending participants in various 
important exposure categories concerning lifestyle. Especially, those missed due to persistent 
diseases may have a different distribution of exposure and may well be individuals at higher 
risk of low bone mineral density and osteoporosis later in life. The invited cohort included 
1117 participants and had an attendance rate of 92.9%. Studies show that non-responders are 
socially and biologically different from responders. Generally, non-responders tend to be 
poorer, younger, have lower socio-economic status and come from a less stable family and 
household [184]. Taken together, one of the strengths of the present studies is that the 
recruitment of the participants was population-based. The TFF1 survey collected data from 
more than 80 % of the background population and we consider the chances of selection bias 
due to non-response to be limited, but the possibility should not be totally ruled out.  
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Changes in aBMD and its predictors is the topic of interest in this thesis. Thus, the criterion 
for inclusion in all the three studies was participation in both TFF1 and TFF2. Although 
prospective study designs make selection bias less probable than other designs, cohort studies 
are prone to dropouts [182]. Loss to follow up is a threat to validity if dropout rates differ 
between study groups; or if drop-outs are different from those who do not drop out. A low 
follow-up rate increases both the risk of a type II error when evaluating the outcome and the 
risk of a non-representative cohort [185].  
The distinction between non-responders and loss to follow-up is that information about 
dropout attributes is available for comparisons with the initial study population. In our 
studies, a large proportion of dropouts were boys. Not counting participants above 17 years of 
age at baseline, 111 girls and 196 boys were lost to follow-up. Among girls, TFF2 dropouts 
(<17 years of age at baseline) had statistically significant higher BMI than responders. This 
could indicate that our study population in paper II had a slightly different body composition 
compared to the reference population. Previous studies have shown associations between 
BMI and bone mineral density. Since BMI is positively associated with BMD, an 
underestimation of the association would be expected.  
Dropouts had significantly higher prevalence of daily smoking, snuff use and alcohol 
consumption (girls only) as well. The differences in use of tobacco among both girls and boys 
may also have influenced results in paper III. A higher proportion of smokers and users of 
snuff in background population will lead to an underestimation of the associations in the 
study population. 
There are numerous reasons for loss of follow-up: difficulties locating participants, migration, 
relocation, change of school and refusals to further participation [184]. It is well recognized 
that healthier people and those who are more concerned about their health condition are more 
motivated, and likely, to participate in epidemiological and clinical surveys [186]. The best 
way to eliminate the impact of bias to loss to follow-up is to keep losses to an absolute 
minimum [187]. A great deal of efforts were put into retaining TFF1 participants, e.g. free 
transport for relocated individuals to TFF2, even by plane if necessary. Studies with less than 
70 - 80 % follow-up should be viewed cautiously and with skepticism regarding this kind of 
bias [180]. Given that TFF2 includes only 66 % of the original baseline cohort, we ought to 
be aware of the possibility that follow-up loss could correlate with both exposure and 
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outcome. Studies indicate that loss to follow-up not necessarily cause bias and undermine 
study results. Minimizing loss, however, increases the precision of the estimates [168, 188, 
189]. The high attendance at baseline gave the opportunity to compare the study population 
with a relatively representative background population. Nevertheless, the possibility of our 
study sample being a healthy subpopulation remains. 
5.2.2 Information bias and misclassification 
Information bias refers to systematic errors in the information collected from the study 
participants. Measurement error and poor quality and accuracy of information carries a risk of 
information bias [168]. A main source of bias in cohort studies relies on the degree of 
accuracy in which participants are classified with respect of exposure status [187]. 
Misclassification of exposure status might be a source of information bias and occurs when 
participants are classified into an incorrect category. The misclassification can be non-
differential or differential. Non-differential misclassification occurs when the probability of 
being misclassified into categories of any variable is the same for all study participants, while 
differential misclassification occurs when the probability is different across groups of the 
study participant. Particularly differential misclassification is a concern in research as it may 
distort effect estimates in both directions, while non-differential misclassification usually 
leads to an attenuation of association between exposure and outcome [186].  
In TFF, a major part of lifestyle variables was collected using computer based self-
administered questionnaires. Subjective assessments and questionnaires may obtain 
inaccurate and insufficient information about lifestyle and other determinants of change in 
bone mineral density. The questionnaire contained some questions on previous behavior (e.g. 
average during last year) and such information are prone recall bias. Participants may give 
incorrect information, consciously or not. They could also be putting low effort into 
interpreting and answering questions adequately and might avoid extreme values or 
exaggerate answers for different reasons [169]. 
Item non-response refers to missing answers to questions or incomplete examinations [168]. 
The TFF questionnaires were relatively large which may lead participants not to respond to all 
questions with the same awareness. During the “TFF-day” at the hospital, participants were 
given time to answer the questionnaire between clinical examinations and various 
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measurements to minimize this kind of bias. Item non-response were otherwise handled by 
multiple imputation approach in the analysis process (see 5.2.8) 
5.2.3 Validity of use of tobacco assessment 
When asking sensitive questions on habits like use of snuff and smoking there is a risk of 
social desirability bias and under-reporting. However, some studies indicate that self-reported 
smoking is fairly valid in adolescence [190], and the relatively wide (and increasing) scale of 
snuff use among adolescents may have made this behavior more socially acceptable. Prior to, 
and during the TFF surveys confidentiality was stressed and no names were attached to the 
questionnaires, which could contribute to truthful reporting.  
There are challenges, however, regarding quantifying and setting the thresholds for tobacco 
exposures and the questions used in TFF on tobacco use are not validated with respect to an 
adolescent population. Adolescence is a time of change and experimentation, and as discussed 
in paper III, responses on use of snuff were unstable, and responses were not always coherent. 
A lot of “sometimes” users of snuff at TFF1 ended up in the daily category in TFF2 and it is a 
challenge to interpret individuals responding “sometimes” use of snuff at TFF1 and “No, 
never” two years later at TFF2. These are indications that the two responses two years apart 
may have shortcomings in determining exposure and the probability of misclassification is 
present. Participants in the “sometimes” reporting “one or less” portion of snuff a week could 
approach the “never-users” group and the “more than 10” portions weekly may exceed “daily-
users” in exposure. An observed clear tendency of increased frequency in portions used a 
week in the baseline “sometimes” group during follow-up may have influenced the degree of 
accuracy in which the participants have been classified with respect to their exposure status.  
We consider the possibility of differential misclassification between “non-users” and “users” 
of snuff to be negligible. However, the possibility of participants denying use of snuff or 
smoking, for some reason, cannot be ruled out. In such cases the associations in paper III 
would be underestimated. The likelihood of misclassification increases between “sometimes” 




5.2.4 Validity of body weight and BMI 
Clinical anthropometric measurements have generally high validity, but it relies on 
standardized training, standard operating procedures, robust equipment and measurement 
resampling [191]. One of the strengths of the TFF studies were that clinical data e.g. 
anthropometric data were measured directly by research technicians according to standard 
protocol.  
However, biological variability is an inherent part of nature and natural variations can be 
misinterpreted as associations. The rate of change in physiological processes may fluctuate 
due to many factors (e.g time), and the variance may be high because of biological factors. In 
paper II, body weight may vary during different seasons, as the follow-up time varied from 
1.50 and 2.67 years. Nevertheless, we consider such variation to random and the risk of bias 
in body weight, height and BMI to be negligible. 
5.2.5 Validity of physical activity assessment 
Physical activity is regarded as a confounding factor1 in all three papers. The four‐level 
questionnaire used to assess physical activity, was initially introduced by Saltin and Grimby 
in 1968. The questionnaire is widely used to assess physical activity in population-based 
studies, especially in the Nordic counties. Since the beginning, it has been used by more than 
600 000 subjects. Over the course of years, minor modifications have been made, such as 
changing practical examples of activities to illustrate the levels of physical activity. The 
modernized Saltin-Grimby Physical Activity Level Scale (SGPALS) was validated in the 
adult population, and recommended as a useful tool for routine risk assessment [192, 193]. 
The questionnaire is validated in the Tromsø Study as well [194]. Self-reported physical 
activity have some disadvantages though, and tends to be over-reported, due to “desirable” 
reporting and this may be exaggerated by the fact that TFF were advertised as a "health 
survey" [195, 196]. Furthermore, participants were asked to give an average for the last year 
and questions about the past are prone to recall bias. Taken together, several studies show that 
                                                 
1 See 5.2.11 for definition 
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questionnaires yield reasonably valid measures for epidemiological research [197, 198] and 
we believe the assessment of the physical activity levels of the TFF participant to be valid.  
5.2.6 Validity of pubertal maturation status 
The influence of puberty on the skeleton must be considered when evaluating change in 
aBMD [103]. Pubertal stages are closely linked to linear growth and bone accrual, thus the 
precision of pubertal maturation estimation is a key to the validity of the inferences made in 
all three studies. In the analysis process, stratification of girls and boys were used to deal with 
the maturational gender differences. 
Tanner staging from physical examination is regarded as the gold standard for assessment of 
pubertal maturation [199]. Due to feasibility issues, this approach was not included during 
planning of TFF study. Pubertal status was self-reported by the participants in TFF, which 
may induce some bias. Questions on menarche age and secondary sexual characteristics may 
be a sensitive subject and therefore answered inaccurately or not at all. However, the 
proportion of missing puberty data in girls was three percent, this is not notably higher than 
other lifestyle variables (2%), and we consider these to be missing at random. 
Menarche is a hallmark female maturational event and the age of onset is used as a proxy for 
sexual maturation in girls. The question of year and month of menarche age has good recall 
accuracy [200]. 
In boys, the PDS-score was utilized as maturation assessment. This questionnaire has shown 
to be a non-invasive alternative to Tanner stages, although its precision has been questioned. 
Previous studies have compared physical examination to self-report and the results are 
diverse. Two studies among Chinese and Canadian adolescents boys found the agreement to 
be strong, with a Cohen’s kappa coefficient between 0.58 and 0.80, while one study with 
black, multiethnic South African youth concluded with a low to fair agreement of 0.26 in 
boys [201]. The late introduction of the PDS item in the TFF1 survey resulted in 23 % 
missing values in boys. This is considered as a limitation in our studies, even though multiple 
imputation techniques were applied. 
Self-reported PDS-score may be used when precise agreement is unnecessary [202]. In paper 
III, additional adjustments for changes in height and weight were necessary, since it turned 
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out to be a major confounder in the use of snuff and bone accretion relationship, indicating 
that PDS-score may be too rough an estimate of maturation in studies during growth.  
5.2.7 Validity of other covariates 
Alcohol consumption and contraceptives use are prone to recall bias and underreporting in 
line with tobacco, as discussed above. A limited number of trained study nurses conducted the 
clinical interviews and we consider the information on medication and diseases that could 
affect bone to be valid.  
5.2.8 Validity of multiple imputation 
Multiple imputation is an approach to deal the problem of missing data and item non-
response. Valid inferences after this technique are obtained because the approach are 
averaging over the distribution of the missing data given the observed data [166]. “The 
imputation procedure must fully account for all uncertainty in predicting the missing values 
by injecting appropriate variability into the multiple imputed values; we can never know the 
true values of the missing data” [166]. The predictive distribution of the observed data is used 
to sample the imputed values. Outcome variables, exposure of interest and covariates in the 
full model were used in the prediction. First, multiple copies of the dataset were created 
where the missing data are replaced by imputed values. The number of copies varies with the 
degree of missing information and tolerance of power falloff, and in our study 20 imputations 
seemed sufficient [167]. Next, models were fitted for the 20 imputed datasets. Estimations 
varied within each dataset because of the variation introduced by the imputed values and we 
reported the pooled values of these estimated associations. 
5.2.9 Validity of DXA measurements 
Generally, DXA scans has excellent precision and are considered to be one of the most 
precise methods of measuring bone mineral density and the reproducibility is far better for 
aBMD scans than for most laboratory tests [203]. However, aBMD measures are 
accompanied with measurement error and any interpretation of change requires knowledge of 
measurement precision [204]. Repeated measurement of the same subject will vary around the 
true value because of measurement error. This could be because of natural variation within 
the individual or variation in the measurement process, or both [205]. With only two repeated 
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measurements there is a modest, but basic, concern to estimate true change of aBMD based 
on observed change with proper regard for reliability of the measurement [176]. 
DXA measures are affected by both precision and accuracy errors. Accuracy refers to whether 
the measured value reflects the true (or actual) value of the object measured. The typical 
accuracy error of a DXA scan is 3-9 % depending on measured site [206]. This is below the 
WHO ten percent criteria for diagnostic tests. These accuracy errors are mainly random errors 
caused by heterogeneous lean-, and fat mass distribution [207].  
In a baseline to follow-up study trying to detect small percentages of bone mineral gain, 
precision is the major concern in order to separate random error from true biological change. 
The latter is only detectable on an individual level if change over time exceeds measurement 
error. In the present thesis, this applies particularly for the girls. Paper I revealed gender 
differences in accretion in late adolescence. Girls seemed to approach the end of longitudinal 
growth, while the boys had not reached their final stature. PBM is not reached at the cessation 
of longitudinal growth, but the bone accumulation will naturally slow down.  
To keep errors to a minimum, we used the same instrument and software at baseline and 
follow-up and followed the manufacturer’s algorithm for calibration as current 
recommendations for longitudinal scans by ISCD. Precision depends on quality assurance of 
the performance of the DXA instrument. Phantom scans were performed each morning 
throughout both surveys and no drift were detected. Another requirement is exact 
repositioning of subjects and introduction of most errors are due to operators and subjects’ 
variability rather than machine performance. [208]. Trained professional staff followed a rigid 
protocol with rigorous attention to detail in positioning. However, because of the high number 
of participants in the study, different technicians operated the DXA from day to day, which 
could influence precision, however these errors were most likely random. The participants 
were asked to remove any jewelry, wear light clothing without zippers or metal closures. 
Subsequently, images were re-analyzed in a scan-quality control. Artifacts, metal objects and 
errors in the automatic image analysis were eliminated if necessary. 
Even if measures were taken to keep errors to a minimum, interpretation of the results of the 
papers in this thesis must take into consideration the precision of the DXA measurements. 
The aBMD values of an individual must change 2.77 times the coefficient of variation of the 
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instrument for real change detection [209]. No exclusive precision study was conducted prior 
to the TFF survey, but the densitometer CV ([SD/mean] x 100) has in a previous study been 
estimated to 1.14 % at the total hip and 1.72 % at FN measured in vivo [210], which is in 
accordance with reports from other devices [28]. These CVs were elicited from an adult 
sample, and there are reports of more favorable variability when measuring young healthy 
subjects [211]. This may be partly because of easier positioning [212]. The CVs gives a least 
significant change for the TH =3.157% and the FN =4.764%. Thus, the significance of the 
observed changes at an individual level is debatable. Nevertheless, the measurement errors are 
assumed to be random with a net effect of zero and the reproducibility of BMD measurement 
by DXA expressed by different means is good at a group level [203]. Our sample size is 
relatively large, we see clear consistent patterns of change, findings are consistent with 
previous research and by epidemiologic standards, bias produced by measurement error is 
relatively minor due to the high precision of DXA scans [181].  
The major limitation of DXA-scans are that it is a two-dimensional projection image and it is 
affected by bone size. To handle the size-related artifact, all analysis were conducted sex 
stratified and all statistical models were controlled for height or change in height, if 
appropriate. These adjustments served to identify changes in bone traits that are independent 
of changes in stature. The relation between aBMD and true volumetric density is non-linear. 
Paradoxically, this error can improve the value of BMD as a predictor of fracture risk, since 
bone size is also a determinant of skeletal strength [40].  
The second limitation is that the body consists of 3 types of tissues bone, lean and fat even 
though DXA is only able to distinguish between two different materials [206]. Shape, body 
habitus and changes in body composition may affect DXA measurements. The impact of 
thickness of body tissue overlaying the measured area could be a concern in longitudinal 
studies of the influence and changes of body weight [213]. However, this implies especially 
to lateral scans not performed in this study [214, 215].  Yu et al. found that changes less than 
6 kg fat layering did not affected DXA results [216]. In paper II roughly 30 % of the 
participants gained or lost > 6 kg between measurements. It is worth noting that if an 
individual changes > 6 kg the amount of fat layering lost or gained in a single skeletal site 
would be less, and the risk of bias in this study population is minimal. 
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5.2.10  Statistical modelling 
Different variations of change from baseline also known as “delta”, “difference scores” and 
“gain scores”, were utilized in all three papers. Change-score is an elementary measure and a 
summary of the observed within-individual change in the response [217]. However, the issue 
of comparing the amount of change between two time points in non-randomized contexts is 
complex and decision making on available statistical approaches is challenging [218]. There 
have been great controversies on the use of such methods. Numerous caveats have been 
identified and described: unreliability [219], ANCOVA vs change from baseline in non-
randomized studies [165, 170, 220], mathematical coupling [221],  regression to the mean 
(RTM) [222], Lords Paradox [223, 224] and baseline adjustments [225].  
However, change-scores is widely used, especially in the field of psychology and the 
approach has its supporters [173, 176, 226, 227]. Early reliability concerns about change-
scores are no longer seen as obstacles and research has shown that these concerns tend to 
apply to unusual situations and that change-scores can be reliable in many typical research 
settings [220]. 
There are several statistical methods of comparing groups concerning change, but change-
scores and analysis of covariance (ANCOVA) are frequently used. The simplicity of 
change-scores is one of its advantages. It is intuitive and easy to understand [170]. An 
outcome score obtained by subtracting initial value from follow-up measure for each 
individual (Y2-Y1) = β0 +β1XExposure+ β2XCovatiate. Where Y is the dependent and X’s are the 
independent variables. When calculating a change-score participants are essentially used as 
their own control. However, change-scores do not differentiate between participants high and 
low initial values at baseline [228]. 
One of the problems inherent in repeated data is that they are correlated by design [229]. 
Measures of aBMD within subjects at baseline and follow-up are naturally correlated, and this 
violates assumptions of independent data in some statistical approaches, like regression 
analyses (if tempted to analyze all individual relationships at both time points at once). 
Simplification of the statistic to a single number for each subject by taking the difference of 
two time points avoids dealing with the longitudinal correlation. Criticism of this approach 
points out that this reduces the dimensions of the data [230].  
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ANCOVA was used in papers II and III and is a special case of a general linear model and 
adjusts each subject’s follow-up measurement according to his or her baseline measurement. 
The approach is sometimes referred to as a model of residualized change, offers high 
statistical power and can be summarized using the equation: Y2 = β0+ β1Y1+β2XExposure+ 
β3XCovatiate…  [222]. The main interest is in the potential influence of some grouping variable 
on a bone parameter at TFF2, but we want to make sure to include the initial value at TFF1 in 
the model to control for baseline levels. Change-scores and ANCOVA asks different 
questions. Change-score asks which group changes most, while ANCOVA answers a 
conditional question: “If the groups had come from a population with the same baseline level, 
which would have increased or decreased more?” [218, 225]. One approach estimates the 
total effect (of exposure on bone accrual) while the other estimates the direct effect, adjusting 
for the initial bone trait level [231]. 
An alternative approach is ANCOVA with difference scores: (Y2-Y1) = β0+ 
β1Y1+β2XExposure+ β3XCovatiate. This model includes the change-score as the dependent 
variable and baseline measurement as an independent variable. If baseline measures have to 
be taken into account anyway and added as a predictor in the equation, it makes no essential 
difference whether the outcome is the change- or follow-up score because the results will be 
identical due to basic algebra [220]. However, ANCOVA with follow-up score were preferred 
in paper II because the residual plots using ANCOVA with difference scores turned out 
heteroscedastic in most models. The ANCOVA with difference scores approach was 
indirectly used in the logistic regression models paper I as positive or negative deviation from 
tracking were based on the follow-up z-scores minus baseline z-scores and then adjusted for 
initial z-scores.  
Regressing the change-score on initial measure have some inherent bias [205]. Two 
methodological concerns have been raised, mathematical coupling and regression to the 
mean (RTM). Mathematical coupling occurs when a variable contains the whole or parts of 
another and then analyzed by regression or correlation. The error term of the baseline measure 
occurs on both sides of the equation making the test of the relationship between initial and 
change-score biased. The relationship tend to be negative and consequently, the statistical 
procedure of testing the null hypothesis might then no longer be appropriate and the results 
must be interpreted with caution [232].  
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RTM is a statistical phenomenon caused by random error of measurement and/or to 
physiological variation that can complicate group comparisons [188]. It occurs with any 
repeated measurement that fluctuates within an individual or a population. Individuals with 
scores far from the mean value of the distribution (extreme measures) in TFF1 will tend to be 
closer to the average value on second measurements in TFF2. Baseline values are negatively 
associated with change-score because the low value at baseline will get a higher follow-up 
score and higher baseline value will be closer to the mean at the follow up measurement. 
RTM a common phenomenon because error free measurements is rare [222]. 
It is in scenarios where the correlations between Y1 and Y2 is low the effects of both 
mathematical coupling and regression to the mean is greatest [233]. When assessing the 
degree of tracking in paper I we showed that the correlations between baseline and follow- up 
bone traits were high (r=0.93-0.96), so the impact of these statistical phenomenons should be 
recognized, but not considered critical to the studies´ validity. 
The rationale behind taking into account the starting situation in studies of change is debated. 
In studies of growth and development it is not always apparent when the trajectory starts and 
the definition of exposure itself may be unclear [234, 235]. Baseline may not even be the 
appropriate term in TFF because there is only one measurement. In paper II, there is an issue 
of temporal order of events. The baseline differences in bone outcomes according to body 
weight and BMI categories were apparent. Looking at the hypothesized causal relationship, 
the baseline bone mineral status may be considered as a mediator between body weight (and 
BMI) and final bone mineral status. This may be explained by of the substantial impact of 
body weight (and size) on bone accrual early in life and especially in puberty [236], and as 
expected, body height and -weight had already influenced our participants skeletons. 
Baseline adjustments in observational studies comparing preexisting or naturally occurring 
groups may inflate the regression coefficients and make change-score and ANCOVA 
approaches reach contradictory conclusions – a bias known as “Lord’s Paradox”. The main 
concern is that this mediation could produce bias when baseline outcome parameters are 
included in ANCOVA models. If baseline outcome and exposure of interest are strongly 
associated, biases induced by baseline adjustment can be quite large [164]. In paper II, this 
applies especially to the TB BMC and body weight/BMI models as the total content of 
minerals in a skeleton is closely related to the size of an individual.  
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Randomization is not present in cohort studies and there is no reason to expect that the 
baseline means for the study groups should be equal. That concerns both measured and 
unmeasured exposures. However, the major consideration in change-score analysis is baseline 
differences in the predictor of interest [165]. Lords paradox is especially common in fields 
were designed experiments and trials are not possible, e.g. to randomly assign adolescents 
that takes recreational drugs is not possible.  
In paper III the relationships and the initial bone scores between comparison groups were 
slightly different. The mean onset of snuff were around just above 14 years of age and bone 
outcomes were relatively equal at baseline, maybe because the hypothesized influence of 
snuff had not been established.  
Ideally, ANCOVA should be used to partial out variance of covariates that have a high 
correlation with the outcome variable and no relationship to exposition [225]. If this approach 
is used, it is essential to note that measurement error always produces under-adjustment, 
which could results in a directional bias. The rule governing this bias is that “consistent” 
differences is magnified. I.e. groups with the higher baseline increasing more or groups with 
the lower baseline decreasing more. On the other hand ANCOVA also masks ‘inconsistent’ 
differences [225]. The rate of type 1 errors increases with both measurement error and 
baseline differences [225]. In paper II, a significant baseline difference were observed and 
this directional bias has to be considered when concluding that baseline body weight is 
positively associated with change in body weight. We handled this dilemma according to 
advice by van Breukelen [165], compared the results from the two approaches, and advocated 
caution in the interpretation of result with discrepancies.  
Each approach has its strengths and limitations and the decision on which one to use depends 
on what assumptions you want to make. Assumption of change-score is that change is 
independent of group, (i.e in a RCT the “never-users” group will not change). The 
assumptions of ANCOVA is that change is a linear function of the baseline and that this holds 
for all subjects in the group. If the study sample comes from one population, the model 
considers it unusual to have group differences at baseline and expects both groups to regress 
to the mean. If the group means stay equal across time this may be considered as an “effect” 
in the model. Change-scores and t-test does not make this assumption. However, these 
assumptions are untestable in an observational study [165].  
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In a wider perspective, it is open to discussion which approach gives the correct “real life” 
answer. It would be expected that skeletal changes are greater in larger individuals than in 
smaller ones and when assuming equal baseline levels, "…then the adjustment is comparing 
entities that not only do not exist, but (probably) cannot exist" [237]. 
To sum up, some assumptions of these models may lack theoretical justification [238]. Two-
wave change-score analysis is not exactly wrong, but it is not quite right either. More 
suboptimal, as stated by Norman & Streiner [239]. However, both cross-sectional studies and 
longitudinal studies are prone to the same fallibility in potential errors [240] and change-score 
could be considered as an unbiased measure of change (a process) between two separate 
status measures (not a process) [241]. The inherent problems in repeated data and their 
relationship with random and measurement error makes it crucial to maximize reliability at 
both baseline and follow-up to make the change-score valid [228]. It is not always about 
reliability of change-scores, but also whether they are more reliable than viable alternatives 
[242]. 
5.2.11 Confounding and interaction 
In cohort studies, confounding is a threat to the internal validity and can be described as: "...a 
situation in which a non-causal association between a given exposure and an outcome is 
observed as a result of the influence of a third variable (or group of variables)" [169, p. 153]. 
The confounder must be causally associated with outcome and non-causally or causally 
associated with exposure. The variable should not be in the causal pathway between exposure 
and outcome, and must be unequally distributed between comparison groups to have an 
impact on the association [168]. 
Analysis of associations relies on the assumption that outcome will be different if the same 
individuals are exposed or not. Individuals in a population cannot be exposed and unexposed 
at the same time. The solution to this problem often referred to as the counterfactual model, 
where a substitute population is used as a comparison group. This introduces confounding and 
the principle of comparing like-with-like in relation to confounding is vital [168]. 
Existing knowledge and previous research on skeletal and bone health are important to 
identify and choose possible confounders, and to avoid data-driven models. There are 
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different strategies to control for confounding. We primarily used restriction, stratification 
and statistical modeling to cope with confounding. We used a restriction of age less than 18 
years, with the disadvantage of a smaller sample size [180]. All analyses in this thesis are 
done sex stratified because of the known biological differences of bone development between 
boys and girls in adolescence. Adjustments through statistical models will reduce the 
probability of confounding. However, the probability of residual confounding is present.  
The measurements in TFF do not cover all differences in compared groups. Imprecision- or 
lack of measurements leads to residual confounding and candidates for potential unmeasured 
confounders in this study is calcium intake, vitamin D and hormonal factors. Nutritional data 
in TFF has been criticized for being incomplete. This is a concern when it is likely that 
nutrition is a part of the causal network and is considered an important determinant of peak 
bone mass. However, validated nutritional data were not prioritized because it would occupy 
a large proportion of the selected questionnaires and would be time consuming to answer for 
the participants.  
Another matter is the choice of baseline vs. change in exposure variables. In paper II change 
in body weight and BMI were investigated. Changes in anthropometry is closely linked to 
bone. The main problem is the lack of information on when the changes took place. The age 
group represented by TFF1 (15 to17 years of age) dropout from organized sports is 
conceivable. Changes in physical activity during follow-up, e.g. resigning from participation 
in hard training or sports competitions right after TFF1 survey would potentially have an 
influence, even if the parameter is only a covariate. 
Interactions (or association modifying) are a major concern in the multiple linear regression 
analysis process and may, if not dealt with appropriately, lead to erroneous interpretations. 
Statistical interaction arises when considering the relationships among three or more 
variables, and the association between outcome and one exposure is moderated depending on 
levels of a second exposure [169]. The strategy of detecting interactions in our studies were 
based on a combination of a priori knowledge and statistical significance, and the risk of 
undetected (clinically interesting) interactions cannot be ruled out. In paper I, age moderated 
the influence of body weight on deviation from tracking, but this interaction attenuated when 
associations between body weight and absolute change in aBMD where explored in paper II. 
On the other hand, a statistically significant interaction between baseline body weight and 
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change in body weight were explored. In addition, menarche age moderated the relationship 
between BMI and change in aBMD. In paper III, age*double use and age*snuff interactions 
in the ∆aBMD TB models were identified and reported in girls and boys, respectively.  
5.3 External validity 
External validity refers to generalizability outside and beyond the source population, i.e. other 
youth populations. To what extent observed associations can be applied to other populations 
relies a great deal on the internal validity of a study. Generalizability depends on similarity in 
characteristics between the study population and the population you want to compare with. 
[180].  
Characteristics of the study participants in the three papers showed similarities compared to 
those in other Norwegian studies, e.g. the Young- HUNT study from middle parts of Norway 
and Bergen Growth Study from the western parts of the country. However, the prevalence of 
overweight and obesity among children and adolescents have been slightly higher in Northern 
parts of Norway than in other comparable cohorts [243] [244] [245]. The physical activity 
levels were also a bit higher in TFF than reported from the Young- HUNT cohort [246]. 
Associations between body weight, physical activity and bone traits indicate that there may be 
regional differences in aBMD in Norway and the results may not be valid for all Norwegian 
adolescents. The prevalence of smokers and users of snuff in TFF is similar to reports from 
the Norwegian Health Institute and Northern Norway is comparable with other regions in 
Norway [144].  
The TFF study sample is a convenience sample. The general criticism of such samples is that 
it may not be representative of the entire population. However, school sampling may be 
representative of certain age groups [168]. Most Norwegian adolescents attend upper 
secondary school and the attendance rate were high at TFF1. Nevertheless, loss to follow-up 
(~39 %) and the high proportion of white ethnicity complicates extrapolations to the entire 
Norwegian youth population. Furthermore, reservations must be made because the study 
population is from two municipalities of Northern Norway and differences in topography, 
exposure to sun etc. may influence the generalizability.  
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The physiological aspects of paper II and paper III may be more applicable to other 
populations. The biological mechanisms behind the influence of body weight and tobacco on 
bone are likely to apply for other populations as well. To sum up, caution of generalizing is 
advised, but we consider the TFF cohort to be fairly representable for Norwegian adolescents 




6 Result discussion 
In this thesis, we have explored how lifestyle influence bone accretion in a Norwegian 
population in late adolescence. The follow-up design with two measurement points gives a 
sequential order of event, but all results in this thesis derives from models that are used to 
show statistical associations, not to infer causation [173]. Nevertheless, the discussion of main 
findings will be based on some of the guidelines Bradford Hills proposed as aid for the 
researcher to judge to what extent a causal interpretation is reasonable when a statistical 
association is found in an epidemiological study [247].  Issues like consistency of results i.e., 
previous research, temporality, strength of relationships, biological plausibility of results and 
biological gradient/dose-response will be discussed if suitable. The influence of lifestyle 
factors on changes in aBMD and BMC links the three papers together. Body weight, BMI, 
∆body weight, ∆BMI, use of snuff and smoking figures as both exposure of interest and/or 
covariates in this thesis. If appropriate, associations were controlled for potential confounders 
like physical activity, alcohol consumption and contraceptives use (girls). The discussion of 
results is organized according to the aims of the three papers: Description of change in bone 
traits, degree of tracking during two years of follow-up, influence of body weight/BMI and 
influence of use of snuff and smoking on bone accretion. 
6.1 Change in aBMD and BMC during two years in late adolescence 
In order to explore determinants of change bone traits in the TFF cohort we first had to 
establish that change occurred during follow-up, and to what degree. Paper I was mainly 
descriptive and aimed to capture the dynamics of bone traits in late adolescence. aBMD 
increased significantly (p < 0.05) at all skeletal sites in both sexes, however changes were 
approximately double in boys compared to girls, e.g. ~4 % vs. 1.6 % in TB during two years 
of follow-up. Based on the ~2 year difference in maturation, and prior research, girls were 
expected to approach PBM at femoral sites and mean changes over two years at the FN were 
down to 0.6 % compared to 3 % among boys. The bone accrual rate had an inverse 
relationship with age and the rate decreased consistently at all skeletal sites, in both sexes, but 
boys did not appear to be approaching cessation of longitudinal growth to the same degree as 
the girls did. As mentioned before, the intra-individual variability is not likely to be detect in 
two-wave studies, but by comparing the accretion at femoral sites in girls at different 
chronological ages, there were indications of accretion levelling off and reaching a plateau in 
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the oldest subgroups. However, the sample size became limited when stratifying by age, 
reflected by the wide confidence intervals.  
A surprise finding in this paper was the decrease in FN aBMD for girls between 17 and 19 
years of age. However, Berger et al. reported similar findings with an average decrease of 
aBMD in girls around 20 years of age until stabilization and consolidation. Disentangling this 
result by exploring BMC and BA showed that BA increased while the BMC measurement 
had stabilized, which is in line with the notion that adolescent skeletal growth is not 
necessarily density, but mostly due increased bone size [84]. Furthermore, Bachrach et al. 
reported cessation of accumulation even earlier than our findings. In girls, gains in aBMD 
leveled off in total hip, spine, and whole body already at the age of 14.1, 15.7, and 16.4, 
respectively. Boys tended to reach plateau at the age of 15.7 in total hip and 17.7 in spine and 
whole body [248]. However, the observed decrease in our study may also be a chance finding 
due to low sample size or measurement error. 
If PBM is a major determinant of future risk of osteoporosis and fractures, the timing of PBM 
is of importance because it provides knowledge of when the “window of opportunity” is open, 
and when it is about to close. There have been some controversy around the timing of PBM 
due to differences in statistical approaches and parameter used, but longitudinal studies with 
appropriate maturational data seems to have brought consensus to the matter of age estimation 
and the sex-, ethnicity- and skeletal variations that exist. PBM is site specific and femoral 
sites reaches its peak at 16 to 19 years of age, while the lumbar spine aBMD peaks more than 
a decade later, between 33 and 40 years of age [10, 248, 249]. Studies with repeated measures 
are preferred in description of PBM because they capture the process of bone accretion. The 
fact that age was a strong predictor of change in aBMD for both girls and boys in this study 
population indicate that PBM is not yet reached.  
6.2 Tracking of bone mineral density 
One of the hypothesis behind the concept of PBM is that individuals with low PBM could 
suffer high fracture risk later in life [85]. However, high PBM counteracts age-related 
inevitable bone loss only if bone trajectories tracks throughout life. We found a high degree of 
tracking using study sample based z-scores. Pearson’s correlation coefficient between TFF1 
and TFF2 aBMD FN, TH, and TB, were 0.960, 0.966, and 0.967 for girls and 0.937, 0.955, 
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and 0.946 for boys, respectively. We detected some changes in the rank order within the 
distribution, but with the relatively short follow-up time of two years, extensive drift between 
quartiles was not expected. Stratification by age showed that the correlation were lowest 
among the youngest participants. 
Several studies have explored tracking with various ages and follow-up time, and most of 
them confirm that bone mineral levels track strongly with a correlation coefficient between 
0.5 and 0.9 [93-95, 250]. Follow-up during peak height velocity is expected to show reduced 
correlation, and lower correlations in younger children than in older have been reported [93]. 
In our cohort, aBMD tracking for boys became successively stronger as annual height change 
reduced gradually between 15 and 17 years of age at baseline, indicating this link between 
statural growth and aBMD tracking. 
There is, however, a paucity in tracking data from adolescence into adulthood and there are 
several well-controlled clinical studies that indicate that acquisition of a high PBM during 
childhood and adolescence will have only transient effects, and advantages will diminish if 
osteogenic determinants (e.g. physical activity) are not sustained [12, 97]. Taking into 
consideration the understanding of the skeleton as a homeostatic that is constantly sculpting 
bone through adaptive processes to meet the mechanical requirements (as elaborated above), 
this transient effect is plausible. On the other hand, there is indications of geometric and 
structural changes accompanying bone accrual, e.g. the racquet arm of tennis players, which 
has a sustained impact on bone strength [77].  
The key issue seems to be “tracking throughout life”. Osteoporosis has been called a pediatric 
disease with geriatric consequences because of its complex and life-course perspective 
etiology [251]. The hypothesized cause of inadequate PBM and supposed effect of increased 
fracture risk is virtually a lifetime apart, and the feasibility of lifelong longitudinal studies is 
low.  
Some tracking studies have also looked at factors that predict deviation from tracking. We 
found that baseline aBMD z-score was the only consistent predictor of deviation from 
tracking in both girls and boys. Among boys, baseline body weight tended to be associated 
with upwards drift in aBMD z-score at femoral sites. Among girls, lifestyle factors such as 
physical activity snuff use and consumption of alcohol appeared important, but not 
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persistently across skeletal sites. The lack of consistency related to skeletal sites and sex is a 
concern related to the validity of our findings and calls for further investigation and 
clarification.  
The use of z-scores and deviation from tracking (paper I) provides a slightly different 
perspective than exploring absolute numbers of bone accrual (paper II and III). The deviation 
from tracking shows how accrual changes in relation to the study population distribution as a 
whole, and if various strong determinants (e.g. physical activity, use of snuff or smoking) also 
tracks during follow-up, no deviation from tracking would be expected because we only 
adjusted for baseline parameters. 
6.3 Association between body weight/BMI and change in BMD/BMC 
After investigating and describing change in bone traits over two years in paper I, the natural 
next step was to explore factors that predict this change. Obesity and overweight in childhood 
and adolescents are a growing concern worldwide with rising prevalence during the past 
decades worldwide [107] and in Norway [106]. In the present study, more than one of five 
adolescents were classified as overweight or obese at baseline and the prevalence increased 
during follow-up in both girls and boys. In paper II, we excluded three participants from the 
initial paper I with various missing outcome variables and included 355 girls and 296 boys in 
the analyses. 
The “osteogenic” influence of body weight and BMI in the adult and older population is well 
established. A low body weight in older individuals is a risk factor of fracture and 
maintenance of-, or body weight gain could have a protective effect by preventing bone loss. 
The hypothesized mechanisms behind this is extensively discussed in paper II and section 
1.4.1. There is, however, conflicting evidence whether excess body weight interferes with 
bone acquisition in the important years before PBM.  
We found that body weight and BMI had an influence on bone accretion as indicated both in 
previous cross-sectional TFF reports [136], reviews [113] and a comprehensive meta-analysis 
[114]. However, van Leeuwen and colleagues pointed out that the meta-analysis comprised 
studies that were mainly cross-sectional and only one longitudinal study exploring the long‐
term consequences of childhood obesity was included. The scope of our study was not 
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restricted to obesity, but rather how body weight influence bone in a young healthy adolescent 
population. Cross-sectionally, underweight appeared to be associated with low aBMD at 
baseline and this pattern persisted during two years of follow up. Particularly among boys, the 
differences compared to “normal weight” was apparent at all measured skeletal sites. Our 
findings suggest that the influence of baseline weight status on ∆aBMD were limited in girls 
compared to boys and that weight change might be strongest among boys with low BMI. This 
sex difference may be attributed to maturation, degree of longitudinal growth during follow-
up, and that modifiable factors are more influential in a growing skeleton.  
We observed indications of the hypothesis of the threshold effect of BMI on bone accretion in 
boys as previous reported [252], however based on a small sample size. Boys in the obese 
category had, on average, lower aBMD levels than overweight did at TFF1 and this 
relationship persisted during follow-up. It has been hypothesized that this could be attributed 
to the hormonal influence of fat on bone.   
We explored change in exposure of body weight and BMI. Whether weight change in a young 
healthy population is enough to evoke an adaptive bone response has been debated [67], but 
previous research is not easy to come by. Studies of weight change are dominated by weight 
loss interventions related to obesity, anorexia nevrosa, menopause and use of medication. In 
the adult population, reduction of BW and BMI could lead to net loss of aBMD [253]. In 
adulthood, the link between body weight and bone mass is dynamic with increments of bone 
mass if the body weight increases and decrease if weight is lost. Net bone loss has not been 
reported in an adolescent population, and we found no indication of this happening in the TFF 
population. Mechanisms behind this age dependence may be explained by genetic driven 
skeletal growth and better muscle function. The accretion rate, however, did slow down and 
we observed a significant difference in ∆aBMD between BMI losers and BMI gainers. 
Our results indicate that bone adapts to weight changes, but on average the influence during 
two years in late adolescence is limited. Exploring the effect of weight change on bone mass 
in obese female adolescents, Rourke and colleagues (41) found no bone loss, but concluded 
that reduction of BW induced a reduced bone growth rate over 12‐month follow‐up—results 
that are comparable to our findings. The effect of weight reduction on bone depends on 
whether it is voluntary or involuntary, the rate of change, age, sex, and initial weight (37). In 
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the current study, we had no information on the reason for BW changes, whether it was based 
on dieting, disease/illness, or natural fluctuations. 
The issue of temporality can be discussed. As mentioned in the methodology discussion in 
section 5.1, baseline measures are a snapshot in a continuum and body weight is a part of the 
mechanical load and the skeleton continuously adapts throughout life. There is, however, a 
temporal lag of influence when association between change and some predictor is assessed. 
Changes in body weight would precede adaptations in bone, and without knowledge about 
when the weight change have occurred, the interpretations gets harder. Only two time points 
also limits the information on the actual relationship.  
BMI is an extensively used tool to assess body weight adequacy, but the use of this parameter 
as a predictor of bone accretion is questionable. Its main advantage is simplicity and 
accessibility in a clinical setting, compared to other body composition measuring techniques 
(e.g. DXA). However, the mechanisms behind the relationship between weight status and 
bone are complex and multifactorial. BMI reflects both muscle and adiposity, which have 
different influence on bone. In a young healthy population it is reasonable to assume that 
excess BMI on average is attributed to excess fat mass, but it is not straightforward. The 
accuracy of BMI in this study population needs to be questioned because of longitudinal 
growth, particularly in boys. It is also worth recognizing that parts of the study population 
were elicited from sport schools and BMI does not account for over-average amounts of lean 
mass. 
6.4 Association between use of tobacco and change in BMD/BMC 
In this study all participants that responded on use of tobacco at both surveys were included, 
349 girls and 281 boys. In girls, we compared 244 “never-users” with 105 “users” of snuff. In 
boys, 185 individuals were compared with 96, respectively. Use of snuff was associated with 
a lower rate of aBMD accretion during two years of follow-up in late adolescence among 
boys, but not among girls. In boys, the combined categories “daily” and “sometimes” users of 
snuff was associated with approximately 1 % lower ∆aBMD compared to “non-users”. Along 
with chronological age, use of snuff were one of the strongest crude determinants of bone 




Smokeless tobacco has been linked to osteoporosis because of the detrimental effect of 
smoking on bone [254], however there is a wide range of types of smokeless oral tobacco 
products e.g. chewing tobacco, dry or moist types, with or without teabags etc. Some studies 
indicate that smokeless tobacco (chewing tobacco, non-combustible tobacco) is detrimental to 
bone in various populations, typically in India [255], Turkey [256] and in older multi-ethnic 
women [257]. It has been argued though, that Swedish snuff has a lower potential of harm 
than many other types of smokeless tobacco [258], and thus may not be comparable with 
studies from other populations and geographic areas. Apart from the cross-sectional study by 
Winther et al based on TFF1 data [136], we were unable to find other studies of the 
relationship between Swedish snuff and bone health in adolescence.  
The study comprises adolescents between the age range 15 to 19 years of age, and this is an 
appropriate age group to explore the influence of use of snuff in terms of the temporal 
sequencing of exposure and outcome considering the mean onset among the participants were 
14.3 years of age. We compared naturally occurring groups, thus there were no reason to 
expect equal baseline parameters. The baseline aBMD parameters did, however, not differ 
significantly between “non-users” and “users” of snuff groups.  
A high degree of drift in the “sometimes” categories, both in regards to category stability and 
frequency, made sensitivity analysis with exclusion of this category the most sensible 
decision. Sensitivity analyses revealed that in girls, use of snuff appeared detrimental for 
femoral accretion when comparing “non-users” and “daily-users”. In boys, associations were 
strong in crude models, but were attenuated when controlling for relevant confounders, 
particularly changes in anthropometry, which may indicate that recreational drug use habits 
may be a marker for maturational aspects. One of the great challenges with the study of 
tobacco and bone is disentangling the influence of use from other lifestyle factors, because 
users of tobacco tend to possess other characteristics associated with low aBMD e.g. physical 
activity, alcohol etc. [12]. 
The findings of the limited associations between smoking and bone accretion may be due to 
the low prevalence of regular smoking. Only eight girls and eight boys reported daily 
smoking. Low prevalence of smokers in adolescence frequently limits statistical power [12]. 
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This also made it difficult to investigate any dose-response relationship. In an extensive 
systematic review of PBM and its determinants, Weaver et al found evidence that supported 
smoking may have a deleterious influence on PBM [12]. However, there were some 
contradictory findings. The inconsistency in associations may be due to various categorization 
of smoking status employed or frequency- and duration-dependent effects of smoking on 
bone. We chose to exclude responses “one or less a week” and ended up with 21 girls and 31 
boys in the “smokers” category for comparison with the “non-smokers”. The rationale behind 
this threshold could be debated, and was not based on any guidelines for what could be 
considered a “substantial” exposure that could influence the skeleton. The decision was 
mainly based on low prevalence of daily smokers. Category- and frequency fluctuations in the 
baseline “sometimes” categories also rises questions of the precision of the constructed 
“double-users”. The group of “double-users” may be considered even more ambiguous as it 
represents mainly “some-timers” for both smokers and users of snuff. However, the point 
estimates in all models were, with a few exceptions, negative for both use of snuff, smoking 
and double use, even though the statistical significance varied and depended on skeletal site 





In summary, we have described changes in aBMD and BMC in Norwegian adolescents 
between 15 to 19 years of age and explored the influence of age, body weight, BMI, smoking 
and snuffing on PBM achievement. The main findings of this thesis were that:  
• Girls between 17 and 19 years of age are approaching PBM at femoral sites. 
• Boys are still accumulating bone mass between 17 and 19 years of age.  
• There is a high degree of tracking of bone traits during 2 years in late adolescence and 
drift between quartiles is limited.  
• Body weight and BMI are associated with bone accretion in late adolescence, but in a 
healthy young population, the modest magnitude of changes limits the implications for 
adolescents with an adequate body weight. However, low body BMI is associated with 
low aBMD and particularly among boys with low BMI, an increase in BMI could be 
beneficial for bone health. 
• Use of snuff and double use are associated with lower rate of bone accretion in boys, 
but its relation to maturation requires further investigation.  
Although the changes in aBMD and BMC associated with body weight and BMI are marginal 
and maybe not clinically relevant during two years of follow-up, there is a potential additive 
effect, which may be significant at a life-long perspective. The fact that we observed 
determinants that represent 1-2 % change during a mean time frame of 24 months, shows that 
lifestyle factors play an essential part of the PMB concept in late adolescence. Combined with 
other hereditary and modifiable determinants at this age, they may accumulate to an 
advantage, or a disadvantage, that represent a substantial effect later in life. An individual 
with low BMI that loses weight, smokes or uses snuff combined with other known 
determinants of low bone mass (e.g. physical activity/sedentary behavior) could be at great 




A better understanding of determinants of bone accrual and their relationships, increases the 
possibility of identifying individuals at risk of low PBM, with potential facilitation of early 
interventions and preventive measures. 
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Abstract
Summary Areal bone mineral density (aBMD) predicts future
fracture risk. This study explores the development of aBMD
and associated factors in Norwegian adolescents. Our results
indicate a high degree of tracking of aBMD levels in adoles-
cence. Anthropometric measures and lifestyle factors were
associated with deviation from tracking.
Purpose Norway has one of the highest reported incidences of
hip fractures. Maximization of peak bone mass may reduce fu-
ture fracture risk. The main aims of this study were to describe
changes in bone mineral levels over 2 years in Norwegian ado-
lescents aged 15–17 years at baseline, to examine the degree of
tracking of aBMD during this period, and to identify baseline
predictors associated with positive deviation from tracking.
Methods In 2010–2011, all first year upper secondary school
students in Tromsø were invited to the Fit Futures study and
1038 adolescents (93%) attended. We measured femoral neck
(FN), total hip (TH), and total body (TB) aBMD as g/cm2 by
DXA. Two years later, in 2012–2013, we invited all participants
to a follow-up survey, providing 688 repeated measures of
aBMD.
Results aBMD increased significantly (p < 0.05) at all skeletal
sites in both sexes.Mean annual percentage increase for FN, TH,
and TBwas 0.3, 0.5, and 0.8 in girls and 1.5, 1.0, and 2.0 in boys,
respectively (p < 0.05). There was a high degree of tracking of
aBMD levels over 2 years. In girls, several lifestyle factors pre-
dicted a positive deviation from tracking, whereas anthropomet-
ric measures appeared influential in boys. Baseline z-score was
associated with lower odds of upwards drift in both sexes.
Conclusions Our results support previous findings on aBMD
development in adolescence and indicate strong tracking over
2 years of follow-up. Baseline anthropometry and lifestyle
factors appeared to alter tracking, but not consistently across
sex and skeletal sites.
Keywords Bonemass . Bone development . Tracking .
Adolescence . Areal bonemineral density . DXA
Introduction
Norway has one of the highest reported incidences of hip frac-
tures [1]. Areal bone mineral density (aBMD) is strongly associ-
ated with fracture risk. aBMD levels in the elderly are a result of
peak bone mass (PBM) achieved during growth and subsequent
bone loss [2]. Adolescence is characterized by massive skeletal
changes due to rapid modeling and remodeling [3]. About 40%
of bone mass are accumulated around the 4 years of peak height
velocity (PHV) during puberty and about 90% by the age of 18
[4, 5]. These rapid changes generate both opportunities and vul-
nerabilities related to future bone health. Previous studies indicate
that one standard deviation increase in bone mass at the end of
skeletal maturation decrease future fracture risk by as much as
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50% [4]. This makes maximization of the genetic potential for
bone mass acquisition a strategy for prevention of osteoporosis
and fragility fractures later in life. The clinical importance of this
concept depends on the degree of tracking or stability of bone
mineral status from younger years into adulthood [6]. Early pre-
ventive measures can be employed if there is a high correlation
between bone mass levels in the younger years and later in life.
Studies report that high aBMD in athletes or low aBMD due to
deficits may persist into adulthood [7, 8]. Previous population-
based longitudinal studies demonstrate strong tracking of aBMD
from childhood to skeletal maturity [9–13]. The degree of track-
ing from adolescence into adulthood is, however, unclear
[14–16]. Potential variation in tracking into adulthood and incon-
sistent evidence [10–12] calls for attention to predictors of devi-
ation from tracking in late adolescence. The objectives of this
population based longitudinal study were (1) to describe the
changes in bone traits over 2 years in Norwegian adolescents
aged 15–19 years, (2) to explore tracking of aBMD status over
2 years, and (3) to identify baseline anthropometric measures and
lifestyle factors associated with deviation from tracking. It is our
hypothesis that participants mainly remain in their original
aBMD quartile between the ages of 15 and 19 years of age and




The Tromsø Study is an ongoing population-based epidemio-
logical study with seven repeated surveys conducted among the
adult population since 1974 [17]. As part of the Tromsø Study,
Fit Futures invited all first year upper secondary school students
in Tromsø and the neighboring municipalities to a comprehen-
sive health survey in 2010–2011 (TFF1, baseline). The invited
cohort comprised 1117 adolescents and 1038 (508 girls and 530
boys) attended the survey (attendance rate 93%). Among those,
95% of the participants were in the range between 15 and
18 years of age. Two years later, in 2012–2013, all third year
upper secondary school students in the same schools and all
TFF1 participants not attending school at that time were invited
to a follow-up survey, Fit Futures 2 (TFF2). In total, 820 ado-
lescents attended, providing 688 repeated measures of aBMD
(66% of the TFF1 cohort) (Fig. 1). The Clinical Research Unit
at the University Hospital of North Norway conducted both
surveys during school days. The Regional Committee of
Medical Research Ethics approved the study (Ref.
2013/1459/REK nord). The study protocol for TFF1 was ap-
proved by The Norwegian Data Inspectorate 27.07.2010 (Ref.
07/00886-7/CGN) and the Regional Committee for Medical
Research Ethics (REK-Nord) 16.09.2010 (Ref. 2009/1282-
23). The study protocol for TFF2 was approved as an extension
of the prior approval by the Data Inspectorate 31.10.2012 (Ref.
07/00886-15/EOL). All participants gave written informed
consent. Participants below 16 years of age had to bring written
consent from their superiors to attend the survey.
Measurements
We measured total body (TB), total hip (TH), and femoral
neck (FN), bone mineral content (BMC; g), bone area (BA;
cm2), and aBMD (g/cm2) by DXA (GE Lunar prodigy) and
performed analyses by Encore pediatric software [18]. The
densitometer coefficient of variation (CV = [SD/mean] ×
100) has been estimated to 1.14% at the total hip measured
in vivo [19]. We used the same densitometer in both surveys,
and no densitometer drift was detected between the surveys.
Trained technicians performed the measurements, and the
quality assessment was done according to the same protocol
in both surveys. We used measurements of left hip at both
femoral sites. In 15 cases, left hip data was missing and the
right hip was used. Measurements from the same hip were
used in both TFF1 and TFF2. Height and weight were mea-
sured to the nearest 0.1 cm and 0.1 kg on the same electronic
scale in both surveys (Dong Sahn Jenix, Korea), with partic-
ipants wearing no shoes and light clothing. We assessed use of
medication, acute and chronic diseases, hormonal contracep-
tive use, and the possibility of pregnancy by clinical inter-
views, and pregnant participants were excluded from DXA
scanning. Participant’s answers on diseases and use of medi-
cation known to affect bone were operationalized into dichot-
omous variables. Hormonal contraceptive use were catego-
rized into no use, combined estrogen and progestogen-based
contraceptive (CHC) use, and progestogen-only contraceptive
use. We collected sexual maturation information by self-
administered questionnaires. In girls, pubertal status was de-
termined through the following questions: “If you have started
menstruating, how old were you when you had your first
menstruation.” Answers were categorized into “early”
(<12.5 years at menarche), “intermediate” (12.5–13.9 years),
or “late” (>14 years) sexual maturation. Boys were examined
according to Pubertal Developmental Scale (PDS). The boys
self-rated secondary sexual characteristics as growth spurt,
pubic hair growth, changes in voice, and facial hair growth
on a scale from 1 (have not begun) to 4 (completed). We
summarized the score and divided by 4. We categorized a
score <2 as “have not begun,” 2–2.9 as “barely started,” 3–
3.9 as “underway,” and a score of 4 as “completed” [20]. The
participants were asked to grade leisure time physical activity
(PA) in an average week during the last year according to a
four-level scale, which are sedentary activities only; moderate
activity like walking, cycling, or exercise at least 4 h per week;
participation in recreational sports at least 4 h per week; or
participation in hard training/sports competitions several times
a week. This question was developed by Saltin and Grimby
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[21] and has previously been validated in the Tromsø Study
[22]. Questions on smoking and snuffing had the following
three alternatives: never, sometimes, or daily, while frequency
of alcohol consumption had the following five alternatives:
“never,” “once per month or less,” “two to four times per
month,” “two to three times per week,” and “four or more
times per week.” We dichotomized answers on smoking,
snuffing, and alcohol into yes and no.
Statistical analyses
All analyses were performed sex stratified. We calculated means
and standard deviations for continuous variables and percentage
for categorical variables to describe the study population charac-
teristics. Differences in anthropometric and DXA measures be-
tween FF1 andTFF2were tested using paired sample t test, while
dichotomous lifestyle factors were tested with McNemar’s test.
We explored differences between participants and non-
responders in TFF2 using Student’s t test and chi-squared testing.
Average absolute change and percentage change for BMC and
aBMD for each skeletal site were calculated by the difference
between the measurements (T2 − T1). We used exact measure-
ment dates to compute annual change to account for differences
in time between measurements. We stratified participants by age
and used one-way ANOVA and multiple comparisons with
Bonferroni post hoc test to examine differences in mean aBMD
change between groups. We calculated individual age and sex-
specific height, weight, FN, TH, and TB aBMD and BMC z-
scores (standard deviations away from the sample specific mean)
and examined correlations between baseline and follow-up using
Pearson’s correlation coefficient. Because height and weight are
known determinants of aBMD and the adjustment for height in
1301 Registered students for first year 
upper secondary school 2010/11. 
1117 was invited to FF1. 
1038 participated FF1. 508 girls and 530 
boys. 
All third upper secondary school students 
year 2012/13 were invited to FF2, including 
all participants of FF1. 820 participated in 
FF2. 132 new cases with only FF2 data 
184 either dropped out of school before 
study started, or we were unable to contact 
or had persistent disease. 
79 did not attend the FF1 survey. 
34 participants over 18 years of age 
350 lost to follow-up 
688 repeated measures (66% of the FF1 
cohort) 
654 eligible for analysis. 358 girls and 296 
boys  
63 with incomplete dataset. 
591 eligible for regression analysis. 348 
girls and 243 boys  
Fig. 1 Flowchart of participation
in Fit Futures 1 (TFF1) 2010–
2011 and Fit Futures 2 (TFF2)
2012–2013
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the two-dimensional DXA scans is incomplete, partial correla-
tion was used to adjust for TFF1 height and weight as well as
change in height and weight. We stratified participants into quar-
tiles of aBMD and BMC z-scores and examined the proportions
of participants that remained within quartiles, drifted upwards, or
drifted downwards between TFF1 and TFF2. Furthermore, an
aBMD z-score change variable were computed (Z2 − Z1). To test
whether baseline age, anthropometric traits (height, weight), and
lifestyle factors (PA, alcohol consumption, smoke use, and snuff
use) were associated with positive deviation from tracking (z-
score change >0), we used logistic regression. The reference
categories were no change or downwards drift (z-score change
≤0). Odds ratios (ORs) with 95% confidence intervals (CIs) for
upwards drift during follow-up were calculated. We simulta-
neously adjusted for age, anthropometric measures, lifestyle var-
iables, sexual maturation, and time between measurements. The
influence of other relevant confounders like baseline aBMD z-
score, ethnicity, chronic disease, and medication known to affect
bone health bone and hormonal contraceptive use (girls) were
explored, and purposeful selection was used to select final model
[23]. We evaluated relevant two-way interactions. We fitted
models for FN, TH, and TB separately and ran logistic regression
diagnostics, and assumptions were met. Significance level was
set to p = 0.05 in all analysis, and all procedures were performed
in SPSS version 23.
Results
Descriptives
We included 654 adolescents, 358 girls and 296 boys aged 15 to
17 at baseline in the present analysis (Table 1). Themajoritywere
16 years of age (n = 534), while a small group of 28 participant
were 15 years at baseline. Mean follow-up time was 1.94 years
(SD 0.20). Thirty-two percent of TFF1 participants were lost to
Table 1 Characteristics at baseline survey Fit Futures 1 (TFF1) and follow-up survey Fit Futures 2 (TFF2) 2 years later: continuous variables presented
as mean (standard deviation) and categorical variables in percentage
Girls Boys
TFF1 TFF2 TFF1 TFF2
n n p n n p
Age 358 16.61 (0.387) 358 18.60 (0.40) 296 16.60 (0.367) 296 18.65 (0.35)
Age groups at baseline
15 9 2.5% 19 6.4%
16 296 82.7% 238 80.4%
17 53 14.8% 39 13.2%
Height (cm) 358 165.07 (6.47) 358 165.77 (6.56) <0.001 296 177.25 (6.52) 296 179.08 (6.49) <0.001
Weight (kg) 358 60.42 (10.61) 358 63.11 (11.91) <0.001 296 69.81 (13.68) 296 75.21 (14.64) <0.001
Sexual maturationa
Early/completed 110 31.3% 22 9.1%
Intermediate/underway 168 47.9% 177 72.8%
Late/barely started 73 20.8% 44 18.1%
Ethnicity
White 350 97.8% 291 98.3%
Others 8 2.2% 5 1.7%
Physical activity
Sedentary 43 12.0% 47 13.3% 77 26.3% 81 28.4%
Moderate 141 39.5% 144 40.8% 75 25.6% 60 21.1%
Sports 110 30.8% 110 31.2% 71 24.2% 77 27.0%
Competition 63 17.6% 52 14.7% 70 23.9% 67 23.5%
Smoking (yes) 68 19.0% 102 28.5% <0.001 62 20.9% 114 38.5% <0.001
Snuff use (yes) 108 30.2% 152 42.5% <0.001 108 36.5% 142 48.0% <0.001
Alcohol consumption (yes) 262 73.2% 336 93.9% <0.001 195 65.9% 272 91.9% <0.001
Diseases known to affect boneb (yes) 4 1.1% 5 1.7%
Medication known to affect bonec (yes) 8 2.2% 6 2.0%
Hormonal contraceptive use (yes) 118 33.0%
Estrogen and progestogens 105 29.3%
Progestogens only 13 3.6%
a Sexual maturation in girls: menarche age. Categories are early (<12.5), intermediate (12.5–13.9), and late (>14). Sexual maturation in boys: Puberty
Developmental Scale. Categories are have not begun (<2), barely started (2–2.9), underway (3–3.9), and completed (4)
b Diseases known to affect bone (ICD10): E03 hypothyroidism, E10 diabetes type 1, F50.9 eating disorders, K90.0 celiac disease, and M13 arthritis
cMedication known to affect bone (ATC): D07A plain corticosteroids, H03A thyroid preparations, N03A antiepileptic, R01AD corticosteroids, R03BA
glucocorticoids (inhalants), and H02A corticosteroids for systemic use
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follow-up. Dropout analysis showed statistically significant
higher proportion of boys, smokers, snuff users, and consumers
of alcohol (girls only) among non-responders compared to those
who participated in both surveys.
Changes in bone traits and anthropometry
In the overall study, population aBMD increased significantly
(p < 0.05) at all sites in both sexes. Mean annual percentage
increase for FN, TH, and TB aBMD (g/cm2) was 0.3, 0.5, and
0.8 in girls and 1.5, 1.1, and 2.0 in boys, respectively
(p < 0.05). A similar pattern was present for BMC. When
stratified into age at baseline, mean annual percent change in
aBMD at all skeletal sites decreased successively by increas-
ing age in both sexes (Fig. 2). The differences in annual
aBMD changes between age groups were statistically signifi-
cant (p < 0.05) at most skeletal sites and ages; the exceptions
were changes in TH aBMD between all age groups and FN
aBMD between age 16 and 17 years in boys, as well as chang-
es in FN and TH aBMD between 15- and 16-year-old girls.
Girls 17 years of age at TFF1 had a mean annual percentage
FN aBMD loss of −0.61 (95% CI −0.15, −1.07) and −0.14
(−0.54, 0.27) at the total hip. Average annual percentage BA
change for FN, TH, and TB were 0.01, 0.09, and 2.30 and
0.23, 0.39, and 2.10 for girls and boys, respectively. The av-
erage annual height and weight changes during the follow-up
period were 0.36 cm (95% CI 0.32–0.41) and 1.37 kg (1.11–
1.63) for girls and 0.93 cm (0.83–1.03) and 2.70 kg (2.35–
3.04) for boys, respectively.
Tracking from baseline to follow-up
Correlations between TFF1 and TFF2 z-scores were high in
both sexes at aBMD FN, TH, and TB, Pearson’s r = 0.960,
0.966, and 0.967 for girls and 0.937, 0.955, and 0.946 for
boys, respectively. Calculations of coefficients for BMC,
height, and weight showed similar strong correlations.
Adjusting for TFF1 height and weight or changes in height
and weight using partial correlation did not change the aBMD
results (not shown). Age-stratified coefficients showed weak-
er correlation at all sites for 15-year-old boys, FN 0.884, TH
0.871, and TB 0.853 (N = 19). All correlation coefficients
were statistically significant (p < 0.0001). Overall, 78.2% of
the girls kept their FN aBMD quartile position between
Fig. 2 Mean annual percent change in femoral neck total hip and total body aBMD and BMC for girls and boys stratified by age at Fit Futures 1 (TFF1)
with 95% confidence intervals
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measurements, correspondingly 73% of the boys. The same
stability within quartiles was found at TH and TB, 79.6 and
77.4% for girls and 79.2 and 77.7% for boys, respectively.
Figure 3 illustrates z-score drift between baseline, and
follow-up and shows proportions of participants remaining
in each specific quartile.
Predictors of positive deviation from tracking
Baseline FN, TH, and TB aBMD z-scores had a statistically
significant association with lower odds of positive deviation
from tracking for both girls and boys (Table 2). Later sexual
maturation tended to be associated with higher odds of
Fig. 3 Scatterplot of aBMD z-score for femoral neck (FN), total hip
(TH), and total body (TB) at baseline vs z-score at follow-up with
proportions of participants remaining in baseline quartile. Lines
represent the cutoff for percentiles 25, 50, and 75%. Measurements
outside diagonal quartiles have changed quartile between baseline and
follow-up. Participants were 15–17 years of age at baseline. Boys
n = 296. Girls n = 358
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positive drift at several skeletal sites, with a statistically sig-
nificant association for TB in girls. For boys, baseline body
weight was associated with higher odds of positive deviation
at TH (p = 0.018), and a statistically significant interaction
between age and weight was detected at FN; when stratified
into younger (<16.66 years) and older (≥16.67 years) boys,
the association between baseline weight and higher odds of
positive deviation in FN aBMD was limited to the younger
boys (p = 0.039). There were no statistically significant asso-
ciations between lifestyle factors and higher aBMD z-scores
in boys; smoking only tended to be associated with decreased
odds for higher TH aBMD z-score at follow-up (p = 0.062). In
girls, snuff and alcohol use were associated with significantly
lower odds of higher TH and TB aBMD z-scores, respective-
ly. Also, CHC use was associated with reduced odds of up-
wards drift during follow-up at FN (p = 0.048). Baseline rec-
reational PA level was positively associated with significantly
higher TB aBMD z-score at follow-up in girls; participation in
recreational sports at least 4 h per week and participation in
hard training/sports competitions several times a week were
associated with a fourfold and threefold increase in the odds of
higher TB aBMD, respectively. Data also indicated a more
moderate effect of PA on FN aBMD in girls (p = 0.080;
Table 3).
Discussion
This study presents results from a large population-based co-
hort of adolescents entering young adulthood. Our results in-
dicate that Norwegian adolescents still accumulate bone mass
and increase aBMD between 16 and 18 years of age, although
bone acquisition decreases significantly with age at all skeletal
sites during these 2 years of follow-up. The results also sug-
gest that girls may be reaching an aBMD plateau at femoral
sites between 17 and 19 years of age, even with an indicated
reduction of aBMD at femoral neck around the age of 19
compared to 2 years earlier. Consistent with our hypothesis,
we report that a stable position within quartiles based on
aBMD z-scores is kept over 2 years in late adolescence.
Baseline z-scores were consistently associated with lower
odds of positive deviation from tracking across all skeletal
sites for both sexes. In boys, anthropometric baseline mea-
sures appeared to be associated with upwards drift. In girls,
several lifestyle factors had statistically significant associa-
tions. Particularly, PA tended to be beneficial for TB aBMD.
The decrease in FN aBMD for girls between 17 and
19 years of age is unexpected. However, Berger et al. reported
similar findings with an average decrease of aBMD in girls
around 20 years of age until stabilization and consolidation
[24]. As no specific characteristic in these girls could account
for this development like late menarche or intensive physical
activity, the relationship between BMC and BA and precision
of measurement could explain these findings. According to
Sundberg et al. [25], pubertal bone growth is due to increased
bone size rather than increased density. aBMD will increase
only if BMC increases proportionally more than BA [4].
Elaborative analysis showed that mean FN BA in girls aged
17 years at baseline increased while mean BMC dropped
slightly resulting in lower mean aBMD. The decreasing trend
of bone acquisition with age is similar at all three sites, and
changes in femoral sites seem to drop in advance of total body
aBMD. This is consistent with other longitudinal studies [26,
Table 2 Mean and (standard deviation) of bone traits and time between measurements: areal bone mineral density (aBMD), bone mineral content
(BMC), and bone area (BA) for femoral neck (FN), total hip (TH), and total body (TB) at baseline survey Fit Futures 1 (TFF1) and follow-up survey Fit
Futures 2 (TFF2) 2 years later
Girls Boys
TFF1 TFF2 TFF1 TFF2
n n p n n p
aBMD FN (g/cm2) 358 1.07 (0.13) 357 1.08 (0.13) 0.008 296 1.11 (0.15) 296 1.14 (0.15) <0.001
aBMD TH (g/cm2) 357 1.06 (0.13) 357 1.07 (0.13) <0.001 296 1.12 (0.15) 296 1.14 (0.16) <0.001
aBMD TB (g/cm2) 357 1.14 (0.08) 358 1.16 (0.07) <0.001 296 1.18 (0.10) 296 1.23 (0.09) <0.001
BMC FN (g) 358 4.92 (0.71) 357 4.94 (0.72) <0.001 296 5.99 (0.99) 296 6.19 (0.99) <0.001
BMC TH (g) 357 32.03 (4.84) 357 32.42 (4.95) <0.001 296 40.17 (6.64) 296 41.26 (6.86) <0.001
BMC TB (g) 357 2524.06 (388.27) 358 2600.95 (381.68) <0.001 296 2963.78 (469.83) 296 3200.96 (476.10) <0.001
BA FN (cm2) 358 4.60 (0.34) 357 4.60 (0.34) 0.866 296 5.38 (0.39) 296 5.41 (0.37) 0.003
BATH (cm2) 357 30.15 (2.32) 357 30.22 (2.38) 0.068 296 35.73 (2.47) 296 35.99 (2.51) <0.001
BATB (cm2) 357 2207.37 (233.59) 358 2241.68 (224.95) <0.001 296 2496.46 (240.06) 296 2598.28 (237.87) <0.001
Time between measurements
(years)
358 1.94 (0.20) 296 2.01 (0.23)
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27]. Bachrach et al. found that, for girls, gains in aBMD leveled
off in total hip, spine, and whole body already at the age of 14.1,
15.7, and 16.4, respectively. Boys tended to reach plateau at the
age of 15.7 in total hip and 17.7 in spine and whole body [28].
Differences in statistical analysis used to localize the age of pla-
teau may explain the slightly earlier age indication compared to
our findings. The 2-year developmental difference between boys
and girls was present in our cohort as well. Hormonal status
influences bone development and PBM depends on biological
rather than chronological age [29].
Our tracking results are comparable with other studies [10,
12, 13]. In contrast, Buttazzoni et al. [16] concluded with low
sensitivity for childhood bone mass scans to predict PBM.
Their study included 65 boys and 56 girls with a time frame
of 11 years. With the extensive follow-up period and a mean
baseline age of 8 years, this study is not directly comparable to
ours. Follow-up during PHV is expected to show reduced
correlation, and Kalkwarf et al. reported lower correlations
in younger children than in older [10]. In our cohort, aBMD
tracking for boys became successively stronger as annual
height change reduced gradually between 15 and 17 years of
age at baseline, indicating this link between statural growth
and aBMD tracking (data not shown). The tendency of stron-
ger degree of tracking with cessation of growth strengthens
the notion that measures in our study potentially can predict
adult bone mineral status. The results for participants in the
lowest quartile are of clinical importance and highlight the
great challenge of changing the bone mineral-level trajectory
of this group. Even though this study has a narrow time span,
the fact that a large proportion of adolescents with low bone
mass levels remains low supports the hypothesis that subjects
susceptible to relatively early osteoporosis risk may be detect-
able early in life.
The importance of PBM makes it interesting to explore
modifiable factors with the potential of altering the bone mass
trajectory. Our study suggested that baseline body weight may
influence aBMD at femoral sites in boys, but not in girls. Age
being an effect modifier of weight for boys at FN is biologi-
cally reasonable because bone adaptation to mechanical load-
ing is greater in a growing skeleton and FN is highly exposed
to weight [30]. No associations between lifestyle factors and
positive drift were detected for boys. For girls, associations
were incoherent both in terms of direction, statistical signifi-
cance, and skeletal sites. PA seemed beneficial for TB aBMD,
but we found no clear dose-response effect. This may indicate
that participants reporting to be in the hard training and com-
petition category at baseline were already at the tail of the z-
score distribution as reported byWinther et al. [31]. Sustained
activity level during follow-up and preservation of high z-
score could lead to classification into the reference group no
change or downwards drift for these participants. Previous
studies report tobacco use to have a duration and dose-
dependent negative effect on aBMD, while the impact of
alcohol is more unclear [32–36]. Snuff use and smoking main-
ly prevented subjects from positive deviation in our study,
although not statistically significant at all skeletal sites.
However, changes in exposure variables during follow-up
make the interpretations of associations challenging.
Proportions of smokers, snuff users, and participants consum-
ing alcohol all increased during follow-up (Table 1). The re-
lationship between hormonal contraceptive use and aBMD
development remains controversial. Our results indicated
CHC use to be disadvantageous for the FN and supports ev-
idence suggesting that CHC use is likely to impair acquisition
of optimal PBM [37]. Recent reviews emphasize the need for
randomized controlled trials to confirm these effects [38].
Progestogen-only contraceptives have also been associated
with reduced aBMD when used before the achievement of
PBM [39]. This association was not confirmed in our cohort,
but participants reporting to use progestogen-only contracep-
tives were few. The underlying mechanisms behind the effects
of contraceptives are complex and data on length of use and
dosage are lacking. Winter et al. reported that late sexual mat-
uration was associated with low aBMD levels in TFF1 [31].
The fact that proportions of sexual maturation categories in
our study are comparable with other Norwegian youth cohorts
[40] and that the association between late sexual maturation
and increased odds for positive deviation in this longitudinal
study is consistent suggest that this adverse effect levels out to
some extent. As reported by previous studies [10, 12], base-
line aBMD z-score appears to be highly predictive of future z-
score. The consistent association between high baseline z-
score and reduced odds of positive deviation could be due to
the phenomenon regression towards the mean. Extreme mea-
sures at the tails of the distribution will when repeated tend to
be less extreme and closer to average because of variation
within the individual or measurement error [41].
The longitudinal design and the large representative sample
are among the strengths of the study. The sample has well-
described characteristics, is homogenous in age and ethnicity,
and included both sexes and participants from both rural and
urban regions. We used the same densitometer through both
surveys with continuous validations. A well-established re-
search unit ensured high quality of data acquisition. There
are, however, limitations to be discussed. Firstly, DXA and
aBMD measurements have their limitations. Interpretation of
DXA measures of growing skeletons could be problematic
because it is a two-dimensional measure and size dependent
[42]. aBMD is furthermore only a surrogate measure of bone
strength, and the broad concept of PBM captures other param-
eters like architecture, geometry, and distribution of trabecular
and cortical bone [6]. Secondly, non-participation and loss to
follow-up could be a problem if only the healthy part of the
population chooses to participate. Fourteen percent of the el-
igible population were not invited because we were unable to
get in contact with them due to chronic illness or dropout from
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school. School dropouts tend be associated with an unhealthy
lifestyle [35]. The detected differences in characteristics be-
tween non-responders and participants attending both surveys
may cause bias. A higher proportion of snuff user among non-
responders would make the statistically significant association
between snuff use and lower odds for positive drift for girls an
underestimation. Thirdly, we acknowledge that the follow-up
time of 2 years may be a limitation. Changes over such a short
time period are at risk of being obscured by variability in DXA
measurements. On the other hand, the recommended mini-
mum interval between DXA scans is 6–12 months [42], and
our findings are in accordance with previous reports.
In conclusion, this study corroborates the findings of pre-
vious research exploring the dynamics of bone mineral levels
in adolescence. We report a high degree of tracking of aBMD
levels over 2 years in late adolescence. Because of the short
time span between measurements, a longer follow-up is nec-
essary for definite conclusions on tracking. Baseline aBMD z-
score was the only consistent predictor of deviation from
tracking in both girls and boys. For boys, baseline body
weight tended to be associated with upwards drift in aBMD
z-score at femoral sites. For girls, lifestyle factors such as PA,
snuff use, and consumption of alcohol appeared important, but
not persistently across skeletal sites. Further studies are need-
ed in order to investigate the possible effect of changes in
anthropometrics and lifestyle factors on development of
aBMD in adolescence. Additional follow-up surveys of the
Fit Futures cohort are required to explore further longitudinal
effects.
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ABSTRACT
Determinants of bone acquisition in late adolescence and early adulthood are not well‐described. This 2‐year follow‐up study
explored the associations of body weight (BW), body mass index (BMI), and changes in weight status with adolescent bone
accretion in a sample of 651 adolescents (355 girls and 296 boys) between 15 and 19 years of age from The Tromsø Study: Fit
Futures. This Norwegian population‐based cohort study was conducted from 2010 to 2011 and was repeated from 2012 to 2013.
We measured femoral neck, total hip, and total body bone mineral content and areal bone mineral density (aBMD) by dual‐energy
X‐ray absorptiometry. We measured height, BW, calculated BMI (kg/m2), and collected information on lifestyle at both surveys.
Mean BMI (SD) at baseline was 22.17 (3.76) and 22.18 (3.93) in girls and boys, respectively. Through multiple linear regression,
baseline BW and BMI were positively associated with ΔaBMD over 2 years of follow‐up at all skeletal sites in boys (p < 0.05), but
not in girls. ΔBW and ΔBMI predicted ΔaBMD and ΔBMC in both sexes, but the strength of the associations was moderate.
Individuals who lost weight during follow‐up demonstrated a slowed progression of aBMD accretion compared with those
gaining weight, but loss of BW or reduction of BMI during 2 years was not associated with net loss of aBMD. In conclusion, our
results confirm that adequate BW for height in late adolescence is important for bone health. Associations between change in
weight status and bone accretion during follow‐up were moderate and unlikely to have any clinical implication on adolescents of
normal weight. Underweight individuals, particularly boys, are at risk of not reaching optimal peak bone mass and could benefit
from an increase in BMI. © 2019 The Authors. JBMR Plus is published by Wiley Periodicals, Inc. on behalf of the American Society
for Bone and Mineral Research.
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Introduction
Osteoporosis is a major public health concern and afrequent cause of disability in Western societies.(1)
Norway has one of the highest reported hip fracture
incidences in the world.(2) Areal bone mineral density
(aBMD) is a surrogate measure of bone strength and a
strong predictor of fracture risk.(3) Although genetics
explain a substantial proportion of the variance of an
individual’s bone mass, lifestyle factors influence skeletal
dynamics particularly during growth. Adolescence is a
critical period for bone accretion and attainment of peak
bone mass, defined as the highest bone mass obtained in a
lifetime.(4) Suboptimal acquisition of peak bone mass may
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lead to increased risk of osteoporosis and fragility fractures
in later life.(5,6)
It has long been established that there is an association
between BW and bone mineral parameters in the adult
population.(7) High BMI is generally considered to have an
osteo‐protective effect, while rapid loss of BW is associated
with bone loss.(8,9) In childhood and adolescence, however, the
relationship between weight status and bone accretion is more
controversial. Both detrimental and protective effects of BW
have been reported.(10–18) There are few studies with repeated
measures exploring bone accretion and longitudinal relation-
ships.(16) Obesity and overweight in childhood and adolescence
are a growing concern worldwide with rising prevalence during
the past decades.(19) In European countries, including Norway,
there has been a shift in the BMI distribution, with an increase
in BMI in the upper percentiles.(20) For health benefits, obese
and overweight individuals are recommended to reduce their
weight by approximately 10%. In older adults, evidence
suggests that a weight reduction of that magnitude will induce
a loss of bone of 1% to 2% and even up to 4% at highly
trabecular sites such as the trochanter.(21)
Associations and interplay between anthropometric traits,
aBMD levels, and bone accretion in late adolescence are not yet
fully described and understood at a population level. The
mechanisms behind the weight and bone relationship are not
clear as both direct and indirect effects related to mechanical
forces, nutrition, age, and hormonal status could be involved.
The objectives of this 2‐year follow‐up population‐based study
were to explore the associations between baseline BW, baseline
BMI, changes in BW (ΔBW), and changes in BMI (ΔBMI) on
changes in bone mineral parameters in a Norwegian popula-
tion from 15 to 19 years of age. We hypothesized that higher
baseline BW and BMI, as well as ΔBW and ΔBMI would be
positively associated with changes in bone parameters, and
that negative ΔBW and ΔBMI could be detrimental to bone
accrual in adolescents entering young adulthood.
Subjects and Methods
Subjects
Detailed information on the Fit Futures Study participants and
study procedures has been published previously.(18) Briefly, the
Fit Futures study, an expansion of the Tromsø study in
Northern Norway,(22) invited all first year upper‐secondary
school students (15 to 17 years of age) in Tromsø and the
neighboring municipalities to a comprehensive health survey in
2010 to 2011 (TFF1). In this initial survey, 1117 participants
were invited and 1038 adolescents (508 girls and 530 boys)
attended (attendance rate of 93%). Two years later, in 2012 to
2013, we invited all TFF1 participants and all third‐year
students in the same upper‐secondary schools to a follow‐up
survey, Fit Futures 2 (TFF2), providing 688 repeated measures
of aBMD (66% of the original cohort; Fig. 1). The Clinical
Research Unit at the University Hospital of North Norway
conducted both surveys during school days. The participants
received information about the study in classrooms and all
participants gave written informed consent at the study site.
Participants younger than 16 years of age had to bring written
consent from their guardians to take part in the survey. The
data collection in TFF1 and TFF2 was approved by the
Norwegian Data Protection Authority and the Regional
Committee of Medical Research Ethics (REK nord) with
project‐specific approval for the present study (Ref. 2013/
1459/REK nord).
Measurements
Femoral neck (FN), total hip (TH), and total body (TB) bone
mineral content (BMC; g), bone area (BA; cm2) and aBMD
(g/cm²) were measured by the same instrument (GE Lunar
Prodigy; GE Lunar, Madison, WI, USA) by DXA and analyzed
with enCORE pediatric software (GE Healthcare, Piscataway, NJ,
USA)(23) in both TFF1 and TFF2. We used auto‐analysis software
and default region of interest, according to a standardized
protocol. The primary outcome of the study was aBMD, but
BMC and BA are reported to complement the understanding of
bone accretion and growth. The precision of measurements
expressed as coefficient of variation ([SD/mean] × 100) has
previously been estimated to be 1.14% at the TH and 1.72% at
the FN measured in vivo.(24) We used measurements of the left
hip. In 15 cases the left hip data were erroneous or missing and
the right hip data were reported for both TFF1 and TFF2. We
measured height and BW to the nearest 0.1 cm and 0.1 kg on a
Jenix DS 102 Stadiometer (Dong Sahn Jenix, Seoul, Korea),
following standardized procedures. BMI was calculated as BW
divided by height squared (kg/m2), and participants were
stratified into BMI quartiles. To explore if relationships changed
with various BMI cut‐off points, we also categorized partici-
pants into underweight, normal weight, overweight, or obese.
Participants <18 years of age were stratified based on their sex‐
and age‐specific BMI according to half‐year cut‐off points
described by Cole and Lobstein.(25) To describe the crude
impact of change‐in‐weight status on bone accretion, we
dichotomized participants into BMI losers and BMI gainers.
Interviews and questionnaires
Information on ethnicity, the possibility of pregnancy (exclu-
sion criterion for DXA), the presence of acute and chronic
disease, and the use of medication and hormonal contra-
ceptives was elicited by clinical interviews. We collected
pubertal maturation information, perceived physical activity
level, alcohol consumption, and tobacco use by electronic self‐
administered questionnaires. Pubertal status for girls was
determined based on age at menarche and answers were
categorized into “Early” (<12.5 years at menarche), “Inter-
mediate” (12.5 to 13.9 years), or “Late” (>14 years) pubertal
maturation. We used the Pubertal Developmental Scale (PDS)
to assess pubertal maturation in boys. Secondary pubertal
characteristics such as growth spurt, pubic hair growth,
changes in voice, and facial hair growth were rated on a scale
from 1 (Have Not Begun) to 4 (Completed), were summarized,
and then were divided by 4. We categorized a score <2 as
“Have Not Begun”, 2 to 2.9 as “Barely Started”, 3 to 3.9 as
“Underway,” and a score of 4 as “Completed.”(26) Perceived
physical activity level was assessed by a scale developed by
Saltin and Grimby.(27) The participants were asked to grade
leisure time physical activity an average week during the last
year with four alternatives: sedentary activities only; moderate
activity like walking, cycling, or exercise at least 4 hours per
week; participation in recreational sports at least 4 hours per
week; and participation in hard training/sports competitions
several times a week. Questions on smoking and snuffing had
three alternatives: Never, Sometimes, or Daily. We assessed the
frequency of alcohol consumption with a scale from 1 to 5:
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“Never,” “Once per Month or Less,” “2‐4 Times per Month,” “2‐3
Times per Week,” and “4 or More Times per Week.” Answers on
the use of medication known to affect bone, presence of
diseases known to affect bone, hormonal contraceptive use,
smoking, snuff use, and alcohol consumption were dichot-
omized into “Yes” and “No.”
Statistical analyses
All analyses were sex‐specific. Population characteristics are
presented by BMI quartiles at baseline. Continuous variables are
presented by means (SDs) and categorical variables by count
(percentages). We compared BMI quartile groups by using one‐
way ANOVA with Bonferroni correction and χ2 test. Welch’s
ANOVA with Games‐Howell post hoc procedure was used if
equal variances assumption was violated. We computed annual
bone‐ and anthropometric‐change variables to account for
differences in time between baseline and follow‐up measures
when describing change and in crude comparisons of groups.
Student’s t test was used to compare BMI losers and BMI gainers.
Associations between the exposure variables baseline BW,
baseline BMI, ΔBW, and ΔBMI and outcomes FN, TH, and TB
ΔaBMD and ΔBMC during follow‐up were assessed by multiple
linear regression using the bone mineral follow‐up score as
outcome and baseline score as a covariate (Y2 = β0 + β1Y1 +
β2XBW + β3…). Initially we conducted a crude univariate
analysis. We then compared the results using change‐score
analysis (Y2 – Y1 = β0 + β1XBW) and checking for consistency
because baseline adjustments in change‐score analysis may
introduce bias.(28,29) All adjusted models included baseline
anthropometric measures, time between measurements, pub-
ertal maturation, and perceived baseline physical activity level.
Other variables previously known to be of clinical importance
like ethnicity, alcohol consumption, smoking, snuff use,
diagnosis known to affect bone, medication known to affect
bone (see Table 1, and hormonal contraceptive use (all baseline
measures) were then added as covariates using a backwards
elimination strategy where p = 0.10 were used as cut‐off to
enter or leave the model. Any covariate with p ≤ 0.10 in a final
model was included in all final models. Based on this
procedure, alcohol consumption and diagnosis known to affect
bone were excluded. We fitted separate models for baseline‐
and change‐exposure variables. Models with ΔBW were
adjusted for Δheight. We checked for confounding and
plausible 2‐way interactions related to age, pubertal matura-
tion, and baseline weight versus weight change relationships.
Because of statistical significance (p < 0.05) we added interac-
tion terms BW *menarche age and BMI * menarche age in
corresponding baseline ΔaBMD FN models in girls. In boys, a
significant interaction between ΔBMI * BMI was detected and
included in three ΔBMI models: FN ΔaBMD, FN ΔBMC, and TB
ΔBMC; ΔBW * BW was added to the ΔBW TB ΔBMC model.
Interactions were further explored and visualized by graphs.
Late introduction of the PDS questions in TFF1 may be the
reason for a relatively high percentage of missing puberty
values for boys: n = 53 (17.9%). Other missing covariates were
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Fig. 1. Flowchart of participation in Fit Futures 1 (TFF1) 2010 to 2011 and Fit Futures 2 (TFF2) 2012 to 2013. The Tromsø Study, Fit Futures.
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Table 1. Characteristics by BMI Quartiles at Baseline TFF1 (2010 to 2011). The Tromsø Study, Fit Futures












(n = 88) p value
Girls (n =
355)
Age (years) 16.61 (0.387) 16.69 (0.44) 16.64 (0.36) 16.60 (0.38) 16.52 (0.35) 0.042
Body height (cm) 165.03 (6.48) 165.77 (6.49) 165.92 (6.15) 164.65 (6.44) 163.95 (6.70) 0.127
Body weight (kg) 60.37 (10.61) 51.31 (4.48) 56.59 (4.03) 60.87 (5.12) 72.97 (11.65) <0.001
BMI (kg/m2) 22.17 (3.76) 18.65 (0.76) 20.54 (0.48) 22.42 (0.62) 27.13 (3.97) <0.001
FN aBMD (g/cm2) 1.07 (0.12) 1.03 (0.11) 1.06 (0.13) 1.07 (0.13) 1.13 (0.11) <0.001
TH aBMD (g/cm2) 1.06 (0.13) 1.02 (0.11) 1.05 (0.13) 1.06 (0.13) 1.12 (0.11) <0.001
TB aBMD (g/cm2) 1.14 (0.08) 1.09 (0.06) 1.13 (0.07) 1.14 (0.07) 1.20 (0.06) <0.001
FN BMC (g) 4.91 (0.71) 4.62 (0.59) 4.82 (0.65) 4.89 (0.68) 5.31 (0.72) <0.001
TH BMC (g) 32.01 (4.84) 30.06 (4.31) 31.39 (4.48) 31.82 (4.51) 34.81 (4.84) <0.001











FN BA (cm2) 4.59 (0.34) 4.50 (0.35) 4.57 (0.29) 4.59 (0.33) 4.73 (0.37) <0.001
TH BA (cm2) 30.15 (2.33) 29.53 (2.26) 30.05 (1.83) 30.07 (2.40) 30.95 (2.58) 0.001











Ethnicity White 347 (97.8%) 84 (94.4%) 89 (100%) 88 (98.9%) 86 (97.7%) 0.068
Others 8 (2.2%) 5 (5.6%) 0 (0%) 1 (1.1%) 2 (2.3%)
Menarche age
(n = 348)
Early 110 (31.0%) 17 (19.3%) 22 (24.7%) 35 (40.2%) 36 (41.4%) 0.002
Intermediate 165 (46.5%) 42 (47.7%) 48 (53.9%) 39 (44.8%) 39 (44.8%)
Late 73 (20.5%) 29 (33.0%) 19 (21.3%) 13 (14.9%) 12 (13.8%)
Physical activity at
baseline
Sedentary 42 (12.0%) 17 (19.1%) 9 (10.0%) 7 (7.9%) 10 (11.2%) 0.054
Moderate 141 (39.5%) 36 (40.4%) 26 (28.9%) 35 (39.3%) 44 (49.4%)
Sports 110 (30.8%) 22 (24.7%) 36 (40.0%) 28 (31.5%) 24 (27.0%)
Competition 63 (17.6%) 14 (15.7%) 19 (21.1%) 19 (21.3%) 11 (12.4%)
Alcohol (yes) 262 (73.2%) 58 (65.2%) 68 (75.6%) 72 (80.0%) 64 (71.9%) 0.160
Smoking (yes) 68 (19.0%) 13 (14.6%) 15 (16.7%) 22 (24.4%) 18 (20.2%) 0.349
Snuffing (yes) 108 (30.2%) 22 (24.7%) 24 (26.7%) 33 (36.7%) 29 (32.6%) 0.282
Hormonal contraceptives use (yes) 118 (33.0%) 24 (27.0%) 32 (36.0%) 32 (36.0%) 30 (25.4%) 0.532
Medication known to affect
bone (yes)a
8 (2.2%) 1 (1.1%) 3 (3.4%) 3 (3.4%) 1 (1.1%) 0.646
Diagnosis known to affect
bone (yes)b












(n = 74) p value
Boys (n =
296)
Age (years) 16.60 (0.37) 16.50 (0.38) 16.63 (0.38) 16.67 (0.33) 16.61 (0.36) 0.034
Body height (cm) 177.25 (6.52) 177.30 (6.45) 177.12 (7.05) 177.56 (6.56) 177.00 (6.10) 0.957
Body weight (kg) 69.81 (13.68) 57.10 (5.16) 64.43 (5.49) 71.46 (5.49) 86.26 (14.11) <0.001
BMI (kg/m2) 22.18 (3.93) 18.14 (.85) 20.50 (.60) 22.64 (.62) 27.45 (3.64) <0.001
FN aBMD (g/cm2) 1.11 (0.15) 1.01 (0.11) 1.12 (0.14) 1.13 (0.13) 1.19 (0.16) <0.001
TH aBMD (g/cm2) 1.12 (0.15) 1.02 (0.11) 1.12 (0.13) 1.15 (0.14) 1.20 (0.16) <0.001
TB aBMD (g/cm2) 1.18 (0.10) 1.10 (0.08) 1.18 (0.08) 1.20 (0.08) 1.24 (0.09) <0.001
FN BMC (g) 5.99 (0.99) 5.32 (0.75) 6.01 (0.87) 6.12 (0.90) 6.53 (1.04) <0.001
TH BMC (g) 40.17 (6.64) 35.61 (5.20) 40.11 (5.76) 41.30 (6.09) 43.65 (6.79) <0.001











FN BA (cm2) 5.38 (0.39) 5.29 (0.43) 5.37 (0.35) 5.40 (0.35) 5.48 (0.39) 0.024
TH BA (cm2) 35.73 (2.47) 34.71 (2.61) 35.69 (2.31) 36.03 (2.21) 36.48 (2.47) <0.001











Ethnicity White 291 (98.3%) 74 (100%) 71 (95.9%) 74 (100%) 72 (97.3%)
(Continues)
menarche age in seven girls and physical activity in one girl and
three boys. Multiple imputations based on predictors and
outcome variables were performed to predict missing values.
We assumed missing at random and 20 imputations were
conducted,(30) and we report pooled estimates. Normal
distribution, linearity, homogeneity, and outliers were explored
by residual analysis. In girls, two outliers were excluded in TH
ΔaBMD: one in FN ΔaBMD and one in TH ΔBMC models. We
used weighted least square regression in all TB ΔBMC models in
girls to account for heteroscedasticity. Significance level was set
to p = 0.05 and all procedures were performed in IBM SPSS
Statistics for Windows, version 24 (IBM Corp., Armonk, NY, USA).




We included 651 adolescents with repeated measurements in
the analyses, 355 girls and 296 boys (45.2% boys). At baseline,
mean age was 16.6 years (range, 15.7 to 17.9), and 18.6 years
(range, 17.8 to 20.1) at follow‐up. Average follow‐up time was
1.94 years (SD 0.2). Table 1 displays the baseline characteristics
according to BMI quartile groups. In girls, mean group BMI for
first to fourth quartile were 18.65, 20.54, 22.42, and 27.13 kg/m2,
respectively. In boys, means were 18.14, 20.50, 22.64, and
27.45 kg/m2, respectively.
One‐way ANOVA analyses showed that cross‐sectional
anthropometric, aBMD, and BMC measures differed signifi-
cantly with a positive linear trend between BMI quartiles at
baseline, except body height. These cross‐sectional differences
persisted at follow‐up 2 years later (not shown). In girls,
menarche age differed significantly with higher prevalence of
early menarche at the two upper BMI quartiles compared with
the bottom quartile (p = 0.002). In boys, physical activity at
baseline differed significantly (p = 0.004) with a higher pre-
valence of sedentary behavior for the upper quartile (39.7%)
compared with the other quartiles, and there was a low
proportion of snuff users in the second quartile compared with
the three other groups (p = 0.003).
Among girls, 5.9% of participants were classified as under-
weight, 75.4% normal weight, 14.0% overweight, and 4.7%
obese according to Cole’s weight classification at baseline with
a mean group BMI of 17.6, 21.9, 26.2, and 33.9 kg/m2,
respectively. Among boys, 8.4% of participants was classified
as underweight, 70.6% normal weight, 14.5% overweight, and
6.4% as obese. Mean group BMI in boys were 17.2, 21.0, 26.2,
and 32.5 kg/m2, respectively. Proportions in the two upper
categories increased during follow‐up. In girls, the prevalence
of overweight and obesity combined had increased to 20.6% in
2 years. In boys, the prevalence of overweight and obesity
combined increased to 28% at TFF2 (data not shown).
In girls, mean annual BW and BMI change was 1.38 kg (95%
confidence interval [CI], 1.12 to 1.64) and 0.41 kg/m2 (95% CI, 0.31
to 0.50). Boys gained 2.70 kg (95% CI, 2.35 to 3.04) and 0.61 kg/m2
(95% CI, 0.51 to 0.72), respectively. Eighty‐eight girls (24.6%) and
48 boys (16.2%) lost BW with an average annual loss of –1.60 (95%
CI, –1.92 to –1.28) and –1.97 (95% CI, –2.43 to –1.51) kg. One‐
hundred eleven girls (31.3%) and 62 boys (20.9%) reduced their
BMI during follow‐up, with a mean annual decrease of −0.56 (95%
CI, –0.66 to –0.46) and –0.66 (95% CI, –0.81 to –0.51) kg/m2. We
observed a clear difference in longitudinal growth between girls
and boys. In girls, 280 (78.9%) of the participants had an













(n = 74) p value





Just started 22 (18.1%) 9 (16.7%) 12 (18.8%) 9 (14.3%) 14 (22.6%) 0.216
Underway 177 (72.8%) 43 (79.6%) 49 (76.6%) 45 (71.4%) 40 (64.5%)




Sedentary 77 (26.3%) 24 (32.9%) 10 (13.5%) 14 (19.2%) 29 (39.7%) 0.004
Moderate 75 (25.6%) 21 (28.8%) 22 (29.7%) 16 (21.9%) 16 (21.9%)
Sports 70 (24.2%) 17 (23.3%) 20 (27.0%) 17 (23.3%) 17 (23.3%)
Competition 62 (23.9%) 11 (15.1%) 22 (29.7%) 26 (35.6%) 11 (15.1%)
Alcohol (yes) 195 (65.9%) 49 (66.2%) 41 (55.4%) 50 (67.6%) 55 (74.3%) 0.109
Smoking (yes) 62 (20.9%) 19 (25.7%) 9 (12.2%) 16 (21.6%) 18 (24.3%) 0.173
Snuffing (yes) 108 (36.5%) 30 (40.5%) 14 (18.9%) 30 (40.5%) 34 (45.9%) 0.003
Medication known to affect
bone (yes)a
6 (2.0%) 1 (1.4%) 2 (2.7%) 1 (1.4%) 2 (2.7%) >0.999
Diagnosis known to affect
bone (yes)b
5 (1.7%) 1 (1.1%) 1 (1.1%) 2 (2.7%) 1 (1.1%) >0.999
Continuous variables are described by mean (SD) and categorical by count (%).Cut-off points for BMI quartiles (kg/cm2) were 19.71, 21.43, and 23.48
in girls and 19.39, 21.56, and 23.77 in boys.
aMedication known to affect bone (ATC): D07A Plain corticosteroids, H03A Thyroid preparations, N03A Antiepileptic, R01AD Corticosteroids, R03BA
Glucocorticoids (inhalants), and H02A Corticosteroids for systemic use.
bDiagnosis known to affect bone (according to the 10th revision of the International Statistical Classification of Diseases and Related Health
Problems): E03 Hypothyroidism, E10 Diabetes type 1, F50.9 Eating disorders, K90.0 Celiac disease, and M13 Arthritis.
aBMD = Areal bone mineral density; BMC = bone mineral content; BA = bone area; FN = femoral neck; TH = total hip; TB = total body; ATC =
Anatomical Therapeutic Chemical.
increment in height between measurements with an annual
mean of 0.053 cm (95% CI, 0.049 to 0.056). Almost all the boys
(93.2%, n = 276) grew taller during the 2 years of follow‐up.
Annual mean change was 1.024 cm (95% CI, 0.928 to 1.120).
Cross‐sectional measures and the individual aBMD trajec-
tories from TFF1 to TFF2 and unadjusted means within baseline
BMI quartiles are illustrated in Fig. 2. Post hoc analysis showed
that, among boys, the first quartile had significantly lower, and
the fourth quartile significantly higher FN, TH, and TB aBMD
than the other quartiles at both time points (p < 0.05). There
were no significant differences in aBMD status between second
and third quartiles in any of the three skeletal sites, neither at
baseline nor at follow‐up. In girls, the pattern appeared similar
to boys, but less polarized in the lower BMI quartiles. The aBMD
levels in girls in the first quartile did not differ significantly from
the two middle quartiles at the femoral sites.
When participants were stratified into BMI categories, the
relationships slightly changed. Figure 3 indicates that although
not statistically significant, and unlike the girls, boys in the
obese category had lower mean FN, TH, and TB aBMD at both
measure points compared with their overweight peers. Boys
classified as underweight had significantly lower aBMD at
baseline compared with those with normal weight (FN:
p = 0.001, TH: p = 0.005, TB: p < 0.001) and this pattern
persisted during the 2 years of follow‐up in crude analyses.
Body weight, body mass index, and bone accretion
Changes in anthropometry, ΔaBMD, and ΔBMC during follow‐up
according to baseline BMI quartiles are presented in Table 2. In
crude comparisons of quartiles, no statistically significant differ-
ences were found, except ΔBW, ΔBMI, and ΔTB BMC in girls. The
first quartile gained more weight compared with the second
quartile, and accumulated more total body bone than the fourth
quartile.
Figure 4 depicts mean ΔaBMD (Fig. 4A) and ΔBMC (Fig. 4B)
among BMI losers and BMI gainers between TFF1 and TFF2.
Reduction of BMI seemed to induce a slower bone accretion
rate, especially in boys, but no mean bone loss was observed in
any BMI loser group in either girls or boys. Among girls,
statistically significant differences between the two groups
were found only at TB ΔBMC (p < 0.001). Among boys, TH
ΔaBMD (p = 0.027), TB ΔaBMD (p = 0.011), FN ΔBMC (p = 0.033),
TH ΔBMC (p < 0.001), and TB ΔBMC (p < 0.001) were significant.
The same pattern was observed with loss of BW. In boys, the
BW loser group (n = 48) had a mean annual increment in TH
aBMD of 0.006 g/cm2 (95% CI, 0.000 to 0.012); the BW gainers
had a mean of 0.012 g/cm2 (95% CI, 0.010 to 0.015; not shown).
The crude and adjusted associations from multiple linear
regression models between baseline BW, baseline BMI, ΔBW,
ΔBMI, and ΔaBMD and ΔBMC are presented in Table 3. In girls, no
associations between baseline measures and ΔaBMD were
identified, but both baseline BW (p= 0.009) and baseline BMI
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Fig. 2. Femoral neck‐, total hip‐, and total‐body aBMD in girls and boys
from TFF1 (2010 to 2011) to TFF2 (2012 to 2013). Individual measures and
group mean according to BMI quartiles at baseline. Girls, n = 355. Boys, n =
296. The Tromsø Study, Fit Futures. In girls, cut‐off points for BMI quartiles
were 19.7, 21.4, and 23.5 and in boys 19.4, 21.6, and 23.8, respectively. The
grey area (violin plot) shows the full population distribution at TFF1 and
TFF2 in both girls and boys. The points specify each individual
measurement and the thin dotted lines show participants individual
accretion during follow‐up. The thick lines indicate the baseline BMI quartile
group mean aBMD accretion between measurements. aBMD = Areal bone
mineral density; BMI = body mass index (kg/m2).
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Fig. 3. Mean aBMD accretion of femoral neck, total hip and total body aBMD in girls and boys between baseline survey TFF1 (2010 to 2011) and the
follow‐up survey TFF2 (2012 to 2013) according to baseline BMI categories underweight, normal weight, overweight, and obese. The Tromsø Study,
Fit Futures. Girls, n = 355. Boys, n = 296. In girls, the BMI intervals for baseline BMI categories were: underweight: 16.2 to 18.2, normal weight: 18.1 to
24.7, overweight: 24.5 to 29.1, and obese: 29.8 to 41.2 (kg/cm2). In boys, the intervals were 16.2 to 17.8, 17.7 to 24.2, 24.2 to 28.9, and 29.6 to 40.3
(kg/cm2), respectively. Error bars = 95% confidence interval. aBMD = Areal bone mineral density; BMI = body mass index (kg/cm2).
(p= 0.021) were significantly associated with ΔBMC in the adjusted
TH models. In boys, baseline BW and BMI were statistically
significant predictors of both ΔaBMD and ΔBMC in most models.
Exceptions were crude FN ΔaBMD/ΔBMC and TB ΔBMC. ΔBW and
ΔBMI had a consistent positive association with both ΔaBMD and
ΔBMC in all adjusted models, except ΔBMI ΔaBMD TH (p= 0.086).
The influence on ΔaBMD was strongest at femoral sites in boys,
but overall changes in aBMD were moderate considering the size
of the units of exposure. A baseline BMI difference of 1 SD (3.93
kg/m2) was associated with a 0.008 g/cm2 difference in TH ΔaBMD
over 2 years (p= 0.002), whereas 1 SD ΔBMI (1.89 kg/m2) during
follow‐up was associated with 0.004 g/cm2 ΔaBMD (p= 0.086).
Statistically significant interactions were detected in six models.
Pubertal maturation moderated the relationship of baseline BW/
BMI and FN ΔaBMD in girls, whereas initial BW and BMI appeared
to influence some of the change in weight–bone accretion
associations in FN and TB among boys. The relationships between
bone accretion and weight change were strongest among boys
with low BMI/BW at baseline (Table 3, Fig. 5A and Fig. 5B).
Discussion
In this population‐based study we explored the associations
between BW, BMI, ΔBW, and ΔBMI with changes in bone
parameters in adolescents entering young adulthood. Under-
weight boys had significantly lower mean aBMD at baseline and
this disadvantage persisted during 2 years of follow‐up. Change in
BW and BMI appeared to be a significant predictor of aBMD
change for both girls and boys in the adjusted models, but the
increments of aBMD for each unit change in exposure were
relatively modest. Findings suggest that the influence of weight
change might be strongest among boys with low BMI. Loss of BW
or reduction of BMI was not associated with net loss of aBMD;
however, our results indicate that the bone accretion rate slowed
down whenever weight was lost or BMI reduced during follow‐up
in both sexes. In the present study, more than one of five
adolescents was classified as overweight or obese at baseline; the
prevalence increased during follow‐up for both girls and boys.
The results supported our initial hypothesis with a few
exceptions. In girls, the influence of baseline weight status on
ΔaBMD was limited compared with the results in boys. This may
be caused by gender differences in maturation. Cessation of
longitudinal growth in girls and strong genetic control reduce the
accumulation of bone mass. Previously published results indicate
that girls reach a femoral aBMD plateau between 17 and 19 years
of age.(18) The influence of baseline BW and BMI may therefore be
less in girls in this age interval because adaptation to mechanical
loading is greater in a growing skeleton.(31)
A positive cross‐sectional association between BMI and aBMD
and a positive association between baseline BW and increased Z‐
score in femoral sites over 2 years in boys have previously been
shown in the Fit Futures cohort.(18,32) In the present study, we
report that cross‐sectional associations between BMI and aBMD
were still present at TFF2 in both girls and boys 2 years later. Our
findings are in accordance with a recent meta‐analysis and
systematic review by Van Leeuwen and colleagues.(16) They
included 27 observational studies on the relationship between
BW and bone mineral parameters in participants between 2 to
18 years of age and concluded that overweight and obese
individuals had significantly higher aBMD and BMC than
counterparts with normal BW. However, only one longitudinal
study exploring the long‐term consequences of childhood
obesity was included in the meta‐analysis. Threshold effects of
BMI´s positive influence on bone have been previously
reported.(33,34) Although nonsignificant and based on a small
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Table 2. Annual change in body height (cm), body weight (kg), BMI (kg/m2), aBMD (g/cm2) and BMC (g) between TFF1 (2010‐2011)
and TFF2 (2012‐2013) by BMI quartiles at baseline. The Tromsø Study, Fit Futures
BMI quartiles at baseline
Total First quartile Second quartile Third quartile Fourth quartile p‐value
Girls
(n = 355)
Δ Body height 0.365 (0.455) 0.419 (0.521) 0.389 (0.388) 0.325 (0.435) 0.326 (0.455) 0.417
Δ Body weight 1.383 (2.501) 1.928 (1.718)2 0.934 (1.944)1 1.275 (2.238) 1.394 (3.614) 0.004
Δ BMI 0.406 (0.910) 0.608 (0.656)2 0.243 (0.699)1 0.381 (0.852) 0.392 (1.280) 0.005
Δ FN aBMD 0.003 (0.019) 0.003 (0.018) 0.003 (0.019) 0.005 (0.020) 0.002 (0.018) 0.755
Δ TH aBMD 0.005 (0.017) 0.006 (0.017) 0.004 (0.018) 0.006 (0.017) 0.005 (0.016) 0.809
Δ TB aBMD 0.009 (0.010) 0.009 (0.010) 0.010 (0.009) 0.009 (0.011) 0.006 (0.010) 0.094
Δ FN BMC 0.014 (0.095) 0.011 (0.093) 0.017 (0.093) 0.017 (0.096) 0.013 (0.099) 0.970
Δ TH BMC 0.180 (0.592) 0.241 (0.605) 0.116 (0.557) 0.171 (0.626) 0.193 (0.580) 0.563
Δ TB BMC 39.609 (60.362) 55.290 (37.087)4 32.229 (50.509) 45.379 (52.165) 25.379 (86.922)1 0.001
Boys
(n = 296)
Δ Body height 0.929 (0.867) 1.076 (1.011) 0.896 (0.619) 0.864 (1.103) 0.882 (0.624) 0.414
Δ Body weight 2.697 (3.022) 2.928 (2.332) 2.974 (2.413) 2.661 (3.370) 2.224 (3.732) 0.481
Δ BMI 0.614 (0.950) 0.692 (0.718) 0.713 (0.736) 0.629 (1.082) 0.424 (1.170) 0.315
Δ FN aBMD 0.16 (0.027) 0.018 (0.025) 0.015 (0.026) 0.013 (0.028) 0.020 (0.028) 0.402
Δ TH aBMD 0.012 (0.022) 0.010 (0.022) 0.010 (0.023) 0.009 (0.023) 0.017 (0.022) 0.093
Δ TB aBMD 0.023 (0.015) 0.024 (0.016) 0.022 (0.015) 0.021 (0.015) 0.024 (0.016) 0.475
Δ FN BMC 0.100 (0.176) 0.107 (0.173) 0.089 (0.175) 0.077 (0.176) 0.129 (0.180) 0.308
Δ TH BMC 0.566 (1.072) 0.514 (1.067) 0.527 (1.177) 0.440 (1.029) 0.783 (0.997) 0.229
Δ TB BMC 118.818 (77.247) 121.371 (67.240) 121.005 (69.577) 118. 124 (81.233) 114.773 (90.133) 0.951
aBMD =Areal bone mineral density (g/cm2), BMC = Bone mineral content (g), FN = Femoral neck, TH = Total hip, TB = Total body, BMI = Body mass
index (kg/cm2), body weight in kg, Δ = change. Cut‐offs points for BMI quartiles were 19.71, 21.43, 23.48 (kg/m2) in girls and 19.39, 21.56, 23.77
(kg/m2) in boys. Average follow‐up time was 1.94 years (SD 0.2).1234 Significantly different from specified quartile (p < 0.05) analysed using bonferroni
post‐hoc test for multiple comparisons.
number of subjects, we observed that adolescent boys classified
as overweight had the highest mean aBMD, higher than those
classified as obese. This pattern was not observed when
participants were stratified into BMI quartiles. The mean BMI
was higher in the obese category (32.5 kg/m2) than the fourth
BMI quartile (27.1 kg/m2), representing the tail of the distribu-
tion. In girls, the associations between baseline BMI categories
and measured bone traits were positive and had a linear trend.
Change in body weight and BMI and accretion of aBMD
Bone loss during weight reduction is well‐documented in older
individuals, but not yet demonstrated in younger populations.(21)
We found no net loss of aBMD or BMC in participants losing BW or
reducing their BMI during follow‐up. However, mean annual BMI
reduction was modest (−0.56 kg/cm2 among girls and −0.66 kg/
cm2 among boys) over 2 years in our study. To investigate more
extreme cases of weight loss, an elaborate analysis stratifying
ΔBMI in deciles was conducted (within 10th percentile, mean
annual ΔBMI of −1.16 kg/m2 in both girls and boys), but a
significant loss of aBMD was still not detected (not shown). The
association between weight loss and loss of bone is more
consistent in older compared with younger individuals.(35) This
may be linked to relatively better maintained muscle function in
the younger age groups.(21) There is a strong relationship between
lean mass and bone, and healthy adolescents are less vulnerable
to loss of muscle function during weight reduction compared
with older peers. Furthermore, older people may be more prone
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Fig. 4. Mean annual (A) aBMD and (B) BMC change in BMI losers and BMI gainers between baseline survey TFF1 (2010 to 2011) and the follow‐up
survey TFF2 (2012 to 2013). The Tromsø Study, Fit Futures. Girls, n = 355. Boys, n = 296. BMI loser girls: n =111, BMI losers boys: n = 62. FN = Femoral
neck; TH = total hip; TB = total body; ΔaBMD = change in areal bone mineral density (g/cm2); ΔBMC = change in bone mineral content (g); BMI = body
mass index (kg/cm2). Error bars = 95% confidence interval. Two‐tailed t‐test for differences in mean: ns: p > 0.05, *p ≤ 0. 05, **p ≤ 0.01, ***p ≤ 0.001.
to bone loss because of reduced efficiency in calcium absorption
with age.(36)
The determinants of bone acquisition in the period of late
adolescence to early adulthood are understudied,(4) and there are
a limited number of studies of weight change and bone in a
comparable population. Most studies are among pre‐, peri‐, and
postmenopausal women, in relation to weight‐reduction inter-
ventions, eating disorders, use of medications, or bariatric
surgery.(21,37,38) Studies on anorexia nervosa in adolescence are
not directly comparable, but longitudinal studies of weight gain
and restoration of BW show significant, although slow, improve-
ment and normalization of aBMD levels.(39) In a recent study,
extensive BMI gain during puberty was associated with lower
increments in aBMD.(40) Exploring the effect of weight change on
bone mass in obese female adolescents, Rourke and colleagues(41)
found no bone loss, but concluded that reduction of BW induced
a reduced bone growth rate over 12‐month follow‐up—results
that are comparable to our findings.
The effect of weight reduction on bone depends on whether
it is voluntary or involuntary, the rate of change, age, sex, and
initial weight.(37) In the current study, we had no information
on the reason for our participants’ BW reduction, whether it
was based on dieting, disease/illness, or natural fluctuations.
Normally, adults’ BW fluctuates by >0.25 kg/year, but in
adolescence BW may be more unstable.(42) Furthermore, we
have no information on when during the 2‐year follow‐up the
weight change occurred. The adaptive response delay of bones
makes interpretations harder. Changes in weight precede
skeletal adaptation to mechanical loads; the bone mass
adaptation rate seems to depend on direction and magnitude
as changes are more rapid during unloading than reloading.(8)
Bone adaptation to weight change has also been shown to be
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Table 3. Adjusted associations between baseline and changes in weight parameters and femoral bone development during two
year follow‐up. The Tromsø Study, Fit Futures
FN TH TB
Crude Adjusted Crude Adjusted Crude Adjusted¤
β p β p β p β p β p β p




BMI .001 .546 .001* .779 .002 .335 .002 .200 .000 .925 −.001 .607
BMI x menarche age −.003 .009
Δ Body weight .004 .057 .002 .002 .005 .005 .005 .004 .002 .026 .002 .083
Δ BMI .001 .560 .001 .001 .004 .030 .004 .016 .002 .110 .001 .169
ΔBMC Body weight .024 .029 .019 .105 .171 .013 .182 .009 9.891 .294 7.074 .461
BMI .009 .378 .010 .339 .112 .076 .148 .021 −3.405 .642 −1.900 .803
Δ Body weight .026 .008 .024 .009 .221 <.001 .218 <.000 64.494 <.001 66.417 <.000
Δ BMI .015 .125 .021 .025 .181 .002 .287 .001 60.323 <.001 63.387 <.000
FN TH TB
Crude Adjusted Crude Adjusted Crude Adjusted
β p β p β p β p β p β p
Boys n = 296 ΔaBMD Body weight .008 .005 .009 .009 .008 .005 .009 .002 .006 .002 .006 .005
BMI .006 .076 .008 .008 .006 .021 .008 .002 .004 .024 .005 .007
Δ Body weight .007 .015 .004 .004 .008 .002 .005 .023 .008 <.001 .007 .003
Δ BMI .003 .333 .005# .081 .004 .083 .004 .086 .006 .001 .006 .001
Δ BMI x BMI −.008 .004
ΔBMC Body weight .059 .009 .078 .001 .072 .023 .374 .005 33.515 .008 34.190 .007
BMI .051 .017 .070 .001 .268 .043 .399 <.000 16.358 .130 18.815 .085
Δ Body weight .064 .001 .040 .030 .548 <.001 .328 .005 93.669 <.001 87.503§ .000
Δ Body weight x body
weight
−19.109 .004
Δ BMI .031 .120 .049# .017 .347 .005 .452 .002 77.863 <.001 84.189# .000
Δ BMI x BMI −.056 .003 −24.348 .001
All β coefficients are per SD change in exposure. BMC = Bone mineral content (g), FN = Femoral neck, TH = Total hip, TB= Total body, BMI= Body
mass index (kg/m2), body weight in kg. Δ = change. adjusted models included age, sexual maturation, physical activity level, baseline aBMD or BMC
measurement, time between measurements, ethnicity, use of medication known to affect bone, hormonal contraceptives use (girls), snuff use and
smoking. In girls, one outlier in FN ΔaBMD (n = 354) models was excluded, two in TH ΔaBMD (n = 353) and one in TH ΔBMC models (n = 354). All
baseline body weight models were adjusted for baseline height. ΔBody weight models were adjusted for baseline height and Δ height, whereas Δ BMI
models adjusted for baseline BMI. Multiple imputation were conducted based on predictors and outcome variables in the adjusted models and
pooled estimates are shown. ¤ Weighted least square regression (n = 348 because imputation were not used). *The effect of weight and BMI should be
measured as (β1 + β3 (menarche age)), #The effect of Δ BMI should be measured as (β1 + β3 (BMI)), § The effect of Δ body weight should be measured
as (β1 + β3 (body weight)). All interactions are based on mean‐centered variables and visually explored in Figure 5.
modified by exercise, nutrition, and medication.(21) Compared
with high initial body weight, leaner individuals have been
demonstrated to suffer greater bone loss during weight
reduction.(21) We detected a statistically significant interaction
between baseline BMI and ΔBMI in ΔaBMD FN model in boys
indicating that the relationship between ΔBMI and bone
accretion were strongest in boys with low BMI at baseline. In
a crude analysis, this could very well be participants in the first
quartile “catching up” based on age and pubertal maturation,
but the relationship persisted after adjustments and the
interaction was still present in the fully adjusted model. This
interaction is potentially interesting; however, associations and
relationships need to be tested and confirmed in other cohorts.
BMI reflects both muscle and adiposity; the mechanisms
behind the relationship between weight status and bone are
complex and multifactorial. Excess weight may have both
negative and positive influences on bone health through
different mechanisms. The process of bone modeling is
sensitive to mechanical loading: It has been stated that high
BW improves bone mineralization by increasing the forces
applied on weight‐bearing bones.(43) This effect has similarities
to the positive effect of weight‐bearing physical activities on
bones.(16,44) Both weight‐bearing activity and excess BW could
lead to more lean mass. Greater lean mass, in addition to
compressive force, produces increased tensile force on bone
load and muscles produce the largest physiologic force on
bone.(45) Results in our study indicate that, in girls, weight‐
based (and weight‐bearing‐based) interventions to maximize
the genetic potential of peak bone mass at femoral sites should
be implemented before the age of 15 years to be most
effective. This is in agreement with studies indicating that
prepuberty is the best time to change bone mass trajectory.(46)
On the other hand, weight‐bearing activity is essential during
growth and excess BW may be associated with sedentary
behavior (in the present study, 39.7% of the boys reported to
be sedentary in the upper BMI quartile). In addition to the
mechanical‐loading factors, adipose tissue may exert an impact
on bone homeostasis and bone turnover through various
adipokines like leptin and estrogen.(15) Mechanisms behind the
correlation between changes in weight and bone changes in
older populations are proposed to be related to estrogen
bioavailability or/and decreased calcium intake. Studies
showing a reduction of BMC in the distal forearm during
dietary weight reduction suggest hormonal aspects are
involved, not just gravity and a response to weight‐bearing
related forces.(47) There is also evidence suggesting that obesity
may influence the timing of puberty. Dimitri and colleagues(10)
highlight the effect of sex‐related changes in body composition
when studying relationships between bone and body size.
Obese children reach peak height velocity earlier than age‐
matched lean children do, and late menarche is a determinant
of lower aBMD and a known risk factor for fractures later in
life.(48) Thus, an early menarche in obese girls may have a long
term osteoprotective effect. In the present study, menarche age
moderated the baseline BMI versus FN ΔaBMD relationship.
Among girls with self‐reported late menarche age, BMI
appeared to be negatively correlated with FN ΔaBMD during
follow‐up. This interaction was, however, partly driven by a few
individuals with baseline BMI >35 with considerable regression
line leverage, and the statistical significance of interaction
attenuated (p = 0.083) when these participants were excluded
in a sensitivity analysis.
Strengths and limitations
The population‐based design and repeated measures from a
well‐described representative sample of both sexes from
different municipalities gave strengths to the present study.
The sample size provided an opportunity to analyze the results
in smaller subsamples, and explorations of the tails of the
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Fig. 5. Visualization of interactions (A) baseline BMI and menarche age in girls and (B) baseline BMI and ΔBMI in boys in femoral neck ΔaBMD
regression models. The Tromsø Study, Fit Futures. Girls: n = 354. Boys: n = 296. Interaction plots show unadjusted relationships from linear regression
models, but the interactions persisted after adjustments of relevant confounders. Menarche age: mean (SD) =12.98 (1.19), baseline BMI in boys: mean
(SD) = 22.18 (3.93). aBMD = Areal bone mineral density (g/cm2); BMI= body mass index (kg/m2); Δ = change.
distribution are of clinical interest. Using a dedicated research
unit at the University Hospital of North Norway ensured the
high quality of the data acquisition. We used the same
densitometer through both surveys, with continuous valida-
tions following a standardized common protocol. The main
limitations of this study were the short follow‐up period of 2
years and that individuals were only measured twice. Short
follow‐up periods increase the risk of being obscured by
variability in DXA measurements. On the other hand, the
recommended minimum interval between DXA scans is 6 to 12
months.(49) Difference scores with two time points have
limitations when exploring growth and development processes
because the shape of the trajectory is unknown and additional
measures would be preferred.(50) There are different ap-
proaches when assessing correlates of change between two
time points. Difference‐score as outcome (Y2 – Y1) and follow‐
up measurement (Y2) as outcome using baseline (Y1) as a
covariate are two frequently used methods. Authors recom-
mend a comparison of methods for agreement because in
some situations these two approaches can lead to a different
conclusion in nonrandomized studies based on the statistical
phenomenon regression to the mean and Lord’s paradox.(29,51)
We found agreement in femoral ΔaBMD models, but discre-
pancy in some of the TB and BMC associations (Supplemental
Table S2). Thus, results from the multiple regression model
concerning some of the TB and BMC in this study should be
interpreted with caution. Nevertheless, discrepancies may also
be explained by the fact that dissimilarities in models as
difference‐scores without baseline adjustment fail to take the
initial aBMD or BMC levels into account, consequently
addressing slightly different concepts.
The 2D areal DXA measures have a tendency of over-
estimating BMC of larger bone because wider bones are also
thicker; hence, the interpretation of measures of growing
skeletons must be done with caution because of this size
dependency.(52) This concern especially applies to our male
participants still experiencing longitudinal growth. Shape,
body habitus, and changes in body composition may affect
DXA measurements; it has been suggested that DXA may
not be a valid technique for evaluating bone/weight
associations.(53) The impact of thickness of body tissue
overlaying the measured area could be a concern in
longitudinal studies of the effect of BW changes.(54,55)
However, this mainly applies to lateral scans not performed
in this study(56,57) and weight loss <6 kg has been shown to
have limited influence on DXA aBMD measures.(37) Dietary
intake information such as calcium intake and vitamin D
levels may play a role in bone accretion. Unfortunately,
information on nutrition was not available in The Fit Future
study. Changes during follow‐up in some of the control
variables, such as increased proportions of smokers and
snuff users, make the interpretations of associations harder
(Supplemental Table S1). Nonparticipation and loss to
follow‐up bias could be a problem. With the high atten-
dance rate of 93% of those invited at baseline, the
nonparticipation exposition is limited. Drop‐out analysis
showed a higher proportion of boys, smokers, snuff users,
and consumers of alcohol (girls) among the 32% lost at
follow‐up compared with those who participated in both
surveys. Girls lost at follow‐up had a moderately higher
mean baseline BMI (p = 0.053). This could lead to under-
estimation of the association between BMI and bone
accretion found in this study.
In conclusion, our results indicate that weight status during
late adolescence could play a part in the concept of maximizing
bone mass and density during growth for prevention of future
fractures. ΔBW and ΔBMI predicted ΔaBMD and ΔBMC in both
sexes. Although statistically significant, the magnitude of these
changes in aBMD during follow‐up was moderate and unlikely
to have significant clinical implication on peak bone mass for
adolescents with an adequate BW. Loss of BW or reduction of
BMI was not associated with net loss of aBMD, but individuals
who lost weight during follow‐up, demonstrated a slowed
progression of aBMD accretion compared with those gaining
weight, especially among boys. Considering that more than
one of five adolescents was classified as overweight or obese at
baseline and with an increasing prevalence during follow‐up
for girls and boys, the bone health perspective must be
compared with other health benefits. However, adequate
weight is important for bone and our results indicate that
underweight adolescent boys may benefit from a BMI increase.
Particularly underweight individuals losing weight during this
critical period of bone accretion could be at risk of a less than
optimal peak bone mass acquisition, thus not achieving their
full genetic potential for skeletal mass. Because of the short
follow‐up of 2 years, results must be interpreted with caution.
Further analyses should also examine the effect of lifestyle
factors present at baseline. Moreover, the cohort should be
followed into adulthood to further explore factors that can alter
the bone mass trajectory.
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Supplemental table 1 Characteristics at baseline survey Fit Futures 1 (TFF1) and follow-up survey Fit Futures 2 (TFF2) 2 years later: 














n  n  p n  n  p 
Age 355 16.61 (0.387) 355 18.60 (0.40)  296 16.60 (0.37) 296 18.65 (0.35)  
Age groups at baseline:  15 9 2.5 %    19 6.4 %    
   16 294 82.8 %    238 80.4 %    
   17 52 14.7%    39 13.2 %    
Height (cm) 355 165.03 (6.48) 355 165.73 (6.57) <.001 296 177.25 (6.52) 296 179.08 (6.49) <.001 
Weight (kg) 355 60.37 (10.61) 355 63.08 (11.94) <.001 296 69.81 (13.68) 296 75.21 (14.64) <.001 
BMI 355 22.17 (3.76) 355 22.97 (4.18) <.001 296 22.18 (3.93) 296 23.42 (4.18) <.001 
Sexual maturation a:  Early / Completed 110 31.0 %    22 9.1 %    
   Intermediate / Underway 165 46.5 %    177 72.8 %    
   Late / Barely started 73 20.5 %    44 18.1 %    
Ethnicity   White 347 97.8 %    291 98.3 %    
   Others 8 2.2 %    5 1.7 %    
Physical activity:   Sedentary 42 12.0 % 47 13.3 %  77 26.3 % 81 28.4 %  
   Moderate 141 39.5 % 144 40.8 %  75 25.6 % 60 21.1 %  
   Sports 110 30.8 % 110 31.2 %  71 24.2 % 77 27.0 %  
   Competition 63 17.6 % 52 14.7 %  70 23.9 % 67 23.5 %  
Smoking (yes) 68 19.0 % 102 28.5 % <.001 62 20.9 % 114 38.5 % <.001 
Snuff use (yes) 108 30.2 % 152 42.5 % <.001 108 36.5 % 142 48.0 % <.001 
Alcohol consumption (yes) 262 73.2 % 336 93.9 % <.001 195  65.9 % 272 91.9 % <.001 
Diseases known to affect bone b (yes) 4 1.1 %    5  1.7 %    
Medication known to affect bone c (yes)  8 2.2 %    6 2.0 %    
Hormonal contraceptive use (yes) 118 33.0 %         
   Oestrogen and progestogens 105 29.3%         
   Progestogens-only  13 3.6%         
aBMD FN (g/cm2)  355 1.07 (0.12) 355 1.07 (0.13) 0.008 296 1.11 (0.15) 296 1.14 (0.15) <0.001 
aBMD TH, (g/cm2)  355 1.06 (0.13) 355 1.07 (0.13) <0.001 296 1.12 (0.15) 296 1.14 (0.16) <0.001 
aBMD TB (g/cm2)  355 1.14 (0.08) 355 1.16 (0.07) <0.001 296 1.18 (0.10) 296 1.23 (0.09) <0.001 
BMC FN (g) 355 4.91 (0.71) 355 4.94 (0.72) <0.001 296 5.99 (0.99) 296 6.19 (0.99) <0.001 
BMC TH (g) 355 32.01 (4.84) 355 32.42 (4.95) <0.001 296 40.17 (6.64) 296 41.26 (6.86) <0.001 
BMC TB (g)  355 2522.89 (387.38) 355 2600.95 (381.68) <.001 296 2963.78 (469.83) 296 3200.96 (476.10) <0.001 
BA FN (cm2)  355 4.59 (0.34) 355 4.59 (0.34) .866 296 5.38 (0.39) 296 5.41 (0.37) .003 
BA TH (cm2)  355 30.15 (2.33) 355 30.20 (2.38) .068 296 35.73 (2.47) 296 35.99 (2.51) <.001 
BA TB (cm2)  355 2207.37 (233.59) 355 2241.68 (224.95) <.001 296 2496.46 (240.06) 296 2598.28 (237.87) <.001 
Time between measurements (years) 355 1.95 (0.20)    296 2.01 (0.23)    
 
a Sexual maturation in girls: menarche age. Missing n=7 (1.97 %). Categories: Early (<12.5), intermediate (12.5-13.9) and late (> 14). Sexual maturation in boys: Puberty 
Developmental Scale. Categories: Have not begun (<2), barely started (2-2.9), underway (3-3.9) and completed (4). b Diseases known to affect bone (ICD10): E03 
Hypothyroidism, E10 Diabetes type 1. F50.9 Eating disorders, K90.0 Celiac disease and M13 Arthritis. c Medication known to affect bone (ATC): D07A Plain corticosteroids, 
H03A Thyroid preparations, N03A Antiepileptic, R01AD Corticosteroids, R03BA Glucocorticoids (inhalants), and H02A Corticosteroids for systemic use. 
Supplemental table 2 Sensitivity analysis of crude models. Comparing regression coefficients for baseline- and changes in weight parameters 
during follow-up with and without baseline adjustments in femoral neck (FN) and total hip (TH) models. The Tromsø Study, Fit Futures.  
 
 
aBMD =Areal bone mineral density (g/cm2), BMC = Bone mineral content (g), FN = Femoral neck, TH = Total hip, BMI= Body mass index (kg/cm2), body weight in kg,  ∆= 
change. All β coefficients are per SD change in exposure. All coefficients are per SD change in exposure. Disagreement between models in bold 
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  β p β p β p β p β p β p 
Baseline body 
weight 
unadjusted 0.003 0.134 0.002 0.191 -0.001 0.246 0.009 0.355 0.100 0.089 -16.315 0.010 
adjusted 0.003 0.099 0.003 0.116 0.002 0.184 0.024 0.029 0.171 0.013 5.562 0.559 
∆ Body weight 
unadjusted 0.004 0.062 0.005 0.006 0.002 0.058 0.018 0.067 0.213 <0.001 52.203 <0.001 
adjusted 0.004 0.057 0.005 0.005 0.002 0.026 0.026 0.008 0.221 <0.001 54.730 <0.001 
Baseline BMI 
unadjusted 0.001 0.602 0.002 0.230 -0.002 0.048 0.001 0.879 0.081 0.173 -18.844 0.003 
adjusted 0.001 0.546 0.002 0.335 0.000 0.925 0.009 0.378 0.112 0.076 -7.260 0.335 
∆ BMI 
unadjusted 0.001 0.538 0.004 0.035 0.001 0.200 0.013 0.177 0.175 0.003 52.960 <0.001 


























  β p β p β p β p β p β p 
Baseline 
body weight 
unadjusted 0.006 0.016 0.006 0.016 0.001 0.688 0.018 0.368 0.232 0.049 3.407 0.706 
adjusted 0.008 0.005 0.008 0.005 0.006 0.002 0.059 0.009 0.072 0.023 33.515 0.008 
∆ Body 
weight 
unadjusted 0.008 0.010 0.008 0.002 0.009 <0.001 0.067 0.001 0.552 <0.001 94.428 <0.001 
adjusted 0.007 0.015 0.008 0.002 0.008 <0.001 0.064 0.001 0.548 <0.001 93.669 <0.001 
Baseline 
BMI 
unadjusted 0.003 0.309 0.005 0.049 0.000 0.990 0.023 0.264 0.174 0.140 0.583 0.949 
adjusted 0.006 0.076 0.006 0.021 0.005 0.021 0.659 0.002 0.222 0.082 16.358 0.130 
∆ BMI 
unadjusted 0.003 0.290 0.005 0.079 0.006 0.001 0.033 0.106 0.350 0.004 78.477 <0.001 
adjusted 0.003 0.333 0.004 0.083 0.006 0.001 0.031 0.120 0.347 0.005 77.863 <0.001 
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Bone mineral accrual in childhood and adolescence is a long term primary preventive strategy 
of osteoporosis. Areal bone mineral density (aBMD) is a surrogate measure of bone strength 
and a predictor of fracture risk. The aim of this population-based 2-year follow-up cohort 
study was to explore associations between use of snuff and smoking and changes (∆) in 
aBMD in Norwegian girls and boys aged 15-17 years at baseline. The first wave of the 
Tromsø study, Fit Futures was conducted from 2010 to 2011. Femoral neck (FN), total hip 
(TH), and total body (TB) bone mineral content (BMC) and aBMD were measured by dual‐
energy X‐ray absorptiometry. Information on use of snuff, smoking habits and other lifestyle 
related variables were collected through self-administered questionnaires. Two years later, 
during 2012-2013, the measurements were repeated in the second wave. The present study 
included 349 girls and 281 boys and compared “non-users” with “users” of snuff and “non-
smokers” with “smokers” using linear regression. The influence of “double-use” on bone 
accretion was also explored. 
In girls, no associations between use of snuff and ∆aBMD were found. In boys, use of snuff 
was associated with reduced bone accretion in all ∆aBMD models. Sensitivity analysis with 
exclusion of “sometimes” users of snuff strengthened associations at femoral sites in girls and 
attenuated all associations in boys. 
In girls, no associations between smoking and ∆aBMD were found. However, the FN ∆BMC 
model showed a significant difference between groups in the full model. In boys, only the 
association with TB ∆aBMD was significant in the fully adjusted models. 
In girls, “double-users” analyses showed similar association to smoking. In boys, nearly all 
models showed statistically significant associations with a difference of ~1-2% in ∆aBMD 
between non-users and double-users during two years of follow-up. 
Our results indicate that tobacco use in late adolescence could be detrimental to bone 







Osteoporosis and its clinical manifestation, fragility fractures, constitute major public health 
challenges worldwide and Norway has one of the highest reported hip fracture incidences in 
the world [1, 2]. Areal bone mineral density (aBMD) is a non-invasive way to assess bone 
strength and fracture risk [3]. Bone mineral levels in the elderly is a result of peak bone mass 
(PBM) achieved during childhood and adolescence and subsequent age-related bone loss [4]. 
The bone-building years until the age of 18 are critical, as accrual of approximately 95 % of 
adult bone mass occurs during these years [5]. Optimizing the genetic potential of PBM in 
adolescence is a long term primary preventive strategy of osteoporosis. Around 20-40 % of 
PBM achievement is attributed to lifestyle choices and several modifiable behavioral 
determinants such as physical activity, body composition and use of recreational drugs have 
been identified [6]. Tobacco use has been associated with lower aBMD during bone-building 
years [7, 8].  
Over the past decades, there has been an increase in the prevalence of snuff users in Norway 
[9]. Snuff (Swedish snus) is smokeless, oral tobacco traditionally produced and mainly 
consumed in the Nordic countries. Within the EU/EEA area, Norway and Sweden are 
currently the only two countries allowing snuff for sale. However, even though the sale of 
snuff is prohibited in Finland and Denmark, data collected from these countries, shows that 
snuff is also used there [10].  
The increase in use of snuff in Norway started around the year 1990 among young men and 
after 2005 among women as well [11]. Whereas the amount of traditional smoking has 
decreased, snuff is now the most commonly used tobacco in the age range 16-24 years of age. 
The prevalence of daily smokers in these age groups has dropped from around 30 % to 
roughly 5 % in the last 20 years, while recent studies estimate that 25 % of men and 15 % of 
women use snuff daily [12, 13]. The prevalence of daily use of snuff is still increasing, 
although the rapid growth in proportion has slowed during the recent years [9].  
There are constituents of snuff with a potentially wide range of adverse health effects, but 
these issues are relatively unexplored and evidence is controversial [14]. However, snuff and 
smoke tobacco expose individuals to many of the same substances, and the adverse influence 
of smoking on bone health in the adult population is well established [15]. The evidence of 
similar effects of tobacco on achievement of PBM during growth is suggestive, however, not 
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compelling [6-8, 16-19]. Winther and colleagues found a negative association between 
smoking and aBMD in boys, but no relationship between use of snuff and bone mass among 
Norwegian adolescents 15 to 17 years of age [20]. Apart from this cross-sectional study, the 
associations between snuff and bone at a population level are hardly described.  
We hypothesized that both use of snuff and smoking may influence accretion of bone in 
adolescence. The aim of this study was therefore to explore possible association between use 
of snuff and change in aBMD (ΔaBMD) during a two-year follow-up in late adolescence. In 
addition, the associations between smoking and double use and changes in bone traits were 
explored.  




The study procedures of The Tromsø study, Fit Futures are published previously [21]. Briefly, 
the Fit Futures study is a school-based cohort initiated in 2010-2011 (TFF1). All first year 
upper-secondary school students in Tromsø and the neighbour municipalities were invited to a 
comprehensive health survey. Out of 1117 invited individuals, 1038 adolescents (508 girls 
and 530 boys) attended, giving a participation rate of 92.9 %. In the follow-up survey, Fit 
Futures 2 (TFF2) two years later (2012-2013), all participants in TFF1 and all new students in 
third year of the same upper-secondary schools were invited. A total of 66% of the TFF1 
cohort met in TFF2 providing 688 repeated measures of aBMD. Participants above 17 years 
of age at baseline were excluded (Figure 1) and 630 individuals 15 to 17 years of age, 349 



























Recruitment of participants to both surveys were conducted in close collaboration with the 
schools. The participants received an oral briefing about the study in classrooms and were 
given additional written information about the study in a leaflet. The Clinical Research Unit at 
the University Hospital of North Norway conducted both health examinations during school 
days. All participants gave written informed consent at the study site. Participants younger 
than 16 years of age had to bring a written consent from their superiors to attend the survey. 
The data collection in TFF1 and TFF2 was approved by the Norwegian Data Protection 
Authority and the Regional Committee of Medical Research Ethics (REK nord) with a 
project-specific approval for the present study (Ref. 2019/31193/REK nord). 
 
 
1301 Registered students for first 
year upper secondary school 
2010/11. 
1117 was invited to TFF1. 
1038 participated TFF1.  
508 girls and 530 boys. 
Not reached by invitation/dropped 
out of school: n=184 
Did not attend TFF1: n=79 
Excluded:  
>17 years at baseline n=34.  
Missing data outcome variables n=3. 
Missing data on tobacco n= 21. 
Lost to follow-up: n=350 
688 repeated DXA measures in TFF2 
 (66% of the TFF1 cohort). 







Changes in bone mineral status were measured by Dual energy X-ray Absorptiometry (DXA) 
as femoral neck (FN), total hip (TH) and total body (TB) bone mineral content (BMC; g) and 
aBMD (g/cm²). The same instrument (GE Lunar prodigy, Lunar Corporation, Madison, WI, 
USA) and analytic program (Encore paediatric software [22] ) were used in both TFF1 and 
TFF2. We used auto-analysis software and default region of interest, according to a 
standardized protocol. Previously, the coefficients of variation ((SD/mean] x 100) for the 
DXA device used have been estimated to 1.14 % at the TH and 1.72 % at the FN measured in 
vivo [23]. We used measurements of the left-sided hip, but in 15 cases, the data was erroneous 
or missing and values of the right hip was reported for both TFF1 and TFF2. The main 
outcome of this study was ΔaBMD, however ΔBMC is frequently reported to support the 




We collected data on use of tobacco by electronic self-administered questionnaires. At TFF1 
the question “Do you use snuff?” had three alternatives: “No, never”, “Sometimes” or 
“Daily”. At TFF2, the answers to this question were slightly modified, and an extra alternative 
was added: “In the past, but not now”. If answers were “Sometimes” or “Daily”, participants 
were asked additional questions on frequency. The questions were: “If you use snuff 
sometimes, how many snuff portions do you usually take per week?” Alternatives were “One 
or less”, “2-3”, “4-6”, “7-10” and “More than 10”. For daily users the subsequent question 
was: “If you use snuff daily, how many snuff portions do you usually take per day?” 
Alternatives were “1”, “2-3”, “4-6”, “7-10” and “More than 10”. Information about the age of 
onset of use of snuff, were elicited by a question at TFF2: How old were you when you 
started to use snuff? The 8 alternatives were: “Below 12 years”, “12 years”, “13 years”, “14 
years”, “15 years”, “16 years”, ”17 years”, ”18 years” and “19 years or above”. Questions on 
smoking had an identical structure as those on use of snuff at both surveys, only “portions” 









We measured height and body weight to the nearest 0.1 cm and 0.1 kg (Jenix DS 102 
Stadiometer, Dong Sahn Jenix, Korea), following standardized procedures with no shoes and 
light clothing. Based on these parameters, body mass index (BMI) was calculated (kg/m2). 
Through clinical interviews, we assessed ethnicity, the possibility of pregnancy (exclusion 
criterion for DXA), acute and chronic diseases, use of medication and use of hormonal 
contraceptives.  
 
Pubertal maturation information, physical activity level, and alcohol consumption were 
elicited by the self-administered questionnaire at TFF1. Frequency of alcohol consumption 
was assessed with a scale from 1 to 5: “Never”, “Once per month or less”, “2-4 times per 
month”, “2-3 times per week” and “4 or more times per week”. We dichotomised the answers 
into no (never) and yes. Covariates of pubertal maturation in boys was based on the Pubertal 
Developmental Scale (PDS). Secondary pubertal characteristics as growth spurt, pubic hair 
growth, changes in voice and facial hair growth rated on a scale from 1 (have not begun) to 4 
(completed) were summarized and divided by four. We categorised a score <2 as “have not 
begun”, 2-2.9 as “barely started”, 3-3.9 as “underway” and a score of 4 as “completed” [24]. 
In girls, pubertal maturation was determined based on self-reported age at menarche and 
answers were categorised into “Early” (<12.5 years at menarche), “Intermediate” (12.5 – 13.9 
years) or “Late” (> 14 years) pubertal maturation.  
 
Self-reported physical activity level was assessed by questions from the modernized Saltin-
Grimby Physical Activity Level Scale (SGPALS) [25]. The participants graded their leisure 
time physical activity in an average week during the last year with four alternatives: 
“sedentary activities only”; “moderate activity like walking, cycling or exercise at least 4 
hours per week”; “participation in recreational sports at least 4 hours per week”; 
“participation in hard training/sports competitions several times a week”. If the activity varied 
much, for example between summer and winter, they were asked to give an average.  
 
Hormonal contraceptives use (girls) was categorized into “no”, “estrogen and progestin” and 
“progestin only”. We dichotomised answers on use of medication known to affect bone, and 






All statistical analyses were conducted stratified by sex and characteristics of the study 
population are presented as means and standard deviations (SD), or count and percentages. 
We explored differences by ANOVA with Bonferroni correction and Pearson´s chi-squared 
test. We calculated absolute change (TFF2 − TFF1) and percentage change ((TFF2 − 
TFF1)/TFF1*100) in bone traits. Through DXA measurement dates, we were able to compute 
exact time of follow-up to compute annual change of anthropometric and bone parameters 
used in crude analyses. For simplicity purposes the snuff and cigarette frequency answers 
were categorized into three groups, “<1”, “2-6” and “>7” units per week/day. 
 
The hypothesis of association between the exposure of tobacco and the outcomes of ΔaBMD 
between TFF1 and TFF2 where investigated by linear regression models.  We used TFF2 
score as outcome and included the TFF1 score as a covariate to estimate the predictive value 
of exposure on change (Y2 = β0+ β1Y1+β2Xsnuff+ β3…). We compared the results with 
change-score analysis (Y2-Y1= β 0+β1Xsnuff) and explored consistency as baseline 
adjustments in change-score analysis may introduce bias in regression models comparing 
naturally occurring groups [26]. 
Initially we conducted crude models. Then potential confounders were added in the following 
way: Model 2, the “anthropometry model” comprised the crude model plus age, baseline 
anthropometry (height and weight) and change in anthropometric parameters. In model 3, the 
full model, pubertal maturation and baseline physical activity level were added to the 
“anthropometry model”. In addition, baseline variables previously known to be of clinical 
importance like ethnicity, alcohol consumption, diagnosis known to affect bone, medication 
known to affect bone (see table 1) and hormonal contraceptives use (girls) were then added as 
covariates using a backwards elimination strategy where p=0.10 were used as cut-off to stay 
or leave the model. Based on these elimination procedures ethnicity was added to all models 
in boys and the TH ΔaBMD was adjusted for medication known to affect bone. In girls, 
hormonal contraceptives use was added to all models. All models were adjusted for time 
between measurements. Use of snuff models were controlled for daily smoking and vice 
versa. 
During the first few weeks of TFF1, the questionnaire did not contain the questions related to 
PDS-score, giving a high percentage of missing puberty values among boys: n=52 (18.5 %). 
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In girls, six had missing information on menarche age. Multiple imputation based on 
predictors and outcome variables used in the full model were conducted to predict missing 
values. We assumed missing at random, 20 imputations were performed and we report pooled 
estimates [27]. Normal distribution, linearity, homogeneity and outliers were explored by 
residual analysis. In both girls and boys, one outlier was excluded in all models. In girls, the 
full TB BMC models residuals showed a heteroscedastic pattern and weighted least square 
regression were applied. We used menarche age and PDS scores as continuous variables in 
multiple regression models. Plausible 2-way interactions related to aBMD, age and pubertal 
maturation were checked and interaction terms for age*snuff were added to boys ΔaBMD TB 
full model, and age*double use to the ΔaBMD TB full model in girls. Significance level was 
set to p=0.05 and all procedures were performed in IBM SPSS Statistics for Windows, 






Table 1 Characteristics at baseline survey Fit Futures 1 (TFF1) and annual change in height, weight, areal bone 
mineral density and bone mineral content between TFF1 and Fit Futures 2 (TFF2) by use of snuff status: 
Continuous variables presented as mean (standard deviation) and categorical variables in count (percentage). 



















Age at baseline 16.61 (.36) 16.58 (.38) 16.67 (.48) .483 16.61 (.35) 16.51 (.46) 16.60 (.37) .404 
Body height (cm) 165.44 (6.64) 164.21 (6.24) 164.16 (5.92) .252 177.48 (6.59) 176.34 (6.24) 177.53 (6.66) .651 
Body weight (kg) 60.43 (10.96) 61.08 (9.39) 59.88 (10.06) .844 68.94 (12.78) 71.11 (17.34) 71.23 (14.75) .434 
BMI, (kg/m2) 22.08 (3.80) 22.72 (3.93) 22.20 (3.45) .546 21.85 (3.59) 22.80 (4.98) 22.56 (4.33) .274 
Maturation a Menarche age/PDS-score 13.02 (1.17) 12.88 (1.14) 13.02 (1.28) .734 3.26 (.43) 3.32 (.45) 3.42 (.43) .65 
Ethnicity white/othersb 236 (96.7%) 51 (100.0%) 54 (100.0%) .311 183 (98.9%) 30 (96.8%) 65 (100.0%) .414 
Physical activity Sedentary 24 (9.8%) 2 (3.9%) 15 (27.8%)  42 (22.7%) 8 (25.8%) 23 (35.4%)  
  Moderate 95 (38.9%) 18 (35.3%) 26 (48.1%)  51 (27.6%) 9 (29.0%) 12 (18.5%)  
  Sports 87 (35.7%) 16 (31.4%) 6 (11.1%)  47 (25.4%) 8 (25.8%) 14 (21.5%)  
  Competition 38 (15.6%) 15 (29.4%) 7 (13.0%) <.001 45 (24.3%) 6 (19.4%) 16 (24.6%) .505 
Portions of snuff  <=1   28 (54.9%) 0 (0.0%)    18 (58.1%) 1 (1.5%)  
weekly/dailyc  2-6   16 (31.4%) 27 (50.0%)    5 (16.1%) 28 (43.1%)  
  >=7   7 (13.7%) 27 (50.0%)    8 (13.7%) 36 (55.4%)  
Do you smoke? No never 226 (92.6%) 33 (64.7%) 26 (48.1%)  177 (95.7%) 19 (61.3%) 33 (50.8%)  
  Sometimes 17 (7.0%) 15 (29.4%) 24 (44.4%)  8 (4.3%) 9 (29.0%) 27 (41.5%)  
  Daily 1 (0.4%) 3 (5.9%) 4 (7.4%) <.001 0 (0.0%) 3 (9.7%) 5 (7.7%) <.001 
Cigarettes  <=1   43 (76.8%) 0 (0.0%)    21 (47.7%) 0 (0.0%)  
weekly/dailyc  2-6   11 (19.6%) 6 (75.0%)    19 (43.2%) 4 (50.0%)  
  >=7   2 (3.6%) 2 (25.0%)    4 (9.1%) 4 (50.0%)  
Do you drink alcohol? (yes) 151 (61.9%) 51 (100.0%) 54 (100.0%) <.001 92 (49.7%) 29 (93.5%) 61 (95.3%) <.001 
Diagnosis (yes)d 4 (1.6%) 0 (0.0%) 0 (0.0%) 1.000 4 (2.2%) 0 (0.0%) 1 (1.5%) 1.000 
Medication (yes)e 4 (1.6%) 3 (5.9%) 1 (1.9%) .133 6 (3.2%) 0 (0.0%) 0 (0.0%) .345 
Hormonal contraceptives  No 186 (76.2%) 28 (54.9%) 19 (35.2%)         
  Estrogen and  
  progestin 52 (21.3%) 22 (43.1%) 29 (53.7%)         
  Progestin only 6 (2.5%) 1 (2.0%) 6 (11.1%) <.001        
aBMD FN (g/cm2) 1.071 (.117) 1.091 (.155) 1.051 (.122) .252 1.108 (.150) 1.128 (.170) 1.113 (.148) .798 
aBMD TH (g/cm2) 1.061 (.114) 1.090 (.156) 1.038 (.136) .101 1.121 (.147) 1.143 (.171) 1.119 (.151) .738 
aBMD TB (g/cm2) 1.142 (.074) 1.148 (.084) 1.123 (.069) .167 1.176 (.092) 1.192 (.100) 1.194 (.101) .349 
BMC FN (g) 4.936 (.691) 4.976 (.852) 4.785 (.587) .296 5.966 (.962) 6.121 (1.126) 6.040 (1.031) .676 
BMC TH (g) 32.137 (4.713) 32.821 (5.393) 31.025 (4.738) .149 39.980 (6.457) 41.382 (7.546) 40.460 (6.747) .531 
BMC TB (g) 2532.361 (387.830) 2548.507 (370.368) 2481.440 (394.242) .620 2940.101 (445.767) 2989.046 (530.478) 3021.854 (517.739) .466 
               
ΔBody height (cm per year) .38 (.47) .24 (.41) .42 (.36) .073 1.06 (.89) .91 (.88) .62 (.74) .002 
ΔBody weight (kg per year) 1.47 (2.59) 1.20 (2.43) 1.15 (2.29) .590 3.00 (3.05) 1.99 (2.91) 2.01 (2.88) .031 
ΔaBMD FN (g/cm2 per year) .004 (.019) .003 (.018) -.004 (.019) .019 .022 (.026) .003 (.024) .010 (.027) <.001 
ΔaBMD TH. (g/cm2 per year) .007 (.017) .005 (.016) -.001 (.015) .012 .016 (.022) .002 (.022) .005 (.021) <.001 
ΔaBMD TB (g/cm2 per year) .009 (.010) .008 (.010) .008 (.009) .679 .026 (.015) .019 (.013) .017 (.014) <.001 
ΔBMC FN (g per year) .022 (.097) .012 (.087) -.013 (.091) .047 .132 (.174) .010 (.194) .055 (.156) <.001 
ΔBMC TH (g per year) .227 (.591) .107 (.621) .038 (.537) .066 .772 (1.080) .067 (.997) .260 (.984) <.001 
ΔBMC TB (g per year) 39.680 (60.349) 47.630 (66.963) 27.898 (55.011) .238 132.075 (81.248) 97.151 (60.081) 94.687 (69.825) .001 
Time between measurements (years) 1.925 (.198) 1.935 (.159) 2.055 (.211) <.001 1.949 (.214) 2.078 (.218) 2.103 (.213) <.001 
 
Δ=change. aBMD= areal bone mineral density, BMC= bone mineral content. a Missing PDS score n=52. b Percentage of white. c 
Sometimes=weekly. d Diseases known to affect bone (ICD10): E03 Hypothyroidism, E10 Diabetes type 1, F50,9 Eating disorders, K90.0 
Celiac disease, and M13 Arthritis. e Medication known to affect bone (ATC): D07A Plain corticosteroids, H03A Thyroid preparations, N03A 
Antiepileptic, R01AD Corticosteroids, R03BA Glucocorticoids (inhalants), and H02A Corticosteroids for systemic use. p= ANOVA. 
We included 630 adolescents in the present study, 349 girls and 281 boys (45 % boys) and 
their descriptive statistics stratified by use of snuff status are presented in Table 1. Mean age 
of the participants at baseline was 16.6 (SD 0.4) years with a range from 15.7 to 17.9 years. 
The majority were 16 years of age, 83.1 % and 80.8 % in girls and boys, respectively. At 
follow-up, the mean age was 18.6 (SD 0.4) years with a range from 17.8 to 20.1 years. Mean 
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follow-up time between TFF1 and TFF2 was 2.0 (SD 0.2) years with a range between 1.5 and 
2.7 years. Drop-out analysis revealed that significantly more boys (n=196) than girls (n=111) 
were lost to follow-up. Girls lost to follow-up had higher BMI (0.894 kg/m2, p=0.039), while 
boys had lower baseline FN aBMD (-0.028 g/cm2, p=0.049). Both girls and boys lost to 
follow-up had a statistically significant higher prevalence of snuff use (girls, p=0.001; boys, 
p=0.005) and smoking (girls, p=0.013; boys, p=0.032). 
Use of snuff 
In girls, 244 (69.9 %) were classified as “non-users”, 51 (14.6%) as “sometimes”, and 54 
(15.5 %) as “daily-users” of snuff at baseline. In boys, the corresponding numbers were 185 
(65.9 %), 31 (11.0%), and 65 (23.1 %), respectively. The distribution of age at onset in the 
“users” group (sometimes or daily) is depicted in figure 2. The age of onset was mainly 
between 13 to 16 years of age and mean age was 14.6 in girls (n=93, 12 missing) and 14.7 
years in boys (n=84, 12 missing; 3 participants responding onset under 12 years had age set to 
11 years).  
Figure 2. Distribution of age when starting to use snuff (“users”). The Tromsø Study, Fit Futures. Girls N =93. 






All but six of the “daily-users” at TFF1 remained “daily-users” during follow-up (51 girls and 
62 boys at TFF2). The prevalence of snuff users increased during follow up. In both girls and 
boys, roughly 18 % “of the non-users” reported sometimes or daily use of snuff two years 
later. In the “sometimes” use of snuff category at baseline, more than half of the girls reported 
to usually take one portion or less per week and 86.3 % reported six portions per week or less. 
In boys, we observed corresponding numbers, with 58.1 % and 74.2 %, respectively. 
Furthermore, we observed that individuals in the “sometimes” category at baseline fluctuated 
during follow-up, and only 15 of the 82 remained in their initial “sometimes” category. In 
main analysis, we compared the “non-users” with the “users” of snuff, combining 
“sometimes” and “daily” users of snuff at baseline. Sensitivity analysis were then conducted 
with the “sometimes” group excluded, comparing “non-users” with “daily-users” group only.  
In both girls and boys, the snuff “users” group differed significantly from the “non-users” 
with a higher prevalence of smokers and alcohol consumers (p<0.001). Among girls in the 
“users” category, fewer reported to be engaged in sports activities (p<0.001) and use of 
hormonal contraceptives was more prevalent in the “users” group (p<0.001). In boys, there 
was a statistically significant difference between the compared groups in annual height- 
(p<0.001), and weight change (p=0.020). No differences in baseline aBMD or BMC between 
the groups were observed. 
Crude analyses of “non-users” and “users” of snuff at baseline 
Crude percentage of bone accretion is shown in figure 3. In girls reporting no use of snuff at 
baseline, mean annual ΔaBMD (95% confidence interval) were 0.42 % (0.19, 0.64) at the FN, 
0.64 % (0.43, 0.84) at the TH, and 0.79 % (0.68, 0.91) at the TB. For comparison mean 
annual ΔaBMD for “daily-users” were -0.08 % (-0.41, 0.26), 0.17 % (-0.12, 0.46) and 0.70 % 
(0.55, 0.87), respectively. 
Figure 3 Crude comparisons of “non-users” and “users” of snuff with regard to mean annual percent change in 
Areal bone mineral density (aBMD) between baseline and follow up measurement two years later for femoral 




In boys, annual changes were, 2.00 % (1.65, 2.35) at FN, 1.46 % (1.16, 1.76) at the TH, and 
2.21 % (2.01, 2.41) at the TB in category “non-users” of snuff. In “users” the changes were 
0.77 % (0.27, 1.28), 0.38 % (-0.01, 0.78), and 1.51 % (1.28, 1.75), respectively.    
Adjusted analyses of snuff use at baseline 
The results of crude and adjusted regression models of ΔaBMD and ΔBMC in relation to use 
of snuff are presented in table 2. In girls, the “users” of snuff group had significantly less 
ΔaBMD compared to the “non-user” group in crude models at both femoral sites (FN: β=-
.004, p=.028 and TH: β=-.019, p=.020), but not at TB. No associations were significant in the 
fully adjusted models. 
In boys, statistically significant associations were observed in both ΔaBMD and ΔBMC, 
except in the adjusted ΔBMC TB models. Estimated ΔaBMD between “non-users” and 
“users” of snuff at the FN was 0.012 and 0.015 g/cm2 at the TH in the full models, a 
difference comprising roughly 1 % change during follow-up. In anthropometry models, 





Table 2 Crude and adjusted associations between snuff use at baseline (use versus non-use) and change in 
femoral neck (FN), total hip (TH) and total body (TB) areal bone mineral density and bone mineral content 
during about 2 years follow up, adjusted for baseline measurement. The Tromsø study, Fit Futures. Girls N 




Values are based on linear regression analysis. Δ=change. aBMD= areal bone mineral density, BMC= bone mineral content. Non-users: girls 
n=243 and boys n=184. Users: girls n=105 and boys n=96. Anthropometry model: crude model + age, body height, body weight, Δbody 
height, and Δbody weight. Full model: anthropometry model +pubertal maturation, physical activity level, daily smoking, hormonal 
contraceptives use (girls only) and ethnicity (boys only). All models were adjusted for time between measurements. #Adjusted for 
medication known to affect bone. § n=342 because of weighted least square model. ¤ Interaction age*snuff use β=.019, p=.022. 
Sensitivity analysis 
In analysis where the “sometimes” group was excluded, comparing “non-users” (girls, n=244; 
boys, n=185) with “daily-users” (girls, n=54; boys, n=65) of snuff, showed estimates with 
negative associations between snuff use and bone accrual. In girls, the “daily-users” of snuff 
group had significantly less ΔaBMD at FN compared to the “non-user” group in adjusted 
models: β=-.012, p=.037, while the TH association also strengthened (β=-.009, p=.071). In 
boys, both ΔaBMD and ΔBMC crude models were statistically significant. However, in partly 
adjusted models, all associations were attenuated and turned out insignificant. In the fully 
adjusted models use of snuff was not statistically significantly associated with ΔaBMD. 
In sensitivity analysis related to multiple imputation and the high percentage of missing 
puberty data in boys, the full models with the original sample (“non-users vs “users” with 
original PDS-score, n=229) showed similar estimates, but FN; β=-.015, p=.059 and TB; β=-
.008, p=.062) turned out insignificant.  
 
 





















 Girls n=348       
ΔaBMD Crude -.004 .028 -.009 .020 -.002 .418 
Age and anthropometry -007 .084 -.007 .063 -.001 .793 
Full model -.004 .304 -.003 .443 .000 .862 
ΔBMC Crude -.045  .036 -.310 .018 -1.848 .893 
Age and anthropometry -.034 .100 -.245 .052 10.107 .404 
Full model -.073  .057 -.122 .357 -9.454 § .783 
        
 Boys n=280       
ΔaBMD Crude -.024 .000 -.019 .001 -.015 .000 
Age and anthropometry -.017 .009 -.013 .014 -.009 .010 
Full model  -.015 .023 -.012 # .027 -.322 ¤ .019 
ΔBMC Crude -.170 .000 -1.095 .000 -74.395 .000 
Age and anthropometry -.120 .004 -.712 .003 -25.073 .084 
Full model -.099¤ .020 -.779 .007 -25.021 .098 
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In elaborate analyses of the influence of baseline snuff use and follow-up bone mineral status, 
we compared TFF2 aBMD and BMC parameters between the TFF1 “users” and “non-users” 
group to see if the two groups differed in bone traits at 17-19 years of age. Overall, “non-
users” showed a mean ~1% advantage on their peers consuming tobacco at baseline, but not 
statistically significant (data not shown). 
Association between smoking and bone accrual 
There was a limited number of daily smokers at baseline in the study population, eight girls 
(2.3 %) and eight boys (2.8 %). In the “sometimes” category consisting of 56 girls (16 %) and 
44 (15.7 %) boys, 76.8 % of the girls and 47.7 % of the boys reported to smoke one or less 
cigarette a week. In order to obtain a larger comparison group and to enhance exposure of 
smoking in the “smokers” category, the “one or less” responders were regarded as non-
smokers and a combined “daily/more than 2 cigarettes weekly” category consisting of 21 girls 
and 31 boys was created.  
 
No statistically significant differences in baseline bone traits between smokers and non-
smokers were observed. Otherwise, the groups differed with a higher prevalence of snuff use, 
alcohol consumption and lower physical activity levels in the smokers group compared to the 
non-smokers group. Crude comparisons of change in ΔaBMD are shown in figure 4. 
The results of crude and adjusted regression models of ΔaBMD and ΔBMC in relation to 
smoking are presented in table 3. In girls, no associations between smoking and ΔaBMD were 
observed, but accumulation of BMC at the FN appeared to be reduced (β=.109, p=.006). 
In boys, the full ΔaBMD TB model was statistically significant (β=-.011, p=.037). The 
association for TH in the crude and anthropometric models was statistically significant, but 




Figure 4 Crude comparisons of “non-smokers” and “smokers” with regard to mean annual percent ΔaBMD 
between baseline and follow up measurement two years later for femoral neck, total hip and total body . The 
Tromsø study, Fit Futures. Girls, N =349 (228/21). Boys, N = 281 (250/31). 
 
 
Table 3 Crude and adjusted associations between smoking status (smoker versus non-smoker) at baseline and 
follow up measurement two years later for femoral neck (FN), total hip (TH) and total body (TB) aBMD and 
BMC, adjusted for baseline measurement. The Tromsø study, Fit Futures. 
 
 
Values are based on linear regression analysis. Δ=change. aBMD= areal bone mineral density, BMC= bone mineral content. Non-smokers: 
girls n=327 and boys n=249. Smokers: girls n=21 and boys n=31. Anthropometry model: crude model + age, body height, body weight, 
Δbody height, and Δbody weight. Full model: age and anthropometry model +pubertal maturation, physical activity level, daily snuff use and 
























 Girls n=348       
ΔaBMD Crude -.011 .121 -.011 .128 -.004 .322 
Age and anthropometry -.011 .142 -.013 .063 -.004 .344 
Full model -.009 .288 -.009 .206 -.003 .521 
ΔBMC Crude -.096  .019 -.343 .176 .342 .990 
Age and anthropometry -.105 .008 -.487 .046 -11.898 .613 
Full model -.097 .012 -.348 .169 -22.099* .264 
        
 Boys n=280       
ΔaBMD Crude -.009 .398 -.021 .016 -.016 .006 
Age and anthropometry -.011 .225 -.013 .006 -.013 .008 
Full model  -.009 .411 -.016 .052 -.011 .037 
ΔBMC Crude -.165 .014 -1.127 .004 -49.356 .108 
Age and anthropometry -.125 .042 -.945 .007 -32.578 .123 





At baseline, 46 girls and 44 boys responded that they were double users, indicating responses 
of either “Daily” or of “Sometimes”, for both smoking and use of snuff at baseline. Among 
the “daily-users” of snuff, 28 (51.9%) of the girls and 32 (49.2%) of the boys reported to be 
double users, i.e. both smokers and daily use of snuff. These individuals were mostly 
sometimes smokers as only eight girls and eight boys reported smoking daily. Only one out of 
the 16 daily smokers at baseline was not double user.  
 
The baseline differences between double users and non-users were similar to use of snuff, 
except that annual change in body weight did not differ in boys. The results of crude and 
adjusted regression models of ΔaBMD, ΔBMC and double use are presented in table 4. 
In girls, no relationship was observed between ΔaBMD and double use, while the ΔBMC was 
significantly reduced at the FN (p=.018). In boys, most models turned out statistically 
significant, except the adjusted ΔaBMD FN models. An estimated difference in ΔaBMD 
between “non-users” and “double-users” at the TH of 0.018 g/cm2 corresponds to ~1.6 % 
change during follow-up. 
Table 4 Crude and adjusted associations between double use of tobacco and change in femoral neck (FN), total 
hip (TH) and total body (TB) aBMD and BMC during two years follow up, adjusted for baseline measurement. 



























 Girls n=348       
ΔaBMD Crude -.009  .123 -.006 .216 -.003 .293 
Age and anthropometry -.010 .074 -.008 .114 -.003 .263 
Full model -.009 .114 -.004 .370 -.249 § .020 
ΔBMC Crude -.066  .024 -.276 .122 2.794 .881 
Age and anthropometry -.073 .009 -.337 .048 -2.055 .900 
Full model -.068 .018 -.210 .224 -4.514 * .728 
        
 Boys n=280       
ΔaBMD Crude -.021 .017 -.024 .001 -.018 <.001 
Age and anthropometry -.012 .128 -.018 .005 -.013 .002 
Full model -.012 .124 -.018 .007 -.013  .002 
ΔBMC Crude -.161 .005 -1.127 .004 -64.944 .013 
Age and anthropometry -.105 .045 -.933 .003 -32.578 .123 
Full model -.103 .047 -.898 .003 -32.191 .073 
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Values are based on linear regression analysis. Δ=change. aBMD= areal bone mineral density, BMC= bone mineral content. Non double 
users: girls n=302 and boys n=236. Double-users (snuffing and/or smoking daily): girls n=46 and boys n=44. Anthropometry model: crude 
model + age, body height, body weight, Δbody height, and Δbody weight. Full model: anthropometry model + pubertal maturation, baseline 
physical activity level and ethnicity (boys only). All models were adjusted for time between measurements.*n=342 because of weighted least 
square model.§ Interaction age*double use β=.015, p=.021.  
 
Discussion 
To our knowledge, this is the first population-based study to explore associations between use 
of snuff and bone accumulation in a young population. In girls, snuff use was not associated 
with bone accretion in main analyses, however with an indicated inverse association at 
femoral sites when “non-users” and “daily-users” of snuff were compared. In boys, negative 
associations between use of snuff and ΔaBMD were observed at all skeletal sites. However, in 
contrast to girls, associations attenuated when comparing “non-user” and “daily-users” of 
snuff in sensitivity analyses. Smoking had limited influence on ΔaBMD, while double use 
was associated with a lower rate of bone accumulation at some of the skeletal sites during 
follow-up, especially among boys. With a few exceptions, the regression coefficients were 
negative for both use of snuff, smoking and double use. However, the statistical significance 
of the associations was not consistent and depended on skeletal site and sex. 
The use of snuff in a young population is a relatively new public health issue in Scandinavia, 
and the health related effects of snuff are not much studied. Winther and colleagues explored 
the cross-sectional associations between aBMD and use of snuff in the TFF1 study population 
and found no statistically significant differences between users and non-users [20]. The 
absence of a relationship may be explained by age of onset, duration of use and temporal 
sequence of events. The majority of daily users of snuff reported onset to be one or two years 
before participation in TFF1 and the influence of snuff on bone mass may not have been 
established yet. The reported average debut age for use of snuff in Norway varies as one study 
from 2014 reported 17.7 years of age at snuff initiation in both men and women [12] and 
another reported age of onset to be between 15 to 17 years of age [28]. In the present study, 
we explored the associations of snuff exposure and changes in aBMD during two years of 
follow-up in a cohort where the age of onset was mainly between 13 to 16 years.  
In a study from 2007, no delayed bone healing was observed in male users of snuff after 
osteotomy [29], but no other population-based studies on the snuff and bone relationship were 
found. Some studies have shown that snuff use status and periodontal bone loss are related 
[30], but these findings concerning the oral cavity are not necessarily comparable to skeletal 
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health. There are some studies showing that smokeless tobacco (chewing tobacco, non-
combustible tobacco) accelerates age-related loss of aBMD in various populations, typically 
in India [31], Turkey [32], and in older multi-ethnic women [33, 34]. However, it has been 
argued that Swedish snuff has a lower potential of harm than tobacco products consumed by 
populations in other geographical areas worldwide [35] and thus, may not be comparable with 
these other types of substances related to bone.  
One crucial confounder in this study is the influence of pubertal maturation. The 
developmental differences of normal puberty are large and hormonal status influences timing 
of bone accretion. The rate of bone accretion largely depends on biological rather than 
chronological age [5]. In girls, there was a dose-response relationship between “no never”, 
“sometimes” and “daily” use of snuff and ΔaBMD. In boys, the “sometimes” group gained 
less on average at femoral sites than the “daily-users” did. This could explain why sensitivity 
analysis showed no differences between the “daily-users” and “non-users” of snuff. The 
“sometimes group” did, however, have a higher initial aBMD value. The attenuation of the 
associations by changes in anthropometrics in boys could indicate that some of the variation 
in bone accretion is due to differences in maturation not explained by pubertal maturation 
variable PDS score. The precision of self-reported PDS-score has been questioned [36], and 
use of snuff could be influenced by timing of pubertal maturation, as previously reported for 
smoking and alcohol consumption in another Norwegian cohort [37]. If pubertal maturation is 
critical to align individuals by biological age the multiple imputation process may have an 
impact on the results because a relatively large number of PDS scores were imputed. 
Sensitivity analyses without imputed data indicated this as they attenuated the associations 
leaving only the ΔaBMD TH model statistically significant. 
The influence of smoking on PBM has been investigated more thoroughly; however, the 
evidence is not compelling and limited by methodological challenges. Weaver et al [6] 
identified 6 prospective and 7 cross-sectional studies published since year 2000 with 
inconsistent conclusions, but overall evidence supported the notion that smoking may have a 
deleterious influence on PBM. Discrepancy of associations may be due to diverse 
classifications of smoking status employed or frequency- and duration-dependent effects of 
smoking on bone. The low prevalence of regular smoking frequently limits statistical power 
[6]. Our study was no exception. Dorn and colleagues [7] found that the effect of smoking on 
bone accrual became more pronounced as girls got older. We could not confirm this 
relationship in the TFF cohort, but this may be related to sample size, low prevalence of 
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smokers and degree of exposure. Operationalization of the combined smoking category in the 
present study is debatable. The main concerns are whether “more than 2 cigarettes weekly” 
qualifies as a “smoker” and insufficient statistical power.  
Adolescence is decisive for establishing habits and the high degree of tracking of smoking 
habits from adolescence into adulthood may possibly increase the risk of future low bone 
mass for these individuals [6]. Individuals that smoke (or use snuff) may be more likely than 
their non-smoking peers to have a lifestyle that could negatively affect aBMD and it may be 
hard to disentangle these factors. Essential confounders like body weight and physical activity 
were adjusted for in the full models. Together with changes in anthropometry, smoke was the 
major confounder of the relationship between bone and use of snuff and the same tendency 
was observed for snuff on smoke. This gave the grounds for analysis of double users. 
Mechanisms 
Potential pathophysiologic mechanisms of the adverse effects of tobacco on bone remains to 
be clarified [38]. Snuff may have different effects on bone than smoking does, because it does 
not undergo combustion. Nevertheless, the influence of tobacco on the skeleton may be both 
indirect and direct. Their common denominator is disturbance or imbalance of osteoclast and 
osteoblast activity [38].  
One of the indirect factors may be influence of appetite and successively change in body 
weight, which is a determinant of aBMD [39]. In our study we found no difference in body 
weight or BMI in non-user and users of snuff or smokers. Tobacco could reduce the blood 
supply to the bones because it may have a negative impact on vascular health [14]. Another 
indirect mechanism is by the balance in calciotropic hormones. Abnormal PTH /vitamin D 
axis have been suspected to influence bone metabolism, but these potential mechanisms are 
mostly untested hypothesis [38] .  
The direct mechanism of nicotine may have an effect on bone metabolism as it reduces 
osteoblast production leading to suppressed bone formation [40, 41]. Studies suggest that 
snuff generates the same amount of blood plasma nicotine level as smoking [42]. There is a 
faster uptake of nicotine by smoking, but the blood plasma nicotine level remains higher over 
a longer period of time by use of snuff [43]. However, the influence of nicotine on bone may 
be different in growing and mature skeletons [44]. Other bone-related factors affected by use 
of tobacco is lower cortisol- and estradiol levels and impaired collagen metabolism [45].  
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Study strengths and limitations 
The main strengths of this study are the population-based design and a relatively large, well-
described, study population where both sexes are represented. The Tromsø Study, Fit Futures 
is one of few studies investigating adolescent’s health and lifestyle. Trained personnel at the 
research unit at the University Hospital of North Norway conducted the data collection in 
order to minimize measurement error. However, the study has some limitations to consider. 
Only two measurement points and the relatively short follow-up time made it challenging to 
differ true change in aBMD from measurement error and regression to the mean may be an 
issue. Even though the precision of DXA is good at a group level, the mean changes of less 
than one percent is debatable given the CV of the DXA scanner. DXA has limitations because 
of the two-dimensional measurement of BMD, leading to overestimation of larger bones. The 
assessment of tobacco exposure by self-administered questionnaire may induce social 
desirability bias and underreporting of exposure [46]. Loss to follow-up bias may influence 
the validity of this study, as the study sample comprises roughly 66 % of the original cohort. 
However, a high attendance rate at baseline (93%) contributed to the information of the drop-
out analysis. Proportions of smokers and users of snuff were higher in drop-outs, which could 
lead to an underestimation of the associations between tobacco and bone accrual in the study. 
The use of baseline adjustments in two-wave observational studies with naturally occurring 
groups is debated. Baseline adjustments combined with measurement error may lead to 
directional bias leaving hypothesis tests vulnerable to type-1 error [47], and comparison with 
simple change scores without baseline adjustments were conducted according to advices by 
van Breukelen [26]. When the two approaches do not agree, results should be interpreted with 
caution. The disagreement was limited to 1 out of 36 models (Supplemental table). 
Nevertheless, disagreement may also partly be explained by the fact that one approach 
estimates the total effect of exposure on bone accrual, while the other estimates the direct 
effect, adjusting for the initial bone trait level [48]. 
Conclusion 
 
Our findings suggest an inverse association between use of snuff and aBMD changes in late 
adolescence. In girls, no differences between “non-users” and “users” were identified, but 
snuff use was associated with lower femoral ΔaBMD when comparing “non-users” with 
“daily-users” of snuff only. In boys, negative associations between use of snuff and ΔaBMD 
were observed at all skeletal sites. However, in contrast to girls, associations attenuated when 
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comparing “non-user” and “daily-users” of snuff in sensitivity analyses. The associations 
between smoking and change in bone traits were limited, while double use appeared to have a 
detrimental influence on bone accrual in boys. The results should be interpreted with caution 
due to limitations of the two wave design, potentially unobserved pubertal maturation 
interactions, low prevalence of smokers and a short follow-up time. However, the study 
findings partly support our hypothesis that the use of snuff and smoking are detrimental to 
bone accretion and should be investigated further in cohorts with multiple waves as the 
consumption of snuff is rising among the adolescent population and future bone health 





Supplemental table Sensitivity analysis of crude models. Comparing regression coefficients for baseline 
Use of snuff, smoking and double use with and without baseline adjustments in femoral neck (FN) and total hip (TH) models. The Tromsø Study, Fit Futures.  
 
 
aBMD =Areal bone mineral density (g/cm2), BMC = Bone mineral content (g), FN = Femoral neck, TH = Total hip, TB=Total body. Disagreement between models in bold 
 
























  β p β p β p β p β p β p 
Use of snuff 
Unadjusted  -0.015 0.006 -0.014 0.003 -0.003 0.505 -0.051 0.017 -0.373 0.027 -16.492 0.360 
adjusted -0.015 0.006 -0.014 0.003 -0.003 0.311 -0.073 0.010 -0.385 0.023 -20.242 0.282 
Smoking 
unadjusted -0.011 0.175 -0.011 0.131 -0.003 0.434 -0.092 0.026 -0.342 0.176 0.977 0.971 
adjusted -0.011 0.121 -0.011 0.128 -0.004 0.322 -0.096  0.019 -0.343 0.176 0.342 0.990 
Double use 
unadjusted -0.009 0.130 -0.006 0.234 -0.002 0.502 -0.058 0.047 -0.264 0.139 -7.241 0.704 





















  β p β p β p β p β p β p 
Use of snuff 
Unadjusted  -0.020 0.012 -0.012 0.006 -0.018 <0.001 -0.151 0.003 -0.933 0.003 -80.298 0.001 
adjusted -0.019 0.008 -0.018 0.006 -0.016 0.000 -0.146 0.004 -1.004 0.001 -76.564 0.001 
Smoking 
unadjusted -0.020 0.046 -0.022 0.008 -0.019 0.001 -0.174 0.010 -1.146 0.005 -55.659 0.068 
adjusted -0.009 0.398 -0.021 0.016 -0.016 0.006 -0.165 0.014 -1.127 0.004 -49.356 0.108 
Double use 
unadjusted -0.019 0.025 -0.023 0.001 -0.018 <0.001 -0.150 0.010 -1.209 0.001 -64.798 0.013 
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2013/1459  Ungdommers livsstil og endring i beinmasse mellom 16 -19 år
 Universitetet i TromsøForskningsansvarlig:
 Nina EmausProsjektleder:
Vi viser til søknad om forhåndsgodkjenning av ovennevnte forskningsprosjekt. Søknaden ble behandlet av
Regional komité for medisinsk og helsefaglig forskningsetikk (REK nord) i møtet 26.09.2013. Vurderingen
er gjort med hjemmel i helseforskningsloven (hfl.) § 10, jf. forskningsetikklovens § 4.
Prosjektleders prosjektomtale
In the Norwegian adult population, fracture risk is among the highest reported. The foundation of fracture
risk in the elderly is laid during growth, through childhood and adolescence to the achievement of peak
bone mass. Previous work has highlighted the importance of the early environment and lifestyle on this
achievement. This proposed project will explore factors connected to achievement of peak bone mass: i) age
and peak bone mass – tracking of bone mass levels over two years in adolescence ii) the effect of baseline
weight and weight changes over two years on peak bone mass and iii) the effect of smoking, snuffing,
alcohol intake and physical activity on peak bone mass achievement in adolescence. Data was collected
from Fit Futures, which is an extension of the population-based Tromsø Study, from August 2010 to May
2011, and from November 2012 to June 2013. The analysis will be based on bone mineral density
measurements and information from questionnaires.
Vurdering
Vurdering av om samtykket fra Fit Futures er dekkende for det som skal gjøres i studien
I samtykkeskrivet er hovedområdene det forskes på angitt slik:
“Beintetthet, Diabetes, D-vitamin, Jernmangel, Genmodifisert mat, Miljøgifter, Fysisk aktivitet og overvekt,
Eksem og kviser, Infeksjoner, Smerte, Øresus, Medisinbruk, Frafall fra skole og Tannhelse.
Informasjonen fra undersøkelsen vil også bli brukt til forskning om de store folkehelseproblemene generelt,
slik som hjerte-karsykdommer, lungesykdommer, kreft, nedsatt fruktbarhet og smerte. Det vil også bli
forsket på arbeidsførhet i skole og yrke i forhold til sykdom, helse og livsstil. En del av prosjektene vil
studere samspillet mellom arv, miljø og sykdom og helse; til slike prosjekter vil det bli hentet ut genetisk
arvestoff fra blodprøvene. I framtiden kan data bli brukt i forskningsprosjekter som i dag ikke er planlagt.
For alle slike nye prosjekter kreves det at prosjektet er godkjent av Regional komité for medisinsk og
helsefaglig forskningsetikk.”
Hovedformålet i den omsøkte studien er å studere bentetthet og faktorer som påvirker denne. Komiteen
anser at samtykket er dekkende for det aktuelle formålet.
Anonyme / avidentifiserte opplysninger
Under punkt 4d i søknaden står det at “All data behandles anonymisert.”
Vi minner om at anonyme opplysninger er opplysninger der navn, fødselsnummer og andre personentydige
kjennetegn er fjernet slik at opplysningene ikke lenger kan knyttes til en enkeltperson, jf. helseregisterloven
§ 2 nr. 3. Det skal heller ikke være mulig å knytte opplysningene til en enkeltperson indirekte, for eksempel
gjennom at andre variabler i datasettet gjør det mulig å finne fram til en person. 
Avidentifiserte helseopplysninger er helseopplysninger der navn, fødselsnummer, biometriske kjennetegn
og andre personentydige kjennetegn er fjernet, slik at opplysningene ikke lenger kan knyttes til en
enkeltperson, og hvor identitet bare kan tilbakeføres ved sammenstilling med de opplysningene som
tidligere har blitt fjernet, jf. helseregisterloven § 2 nr. 2.
Vedtak
Med hjemmel i helseforskningsloven § 10 og forskningsetikkloven § 4 godkjennes prosjektet.
Sluttmelding og søknad om prosjektendring
Prosjektleder skal sende sluttmelding til REK nord på eget skjema senest 30.06.2017, jf. hfl. §
12. Prosjektleder skal sende søknad om prosjektendring til REK nord dersom det skal gjøres vesentlige
endringer i forhold til de opplysninger som er gitt i søknaden, jf. hfl. § 11.
Klageadgang
Du kan klage på komiteens vedtak, jf. forvaltningslovens § 28 flg. Klagen sendes til REK nord. Klagefristen
er tre uker fra du mottar dette brevet. Dersom vedtaket opprettholdes av REK nord, sendes klagen videre til
Den nasjonale forskningsetiske komité for medisin og helsefag for endelig vurdering.
Med vennlig hilsen
May Britt Rossvoll 
sekretariatsleder
Kopi til: postmottak@iho.uit.no  
Alle skriftlige henvendelser om saken må sendes via REK-portalen
















31193 Påvirkes ungdommer beinmasse av tobakksbruk?
Forskningsansvarlig: UiT Norges arktiske universitet
Søker: Nina Emaus
 
Søkers beskrivelse av formål:
Den oppnådde beinmassen - peak bone mass - rundt 20 års alder har stor betydning for
fremtidig bruddrisiko. Basert på data fra ungdomsundersøkelsen Fit Futures har vi
gjennom flere studier vist at beinmassen fortsatt endrer seg mellom 16 - 20 år og at flere
viktige livsstilsfaktorer påvirker denne. I dette arbeidet skal vi studere hvorvidt bruk av
tobakk og spesielt snus, har en negativ effekt på de unges beinmasse. I den gjennomførte
Fit futures-undersøkelsen i 2010-11rapporterte 19% av jentene og 30% av guttene at de
var daglige snusbrukere. Vi har derfor her et godt materiale for å studere effekten av
snusbruk på ungdommers beinhelse og dermed fremtidig bruddrisiko.
 
REKs vurdering 
Vi viser til søknad om forhåndsgodkjenning av ovennevnte forskningsprosjekt. Søknaden
ble behandlet av Regional komité for medisinsk og helsefaglig forskningsetikk (REK nord)
i møtet 19.09.2019. Vurderingen er gjort med hjemmel i helseforskningsloven § 10.
Formål
Av søknaden følger at formålet med prosjektet er å «studere hvorvidt bruk av tobakk og
spesielt snus, har en negativ effekt på de unges beinmasse.»
Om prosjektet
Alle skriftlige henvendelser om saken må sendes via REK-portalen
Du finner informasjon om REK på våre hjemmesider  rekportalen.no
Prosjektet er en del av en ph.d.
Den 27.08.13 søkte prosjektleder om prosjektet «Ungdommers livsstil og endring i
beinmasse mellom 16-19 år» (2013/1459). Prosjektet ble godkjent med sluttdato
31.12.2016.
Av søknaden til nå omsøkte prosjekt følger at: «Prosjektet med nummer 2013/1459, som
var den opprinnelige søknaden for dette doktorgradsprosjektet er i dag meldt som
avsluttet. Prosjektet har forløp som planlagt, bare med forlenget tidsplan. Da REK
godkjenning var utgått har vi bedt om formell avslutning av det opprinnelige prosjektet
som har produsert to artikler. Nå gjenstår siste artikkel i arbeidet og det er det vi søker om
godkjenning for her.»
Prosjektstart er i søknaden satt til 02.09.19. REK forutsetter at datainnsamling ikke
igangsettes før det foreligger endelig godkjenning.
Data/materiale
Data skal hentes fra Fit Futures 1 og 2, Tromsøundersøkelsen.
Data som skal innhentes er: Kjønn, alder, høyde, vekt, fysisk aktivitet, røyking, snusbruk,
alkohol, pubertetsstatus, beinmasse.
Av søknaden følger at det hentes ut ca. 50 variabler på de til sammen 1.200 deltakerne.
Deltakere
Av søknaden følger at alle deltakere i Fit Futures 1 og 2 skal inkluderes, 1.200 deltakere.
Forespørsel/informasjon/samtykkeerklæring
Deltakerne i Fit Futures 1 og 2 har avgitt samtykke. Av informasjonsbrosjyren til
deltakerne fremkom at hovedområdene det forskes på er:
«Beintetthet, Diabetes, D-vitamin, Jernmangel, Genmodifisert mat, Miljøgifter, Fysisk
aktivitet og overvekt, Eksem og kviser, Infeksjoner, Smerte, Øresus, Medisinbruk, Frafall
fra skole og Tannhelse.
Informasjonen fra undersøkelsen vil også bli brukt til forskning om de store
folkehelseproblemene generelt, slik som hjerte-karsykdommer, lungesykdommer, kreft,
nedsatt fruktbarhet og smerte. Det vil også bli forsket på arbeidsførhet i skole og yrke i
forhold til sykdom, helse og livsstil. En del av prosjektene vil studere samspillet mellom
arv, miljø og sykdom og helse; til slike prosjekter vil det bli hentet ut genetisk arvestoff fra
blodprøvene. I framtiden kan data bli brukt i forskningsprosjekter som i dag ikke er
planlagt.
Alle skriftlige henvendelser om saken må sendes via REK-portalen
Du finner informasjon om REK på våre hjemmesider  rekportalen.no
For alle slike nye prosjekter kreves det at prosjektet er godkjent av Regional komité for
medisinsk og helsefaglig forskningsetikk.»
Hovedformålet i den omsøkte studien er å studere hvorvidt bruk av tobakk påvirker
ungdommers beinmasse. REK anser at de avgitte samtykker er dekkende for det aktuelle
formålet.
Oppbevaring av data





Med bakgrunn i ovennevnte har REK ingen innvendinger til at studien gjennomføres som
beskrevet i søknad og protokoll.
REK har gjort en helhetlig forskningsetisk vurdering av alle prosjektets sider og
godkjenner det med hjemmel i helseforskningsloven § 10.
Prosjektet er godkjent frem til omsøkt sluttdato 01.07.2021. Data kan oppbevares for
kontrollhensyn i inntil 5 år etter prosjektslutt. Etter dette skal data slettes eller
anonymiseres.
Vi gjør samtidig oppmerksom på at etter personopplysningsloven må det også foreligge et
behandlingsgrunnlag etter personvernforordningen. Dette må forankres i egen institusjon.






Alle skriftlige henvendelser om saken må sendes via REK-portalen
Du finner informasjon om REK på våre hjemmesider  rekportalen.no
Appendix B 
 
Pamphlet of information, The Fit Futures 1 
 
Pamphlet of information, The Fit Futures 2 
 
Consent of participation, The Fit Futures 1 
 
Consent of participation, The Fit Futures 2 
 







PERSONVERN OG SIKKERHET 
Alle medarbeidere som jobber med undersøkelsen, har taushetsplikt. Opplysningene som 
samles inn, vil bare bli brukt til godkjente forskningsformål, som beskrevet over. 
Opplysningene og prøvene vil bli behandlet uten navn og fødselsnummer eller andre direk-
te gjenkjennende opplysninger. En kode knytter deg til dine opplysninger og prøver. Koden 
oppbevares separat ved Universitetet i Tromsø, og kun noen få autoriserte personer har til-
gang. Den enkelte forsker får ikke tilgang til opplysninger som gjør det mulig å identifisere 
enkeltpersoner. Det vil ikke være mulig å identifisere deg i resultatene av studien når disse 
publiseres.
I noen tilfeller kan det være aktuelt å gjøre analyser av blodprøver eller genetiske analyser 
ved forskningsinstitusjoner i utlandet. Hvis dette gjøres, vil våre utenlandske samarbeids-
partnere ikke få opplysninger som kan knytte prøvene opp mot deg som person.
Tromsøundersøkelsen gjennomfører Fit futures i samarbeid med Universitetssykehuset 
Nord-Norge og Nasjonalt folkehelseinstitutt. Data som samles inn på sykehuset, overføres 
til Universitetet i Tromsø når datainnsamlingen er avsluttet. Ingen av opplysningene som 
framkommer i undersøkelsen, lagres i journalsystemet på sykehuset. Databehandlings-
ansvarlig er Universitetet i Tromsø. Tromsøundersøkelsen administrerer utlevering av data 
til forskningsprosjekter. Hvem som er ansvarlig for forskningsprosjektene, finner du her 
http://www.tromsoundersokelsen.no. Fit futures er godkjent av Datatilsynet og Regional 




Det er frivillig å delta i studien. Du kan når som helst og uten å oppgi noen grunn trekke ditt 
samtykke til å delta i undersøkelsen, og dette vil ikke få noen konsekvenser for deg. Der-
som du senere ønsker å trekke deg eller har spørsmål til studien, kan du kontakte Tromsø-
undersøkelsen, Institutt for samfunnsmedisin, Universitetet i Tromsø, 9037 Tromsø, telefon 
77644816, e-post: tromsous@uit.no.
RETT TIL INNSYN OG SLETTING AV PRØVER OG OPPLYSNINGER OM DEG 
Hvis du sier ja til å delta i studien, har du rett til å få innsyn i hvilke opplysninger som er 
registrert om deg. Du har også rett til å få korrigert eventuelle feil i de opplysningene vi har 
registrert. Dersom du trekker deg fra studien, kan du kreve å få slettet innsamlede prøver og 
opplysninger, med mindre opplysningene allerede er inngått i analyser eller brukt i viten-
skapelige publikasjoner. 
 
VIL DU DELTA? 
Hvis du er fylt 16 år, gir du selv ditt samtykke til å delta. Du kan da signere vedlagte 
skjema (hvitt ark) og ta det med til undersøkelsen. Det er også mulig å undertegne 
skjemaet når du kommer til Forskningsposten.
Hvis du ikke er fylt 16 år, må du be dine foreldre/foresatte om lov til å delta. Da må 
både du og dine foreldre/foresatte signere vedlagte skjema (hvitt ark) som du tar 
med deg til undersøkelsen. 
ANSVARLIGE FOR GJENNOMFØRING AV FIT FUTURES 
UNDERSØKELSEN
Fit futures ledes av en styringsgruppe, og følgende forskere er ansvarlige for 
gjennomføringen:
Anne-Sofie Furberg
prosjektleder, lege, Universitetssykehuset Nord-Norge
e-post: anne-sofie.furberg@unn.no, telefon 77 75 58 24
Christopher Sivert Nielsen
psykolog, Nasjonalt folkehelseinstitutt
e-post: Christopher.Sivert.Nielsen@fhi.no, telefon 21 07 82 77
Guri Grimnes
lege, Universitetssykehuset Nord-Norge og Universitetet i Tromsø
e-post: guri.grimnes@unn.no, telefon 77 66 94 83
SPØRSMÅL? 
Dersom du/dere har spørsmål om undersøkelsen, kontakt Forskningsposten 









HVA ER FIT FUTURES? 
Fit futures er et forskningsprosjekt der vi undersøker ungdommers fysiske helse og livsstil. 
 
HVORFOR ER DETTE VIKTIG? 
Voksnes helse undersøkes i mange studier, men man har mindre kunnskap om helse blant 
ungdom. Selv om få ungdommer har alvorlige sykdommer, legges mye av grunnlaget for 
fremtidig helse i ungdomsårene. Denne undersøkelsen kan bidra til at vi får økt kunnskap 
om hvordan man kan forebygge sykdom og om hvordan diagnoser kan stilles på et tidligere 
tidspunkt.
HVA FORSKES DET PÅ? 
Hovedområdene det forskes på er:
· Eksem og kviser
· Infeksjoner





Informasjonen fra undersøkelsen vil også bli brukt til forskning om de store folkehelseproble-
mene generelt, slik som hjerte-karsykdommer, lungesykdommer, kreft, nedsatt fruktbarhet 
og smerte. Det vil også bli forsket på arbeidsførhet i skole og yrke i forhold til sykdom, helse 
og livsstil. En del av prosjektene vil studere samspillet mellom arv, miljø og sykdom og helse; 
til slike prosjekter vil det bli hentet ut genetisk arvestoff fra blodprøvene. I framtiden kan data 
bli brukt i forskningsprosjekter som i dag ikke er planlagt. For alle slike nye prosjekter kreves 
det at prosjektet er godkjent av Regional komité for medisinsk og helsefaglig forskningsetikk. 
En oversikt over godkjente prosjekter finner du her (www.tromsoundersokelsen.no). Nett- 
siden holdes løpende oppdatert. Her kan du også lese om våre forskningsresultater.
HVEM KAN DELTA? 
Alle ungdommer på VG1 blir invitert til å delta. Hvis du er 16 år eller mer, kan du selv bestem-






· Frafall fra skole
· Tannhelse
SLIK FOREGÅR UNDERSØKELSEN 
Undersøkelsen gjennomføres i skoletiden. Selve undersøkelsen tar 2-3 timer, og du må på-
regne å være borte fra skolen en halv dag. Skolen anser dette som gyldig skolefravær. Du blir 
undersøkt på Forskningsposten, Universitetssykehuset Nord-Norge, av erfarne forsknings-
sykepleiere og tannleger/tannhelsesekretærer. Undersøkelsen består av følgende deler:
· Spørreskjema der vi spør om livsstil, trivsel, sykdommer og helseplager gjennom livet, og 
 familieforhold.
· Intervju der vi spør om hvilke medisiner du bruker, om du har noen sykdom i dag og litt  
 om sosialt nettverk. Kvinner spørres også om menstruasjon og graviditet.
· Generell helseundersøkelse der vi måler høyde, vekt, livvidde og hoftevidde, blodtrykk og 
 puls, samt tar blodprøve, en hårprøve fra nakken, og en bakterieprøve fra nesebor og hals  
 med en fuktet vattpinne. 
· Måling av smertefølsomhet der vi måler følsomhet for trykk, kulde og varme. Smerten 
 kommer gradvis, og du kan selv avbryte når som helst. 
· Kroppsscan (DEXA) der vi måler beintetthet og forholdet mellom fett- og muskelvev. 
 Dette skjer ved at du ligger rolig i ca. 10 minutter mens kroppen scannes. 
· Tannundersøkelse som blir din årlige undersøkelse ved den offentlige tannhelsetjenesten og 
 omfatter klinisk undersøkelse, tannrøntgen, kliniske foto og avtrykk for studiemodeller.
Etter undersøkelsen vil du få utlevert en liten aktivitetsmåler som er festet i et smalt strikkbelte 
til å ha under klærne. Denne måler hvor mye du beveger deg i løpet av dagen. Apparatet leve-
res på skolen etter en ukes bruk. Da vil det samtidig tas ny bakterieprøve fra nesebor og hals. 
Noen deltakere vil bli forespurt om å undersøkes en gang til. Det vil da være aktuelt å gjenta 
noen av undersøkelsene og gjøre enkelte utvidede undersøkelser. 
HVA SKJER MED DE BIOLOGISKE PRØVENE? 
Med blodprøven gjøres analyser av bl.a. hormonnivåer, fettstoffer, blodsukker, vitaminer, 
miljøgifter og markører på betennelse og sykdommer. Det blir også hentet ut arvestoff (DNA 
og RNA) for genetiske analyser. Bakterieprøvene brukes til å måle forekomst av gule stafy-
lokokker. Hårprøven analyseres for å se på nivå av kvikksølv. Prøvene lagres i Forsknings-
biobanken for Tromsøundersøkelsen ved Universitetet i Tromsø. Hvis du sier ja til å delta, 
gir du også samtykke til at de biologiske prøvene og analyseresultatene inngår i biobanken.
INFORMASJON FRA ANDRE KILDER OG BRUK AV DATA I FRAMTIDEN
Opplysninger og prøver som du gir, blir oppbevart på ubestemt tid til bruk i forskning om-
kring helse og sykdom som omtalt i denne brosjyren. Det kan også hende at vi tar kon-
takt med deg igjen for å spørre om du vil være med på en ny undersøkelse. For spesielle 
forskningsprosjekter kan det være aktuelt å sammenstille informasjon fra Fit futures med 
nasjonale helseregistre som Reseptregisteret, Medisinsk fødselsregistrer, Kreftregisteret, 
Norsk pasientregister, Dødsårsaksregisteret og andre nasjonale registre over sykdommer 
som det forskes på i Tromsøundersøkelsen. I tillegg kan det være aktuelt å innhente helse-
opplysninger fra spesialist- og primærhelsetjenesten, for eksempel informasjon om bein-
brudd og høyde- og vektdata fra helsestasjon, til bruk i forskning på sykdommer og helse-
problemer som det forskes på i Tromsøundersøkelsen. Det kan også bli innehentet data fra 
registre i Statistisk sentralbyrå slik som miljø, befolkning, utdanning, inntekt, offentlige 
ytelser, arbeidsdeltakelse og andre forhold som kan ha betydning for helsa. For å undersøke 
om sykdommer går i arv, kan opplysninger om deg sammenstilles med opplysninger om 
dine slektninger, dersom disse har deltatt i deler av Tromsøundersøkelsen. Dette blir gjort 
ved å innhente opplysinger om slektskap fra Familieregisteret. Fra skolen vil vi innhente 
dine opplysninger om studieprogram, klasse, kjønn, antall fraværsdager, om du fullfører 
skoleåret og om karakterer i fagene norsk, matematikk og engelsk.
 
Sammenstillinger av informasjon krever noen ganger nytt samtykke og/eller annen type 
godkjenning slik som dispensasjon fra taushetsplikten eller godkjenning av offentlige in-
stanser, for eksempel Regional komité for medisinsk og helsefaglig forskningsetikk, Data-
tilsynet eller NAV. 
MULIGE ULEMPER OG FORDELER 
Deltakelse innebærer at du må bruke noe tid. Deler av undersøkelsen kan også innebære 
ubehag. Dette gjelder særlig blodprøven. Dersom du vet at du har problemer med å ta blod-
prøve, kan du kontakte Forskningsposten på telefon 77 62 69 09 eller snakke med sykepleier 
når du kommer til undersøkelsen for å finne en løsning på dette.
Dersom resultatet av prøvene dine viser at det er nødvendig med oppfølging av tannlege, 
lege eller henvisning til spesialist, vil du bli orientert om det. Ved behov for henvisning til 
spesialist, vil vi sørge for henvisning og tilbud om oppfølging ved sykehuset. 
Deltakere får et gavekort til en verdi av kr. 200 ved oppmøte som kan brukes i de fleste butik-





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Samtykke til å delta i studien Fit Futures 2
Jeg er villig til å delta i studien
_________________________________________________________________
 (DITT FULLE NAVN I BLOKKBOKSTAVER)






Interview guide, TFF1 
Printout of Electronic Questionnaire, TFF1 









FF - Generelt spørreskjema - Uke 1
Vi ønsker å vite mer om livsstil og helse. 
 
Bruk den tiden du trenger til å svare så presist du kan. 
 
Alle svarene dine blir behandlet med taushetsplikt. 
 
Bruk "neste >>" og "<< tilbake" - knappene i skjema for å bla deg fremover og bakover. 
 
Lykke til og tusen takk for hjelpen! 
 




















3) Hvor lenge er det siden du yttet hjemmefra?
Mindre enn 6 måneder
6 - 11 måneder
1 - 2 år
Mer enn 2 år
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6) Hva er den høyeste fullførte utdanningen til dine foreldre? (sett kryss for alle utdanningene du 



























Annet, spesi ser her
8) I hvilken kommune bodde du da du var 5-6 år (førskolealder/1.klasse)?
Velg kommune  
9) Er du født i Norge?
Ja
Nei, spesi ser hvilket land
10) Er din biologiske mor født i Norge?
Ja
Nei, spesi ser hvilket land
11) Er din biologiske far født i Norge?
Ja
Nei, spesi ser hvilket land
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Hvis det har vært ere opphold, oppgi varighet av siste opphold.
13) Hvor lenge varte oppholdet?
Mindre enn 2 måneder
2-6 måneder
Mer enn 6 måneder
 
Hvis det har vært ere opphold, oppgi når du hadde siste opphold.
14) Når var oppholdet? (Oppgi årstall når oppholdet sluttet - 4 si er)
VENNER OG SKOLE
15) Har du vurdert å avbryte eller ta pause fra den videregående opplæringen du er i gang med?
Ja  Nei
16) Hvor sannsynlig er det at du fullfører den utdanningen du er i gang med?
Liten - kommer til å slutte
God - kommer sannsynligvis til å fullføre










Mer enn 50 meldinger














Jeg synes det er ganske vanskelig å få venner
Jeg har mange venner
Andre ungdommer har vanskelig for å like meg
Jeg er populær blant jevnaldrende
Jeg føler at jevnaldrende godtar meg
19) Hvilke avgangskarakterer kk du fra ungdomsskolen? (sett ett kryss for hvert fag)









20) Hvordan vurderer du din egen helse sånn i alminnelighet?
Meget god
God
Verken god eller dårlig
Dårlig
Meget dårlig













Smertestillende på resept (f. eks. Paralgin forte, Pinex forte)





22) Har du diabetes?
Ja  Nei
23) Har din biologiske mor diabetes?
Ja  Nei  Vet ikke
24) Har din biologiske far diabetes?




25) Bruker mor insulin? (Penn eller pumpe)
Ja  Nei  Vet ikke
26) Hvor gammel var mor da hun kk diabetes?
< 20 år  20 - 40 år  > 40 år
 
27) Bruker far insulin? (Penn eller pumpe)
Ja  Nei  Vet ikke
28) Hvor gammel var far da han kk diabetes?
< 20 år  20 - 40 år  > 40 år
PSYKISKE VANSKER














Plutselig frykt uten grunn
Føler deg redd eller engstelig
Matthet eller svimmelhet
Føler deg anspent eller oppjaget
Lett for å klandre deg selv
Søvnproblemer
Nedtrykt, tungsindig
Følelse av å være unyttig, lite verdt
Følelse av at alt er et slit
Følelse av håpløshet med hensyn til framtida







Jeg var lei meg eller ulykkelig
Jeg følte meg så trøtt at jeg bare ble sittende uten å gjøre noen ting
Jeg var veldig rastløs
Jeg var ikke glad for noe
Jeg følte meg lite verdt
Jeg gråt mye
Jeg hatet meg selv
Jeg tenkte at jeg aldri kunne bli så god som andre ungdommer
Jeg følte meg ensom
Jeg tenkte at ingen egentlig var glad i meg
Jeg følte meg som et dårlig menneske
Jeg gjorde alt galt







Her har vi noen spørsmål om kroppslige forandringer som skjer gjennom ungdomstiden: 
32) Har du fått menstruasjon?
Ja  Nei
 






35) Har du fått eller begynt å få kjønnshår?
Ja  Nei
36) Har du fått eller begynt å få bryster?
Ja  Nei
 
37) Har du fått eller begynt å få kjønnshår?
Ja  Nei
 




KROPP OG VEKT 
 
39) Hvilken av disse kroppsfasongene likner mest på kroppen til moren din?
1  2  3  4  5  6  7  8  9
40) Hvilken av disse kroppsfasongene likner mest på kroppen til faren din?




41) Hvilken av disse kroppsfasongene likner mest på din kropp slik du er i dag?
1  2  3  4  5  6  7  8  9
 
42) Hvilken av disse kroppsfasongene likner mest på din kropp slik du er i dag?
1  2  3  4  5  6  7  8  9
RØYK, SNUS OG ALKOHOL
43) Røyker du?
Nei, aldri  Av og til  Daglig
44) Bruker du snus eller skrå?
Nei, aldri  Av og til  Daglig
 





























49) Hvor ofte drikker du alkohol?
Aldri
1 gang per måned eller sjeldnere
2-4 ganger per måned
2-3 ganger per uke










51) Hvor ofte drikker du 6 eller ere enheter alkohol ved en anledning?
Aldri
Sjeldnere enn 1 gang per måned
1 gang per måned
1 gang per uke
Daglig eller nesten daglig
FYSISK AKTIVITET 
52) Hvilken beskrivelse passer best når det gjelder din fysiske aktivitet på fritiden det siste året?
Sitter ved PC/TV, leser eller annen stillesittende aktivitet.
Går, sykler eller beveger deg på annen måte minst 4 timer i uken (her skal du også regne med tur
til/fra skolen, shopping, søndagsturer med mer).
Driver med idrett/trening, tyngre utearbeid, snømåking eller liknende minst 4 timer i uka.
Trener hardt eller driver konkurranseidrett regelmessig og ere ganger i uka.







54) Hvor lang tid bruker du vanligvis til og fra skolen (en vei) i sommerhalvåret?
Mindre enn 5 minutter
6 til 15 minutter
16 til 30 minutter
1/2 til 1 time
Mer enn 1 time





56) Hvor lang tid bruker du vanligvis til og fra skolen (en vei) i vinterhalvåret?
Mindre enn 5 minutter
6 til 15 minutter
16 til 30 minutter
1/2 til 1 time
Mer enn 1 time






58) Hvor mange dager i uken driver du med idrett/fysisk aktivitet utenom skoletid?
Aldri
Sjeldnere enn 1 dag i uka
1 dag i uka
2-3 dager i uka
4-6 dager i uka
Omtrent hver dag




Omtrent 1 - 1 1/2 time
Omtrent 2 - 3 timer
Omtrent 4 - 6 timer
7 timer eller mer






Utenom skoletid: Hvor mange timer per dag ser du på PC, TV, DVD og liknende?
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61) Hverdager, antall timer per dag:
Ingen
Omtrent 1/2 time
Omtrent 1 - 1 1/2 time
Omtrent 2 - 3 timer
Omtrent 4 - 6 timer
Omtrent 7 - 9 timer
10 timer eller mer
62) Fridager (helg, helligdager, ferie), antall timer per dag:
Ingen
Omtrent 1/2 time
Omtrent 1 - 1 1/2 time
Omtrent 2 - 3 timer
Omtrent 4 - 6 timer
Omtrent 7 - 9 timer
10 timer eller mer
Svar på en skala fra 1 til 5, der 1 tilsvarer svært sjelden eller aldri og 5 tilsvarer svært ofte.
63) I hvilken grad har andre oppmuntret deg til å være fysisk aktiv







Svar på en skala fra 1 til 5, der 1 tilsvarer helt enig og 5 tilsvarer helt uenig.
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64) Hvordan passer disse utsagnene for deg?
1 2 3 4 5
Det er morsommere å drive med trening eller fysisk aktivitet
enn å gjøre andre ting...
Jeg skulle ønske jeg kunne drive mer med trening eller fysisk
aktivitet enn det jeg har anledning til å gjøre...
Jeg føler at jeg er bedre enn de este på min alder i
idrett/fysisk aktivitet...
Jeg føler at jeg lett kan holde følge med de andre på min alder
når vi driver med idrett/fysisk aktivitet...
Svar på en skala fra 1 til 5, der 1 tilsvarer helt enig og 5 tilsvarer helt uenig.
65) Hvordan passer disse utsagnene for deg?
1 2 3 4 5
Jeg liker ikke å trene mens noen står å ser på...
Tilgang til egen garderobe hadde gjort det lettere å trene...
Jeg blir ubehagelig andpusten, svett eller får vondt i kroppen
ved trening...
Gymtimene er organisert slik at jeg ikke henger med...
Jeg har ingen å trene sammen med...
Jeg mangler utstyr for å drive med den aktiviteten jeg har lyst
til...
Jeg har for mange andre oppgaver som gjør at jeg ikke får tid til
å trene (f.eks lekser, hjemmeoppgaver)...
Det mangler egnede haller eller gode uteområder for å drive


















67) Hvor ofte spiser du matpakke hjemmefra på skolen?
Hver dag
3-4 ganger per uke
1-2 ganger per uke
Sjelden eller aldri


















Fet sk (f.eks. laks, ørret, makrell, sild)
Mager sk (f.eks. torsk, sei, hyse)
Pizza, hamburger eller pølser
Hermetisert mat (fra metallbokser)
Godteri (f.eks. sjokolade, drops)


































70) Hvor mange ganger i året spiser du vanligvis disse matvarene?


































Brus med sukker (1/2 liters aske = 2 glass)










73) Når pleier du å legge deg for å sove på ukedagene?
Velg...
74) Når pleier du å legge deg for å sove i helgen?
Velg...
75) Hvor lenge pleier du å ligge våken før du får sove på ukedagene?
Velg...
76) Hvor lenge pleier du å ligge våken før du får sove i helgen?
Velg...
77) Når pleier du å våkne på ukedagene (endelig oppvåkning)?
Velg...
78) Når pleier du å våkne i helgen (endelig oppvåkning)?
Velg...




80) Hvor mange timer søvn trenger du pr. natt for å føle deg uthvilt?
Velg...
81) Synes du at du får tilstrekkelig med søvn?
Ja, absolutt tilstrekkelig
Ja, stort sett tilstrekkelig
Nei, noe utilstrekkelig
Nei, klart utilstrekkelig





Her har vi noen spørsmål om vanlige hudplager/hudsykdommer.  
 
82) Har du hatt kløende utslett i løpet av de siste 12 månedene?
Ja  Nei  Vet ikke
 
83) Har dette utslettet sittet på noen av de følgende stedene: rundt hals, ører eller øyne, i 
albuebøyene (på innsiden), under baken, bak knærne eller foran på anklene?
Ja  Nei
84) Hvor gammel var du første gang du kk denne typen utslett?
Velg...
Hvor mye plaget er du av dette utslettet i dag?  
Svar på en skala fra 0-10, der 0 tilsvarer ingen plager og 10 tilsvarer verst tenkelige plager.
0  1  2  3  4  5  6  7  8  9  10
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86) Har du hatt håndeksem ere ganger?
Ja  Nei  Vet ikke
Hvor mye plaget er du av håndeksem i dag?  
Svar på en skala fra 0-10, der 0 tilsvarer ingen plager og 10 tilsvarer verst tenkelige plager.
0  1  2  3  4  5  6  7  8  9  10
88) Har du noen gang vært plaget av kviser?
Ja  Nei  Vet ikke
Hvor mye plaget er du av kviser i dag?  
Svar på en skala fra 0-10, der 0 tilsvarer ingen plager og 10 tilsvarer verst tenkelige plager.
0  1  2  3  4  5  6  7  8  9  10
90) Har du noen gang oppsøkt lege på grunn av kviser?
Ja  Nei
 




Lokalbehandling (f.eks. kremer eller oppløsninger)




92) Har du eller har du noen gang hatt psoriasis?
Ja  Nei  Vet ikke
Hvor mye plaget er du av psoriasis i dag?  
Svar på en skala fra 0-10, der 0 tilsvarer ingen plager og 10 tilsvarer verst tenkelige plager.
0  1  2  3  4  5  6  7  8  9  10
Verkebyller er svært store kviser som er ømme/smertefulle og som ofte gir  
arr.




95) Har du noen gang oppsøkt lege pga verkebyllene?
Ja  Nei







97) Har du noen gang oppsøkt lege på grunn av verkebyllene?
Ja  Nei






barneeksem eller atopisk eksem?
SMERTER
99) Har du langvarige eller stadig tilbakevendende smerter som har vart i 3 måneder eller mer?
Ja  Nei
 
100) Hvor lenge har du hatt disse smertene?  (Dersom du har ere typer smerte, svar for den som 
har vart lengst)
3 - 6 måneder
6 - 12 måneder
1-2 år
3-6 år
Mer enn 6 år
101) Hvor ofte har du vanligvis disse smertene?
Hele tiden, uten opphør
Hver dag, men ikke hele tiden
Hver uke, men ikke hver dag




Hvor er det vondt? 























104) Hva mener du er årsaken til smertene? ( ere svar mulig)












Annet, spesi ser her
Vet ikke





Hvor sterke vil du si at smertene vanligvis er?  
Svar på en skala fra 0-10, der 0 tilsvarer ingen smerte og 10 tilsvarer verst tenkelig smerte. 
 
Dersom du har ere typer smerte, svar den som plager deg mest.
0  1  2  3  4  5  6  7  8  9  10
Hvor sterke er smertene når de er på sitt sterkeste? 
Svar på en skala fra 0-10, der 0 tilsvarer ingen smerte og 10 tilsvarer verst tenkelig smerte.  
 
Dersom du har ere typer smerte, svar den som plager deg mest.
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0  1  2  3  4  5  6  7  8  9  10
I hvor stor grad påvirker smertene søvnen din?  
Svar på en skala fra 0-10, der 0 tilsvarer ingen smerte og 10 tilsvarer verst tenkelig smerte.  
 
Dersom du har ere typer smerte, svar den som plager deg mest.
0  1  2  3  4  5  6  7  8  9  10
I hvor stor grad hindrer smertene deg i å utføre vanlige aktiviteter hjemme og på skolen?  
Svar på en skala fra 0-10, der 0 tilsvarer ingen smerte og 10 tilsvarer verst tenkelig smerte.  
 
Dersom du har ere typer smerte, svar den som plager deg mest.
0  1  2  3  4  5  6  7  8  9  10
MAGE- OG TARMPROBLEMER
109) I løpet av de siste 2 månedene: Hvor ofte har du hatt smerte eller ubehag i magen?
Aldri
1-3 ganger i måneden
En gang i uka
Flere ganger i uka
Hver dag
 
110) Hvor lenge har du vært plaget av smerte eller ubehag i magen?












112) Når du har smerter eller ubehag i magen, hvor lenge varer det vanligvis?





Når du har smerte eller ubehag i magen, hvor sterke smerter har du vanligvis?  
Svar på en skala fra 0-10, der 0 tilsvarer ingen smerte og 10 tilsvarer verst tenkelig smerte.  
 
Dersom du har ere typer smerte, svar den som plager deg mest.
0  1  2  3  4  5  6  7  8  9  10
114) Når du har smerter eller ubehag i magen, hvor ofte blir det bedre etter at du har hatt avføring?
Sjelden eller aldri
En del ganger
For det meste/hver gang
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har fastere eller mer klumpete avføring enn vanlig?
har løsere eller mer vannaktig avføring enn vanlig?
hadde avføring oftere enn vanlig?
hadde avføring sjeldnere enn vanlig?
HODEPINE
116) Har du vært plaget av hodepine det siste året?
Ja  Nei
 
117) Hva slags hodepine er du plaget av? (Du kan sette ere kryss)
Migrene  Annen hodepine  Vet ikke
118) Omtrent hvor mange dager per måned har du hodepine?
Mindre enn 1 dag
1-6 dager
7-14 dager
Mer enn 14 dager




Ensidig smerte (høyre eller venstre)
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120) Hvor lenge varer hodepinen vanligvis?
Mindre enn 4 timer
4 timer - 1 døgn
1-3 døgn
Mer enn 3 døgn
121) Før eller under hodepinen, kan du da ha forbigående:
Ja Nei
Synsforstyrrelse? (takkede linjer, imring, tåkesyn, lysglimt)
Nummenhet i halve ansiktet eller i hånden?
Forverring ved moderat fysisk aktivitet?
Kvalme og/eller oppkast?
122) Hvor ofte pusser du vanligvis tennene dine? (sett ett kryss)
Sjeldnere enn 1 gang per uke
1 gang per uke
 2-3 ganger per uke
4-6 ganger per uke
 1 gang daglig
2 eller ere ganger daglig
Hvor smertefullt, jevnt over, synes du det er å gå til tannlegen?  
Svar på en skala fra 0-10, der 0 tilsvarer ingen smerte og 10 tilsvarer verst tenkelig smerte.
0  1  2  3  4  5  6  7  8  9  10
Nedenfor er det re spørsmål om hvordan du opplever det er å gå til  
tannlege. Les hvert spørsmål og velg det svaralternativet som du synes  
passer best for deg.
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124) Dersom du skulle gå til tannlegen i morgen, hva ville du føle?
Jeg ville se frem til det som en ganske hyggelig opplevelse
Det ville være det samme for meg, ikke bety noe
Det ville gjøre meg litt urolig
Jeg ville bli redd for at det skulle bli ubehagelig og vondt
Jeg ville bli svært redd med tanke på hva tannlegen kanskje skulle gjøre





Så redd at jeg av og til begynner å svette eller nesten føler meg syk
126) Når du sitter i tannlegestolen og venter på at tannlegen skal begynne  behandlingen,  hvordan 





Så redd at jeg av og til begynner å svette eller nesten føler meg syk
Tenk at du sitter i tannlegestolen og skal få tennene renset og pusset. Mens du sitter og venter på at
tannlege skal nne frem instrumentene som brukes til å skrape og pusse med,





Så redd at jeg av og til begynner å svette eller nesten føler meg syk
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128) Har du øresus?
Aldri  Sjelden  Ofte
 
129) Hvor ofte har du øresus?
Hele tiden, uten opphør
Hver dag, men ikke hele tiden
Hver uke, men ikke hver dag
Sjeldnere enn hver uke
130) Hvor lenge varer vanligvis periodene med øresus?
Mindre enn 10 minutter  10 minutter - 1 time  Mer enn 1 time
131) Når får du vanligvis øresus?
Etter sterke lyder  Når det er stille  Vet aldri når
Noen bryr seg ikke om lyden, for andre oppleves det svært plagsomt å ha øresus. Angi hvor plaget
du er av øresusen.  
Svar på en skala fra 0 til 10, der 0 tilsvarer ingen plager og 10 tilsvarer verst tenkelige plager.
0  1  2  3  4  5  6  7  8  9  10
133) På hvilket øre har du vanligvis øresus?
Bare høyre
Bare venstre
Begge, men mest høyre
Begge, men mest venstre
Like mye på begge
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134) Omtrent hvor gammel var du når du begynte å ha øresus ofte?
Velg...
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28) Når man er tenåring, er det perioder da man vokser raskt. Har du merket at kroppen din
har vokst fort (blitt høyere)?
 Nei, den har ikke begynt å vokse
 Ja, den har såvidt begynt å vokse
 Ja, den har helt tydelig begynt å vokse




<< Tilbake  Neste >>
 
 
12 % completed   
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29) Og hva med hår på kroppen (under armene og i skrittet)? Vil du si at håret på kroppen din
har:
 Ikke begynt å vokse enda
 Såvidt begynt å vokse
 Helt tydelig begynt å vokse




<< Tilbake  Neste >>
 
 
13 % completed   
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30) Hvor gammel var du da du begynte å få hår i skrittet (kjønnshår)?




<< Tilbake  Neste >>
 
 
13 % completed   
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31) Har du begynt å komme i stemmeskifte?
 Nei, har ikke begynt ennå
 Ja, har såvidt begynt
 Ja, har helt tydelig begynt
 Det virker som om stemmeskifte er ferdig
32) Har du begynt å få bart eller skjegg?
 Nei, har ikke begynt ennå
 Ja, har såvidt begynt
 Ja, har helt tydelig begynt




<< Tilbake  Neste >>
 
 
14 % completed   
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